Heterocyclic compounds as protein kinase inhibitors

ABSTRACT

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R 1 , R 2  and R 3  are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

FIELD OF THE INVENTION

The present invention provides a heterocyclic compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein A, B, R′, R″, R¹, R² and R³ are as defined herein, apharmaceutical composition comprising a compound of formula (I) as anactive ingredient, methods of production, and methods of use thereof.Particularly, the present invention provides a compound of formula (I)useful for treating or preventing a disease, condition or disorderassociated with protein kinases, preferably Janus Kinase family.

BACKGROUND OF THE INVENTION

The importance of protein phosphorylation as a fundamental mechanismthat controls cell physiology was established by the pioneering work ofKrebs and Fisher (Fed. Proc., 1996, 25, 1511-1520). Protein kinasesmodify protein function by transferring phosphate groups from ATP or GTPto free hydroxyl groups of amino acids. Most protein kinasesphosphorylate serine and threonine residues, but a subset of proteinkinases selectively phosphorylate tyrosine residues. There are 90protein tyrosine kinases (PTKs) which play specific roles (Hunter, Cell,1987, 50, 823-829). PTKs can be further divided into the two mainsubgroups, receptor tyrosine kinase (RTKs) and non-receptor, cytosolictyrosine kinases. RTKs contain an extracellular ligand binding domain,transmembrane region and intracellular cytoplasmic kinase domain. PTKshave a conserved kinase domain structure that consists of an N-terminallobe (N-lobe) composed of a five-stranded p-sheet and a single α-helix,connected to a larger C-terminal lobe (C-lobe) by a hinge region. Theprotein substrate binds to a surface groove formed by the α-helicalC-lobe, and an ATP binding pocket is formed by the hinge region and N-and C-lobes. The C-lobe contains the activation loop (A-loop), whichbecomes phosphorylated. Phosphorylation leads to the conformationalstabilization and activation, allowing the transfer of the γ-phosphatefrom bound ATP to the bound substrate protein. All protein kinases sharestructural similarities but show greater structural distinction in theirinactive state (Schinlder et. al., Science, 2000, 289, 1938-1942).

Janus Kinases (JAKs) are non-receptor tyrosine kinases and werediscovered in searches for novel protein tyrosine using PCR basedstrategies (Firmbach-Kraft et al., Oncogene, 1990, 5, 1329-1336 and WilsA F, Proc. Natl. Acad. Sci. USA, 1989, 86, 1603-1607). In mammalians,JAKs have four members JAK1, JAK2, JAK3 and TYK2 enzymes. Since thesequencing of other vertebrate genomes has been completed, we know thatthere are four JAK family members in mammals, birds and fishes. Inhumans, the JAK1 gene is located on chromosome1p31.3 and JAK2 is on9p24; JAK3 and TYK2 genes are clustered together on chromosome19p13.1and 19p13.2, respectively. The three-dimensional structure of the JAKsis at present unknown but seven JAK homology (JH) domains have beenidentified, numbered from carboxyl to the amino terminal. The JH1 domainat the carboxyl terminal has all the features of a typical eukaryotictyrosine kinase domain. Interestingly, this domain is most closelyrelated to the kinase domains of the epidermal growth factor family ofreceptor tyrosine kinases, suggesting that JAK family may have arisenfrom the larger family of protein kinases (Manning et al., Science,2002, 298, 1912-1934).

In mammals, JAK1, JAK2 and TYK2 are ubiquitously expressed. In contrastthe expression of JAK3 is more restricted; it is predominantly expressedin hematopoietic cells and is highly regulated the cell development andactivation. At the cellular level, JAKs can be found in the cytosol whenthey are experimentally expressed in the absence of cytokine receptors,but, because of their intimate association with cytokine receptors, theyordinarily localize to endosome and the plasma membrane, along withtheir cognate receptors (Kawamura et al., Proc. Natl. Acad. Sci. USA,1994, 91, 6374-6378 and Musso et al., J. Exp. Med., 1995, 181,1425-1431). A large number of cytokines are dependent upon JAK1,including a family that use a shared receptor subunit called common γchain (γc), which includes interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15and IL-21. These cytokines are also dependent on JAK3, because JAK3binds γc. JAK1 is also essential for another family that uses the sharedreceptor subunit gp130 (IL-6, IL-11, oncostatin M, leukemia inhibitoryfactor (LIF), ciliary neutrophilic factor (CNF) as well as granulocytecolony-stimulating factor (G-CSF) and IFNs. JAK2 is essential for thehormone-like cytokines such as growth hormone (GH), prolactin (PRL),erythropoietin (EPO), thrombopoietin (TPO) and the family of cytokinesthat signal through the IL-3 receptor (IL-3, IL-5 and GM-CSF). JAK2 isalso important for cytokines that use the gp130 receptor and for someIFNs.

JAK3 probably has the most discrete function, as is associated with onlyone cytokine receptor-the common gamma chain or γc. This is a sharedreceptor subunit that pairs with other ligand-specific subunits to formthe receptors for IL-2, IL-4, IL-7, II-9, IL-15 and IL-21. The immuneabnormalities associated with JAK3 deficiency were confirmed with thegeneration of JAK3 knockout mice; similar to humans, these mice haveSCID that resembles γδ deficiency with small thymuses, absence of lymphnodes and reduced numbers of α/β and γ/δ T-cells. JAK3 mice also have aprofound reduction in thymic progenitor cells and reduced ability toreconstitute T cell development. No effect on myeloid or erthyroid cellswas noted in JAK3 deficient mice consistent with observations in humansand indicative of a specific effect on lymphoid precursors. However,murine JAK3 deficiency is associated with a T-cell dependent autoimmunedisease characterized by infiltration of tissues by mononuclear cells,splenomegaly, and expansion of neutrophils and monocytic cells. Theseauto-immune diseases are T-cell dependent.

TYK2 was the first JAK to be implicated in IFN signaling, but subsequentstudies indicate that TYK2 is essential for IL-12, IL-6, and IL-10signaling, but not for cytokines that use gp130. IL-12 induced IFN-γproduction by NK cells and activated T-cells was highly dependent onTYK2. Infact, TYK2 was shown to be involved in IL-23 induced STAT3phosphorylation of activated T-cells and in IFN-γ production.Furthermore, TYK2 plays a crucial role in IL-23 induced IL-17aproduction by γδ T cells. The importance of TYK2 in the in vivodifferentiation of Antigen-specific Th1 cells has also not been defined.TYK2 mice also have defective responses to lipopolysaccharide (LPS, acomponent of the outer membrane of gram-positive bacteria), but whetherthis is a direct or indirect effect has not been defined. In particular,a role of TYK2 in signaling through the Toll receptor, which mediatesthe response to LPS, has not been established (Shimoda et al., Immunity,2000, 13, 561-571; Karaghiosoff et al., Immunity, 2000, 13, 549-560).

JAKs are continuously associated with the membrane-proximal regions ofcytokine receptors, although in some cases interaction between the JAKand the receptor is increased upon ligand binding. It has been proposedthat ligand binding brings a conformational change in the receptor,which promotes JAK activation through reciprocal interaction of twojuxtapositioned JAK kinases and auto- and/or trans-phosphorylation oftyrosine residues on the activation loop of the JAK kinase domain. Likeother tyrosine kinases, JAKs undergo autophosphorylation, but theimportance of this modification in JAK-dependent signaling is not verywell understood. Autophosphorylation within the activation looppositively regulates kinase activity; in JAK3, however, phosphorylationin this region can enhance or inhibit catalytic activity, depending uponthe site of phosphorylation. Other sites of phosphorylation haverecently been identified, e.g., a conserved residue in the hinge regionbetween JH1 and JH2 is a prominent site of auto-phosphorylation (Tyr813in JAK2 and Tyr785 in JAK3). This site serves to recruit the adapterprotein Sh2-Bb, which positively regulates JAK2 activity (Feener et al.,Mol. Cell. Biol., 1994, 24, 4968-4978).

Tyrosine phosphorylation of cytokine receptors provides binding sitesfor signaling molecules. The main family of DNA-binding signalingproteins with transcriptional activity responsible for mediating signalsfrom cytokine receptors is the STAT family. The seven members of themammalian signal transducer and activator of transcription (STAT) familyparticipates in a wide range of biological processes with impact both onthe generation and the functional regulation of the cells involved inimmunity. STATs bind phosphorylated receptors and in turn are substratesfor the JAKs. Phosphorylated STAT can interact, dimerize, traffic intothe nucleus, and regulate gene expression. The mechanisms by whichcytokine activation of a restricted number of JAKs results in suchdifferent and specific downstream signaling events are still notunderstood. A large number of cytokines uses only four PTKs and sevenSTAT proteins for their specific signaling transmission. Activation ofSTATs by JAKs is a hallmark of both innate and adaptive immuneresponses. Hence, lymphocyte development, survival, and proliferationresulting in the outcome of an immune response by T-helper (Th) celllineage-defining cytokines all depend on JAK activation as a primarystep. Genetic analysis of JAKs in human with certain immune diseases andthe generation of JAK-specific knockout (KO) mice helped inunderstanding the exact role of JAKs in immune cell signaling (Darnellet al., Science, 1994, 264, 1451-1421; Ihle et al., Annu. Rev. Immunol.,1995, 13, 369-398; Leonard et al., Ann. Rev. Immunol., 1998, 16,293-322; Liu et al., Curr. Opin. Immunol., 1998, 10, 271-278 and Levy etal., Nat. Rev. Mol. Cell. Biol., 2002, 3, 651-662).

Cytokines are crucial for development, survival, proliferation anddifferentiation of hematopoietic cells. Type I and type II cytokinereceptors lack receptor-intrinsic tyrosine kinase activity and insteadtransmit their signals through receptor associated JAKs. In principle,all four JAKs might be considered as useful therapeutic targets.

Due to T-cell dependencies and their Th1 and Th17 modulation activitiesTYK2 enzyme inhibitors may have roles in auto-immune disorders such asrheumatoid arthritis, multiple sclerosis, psoriasis, intestinal boweldisease, and also in a few inflammatory disorders such as chronicobstructive pulmonary disease or allergy. A fully human monoclonalantibody targeting the shared p40 subunit of the IL-12 and IL-23cytokines was recently approved by the European Commission for thetreatment of moderate to severe plaque psoriasis (Krueger et al., N.Engl. J. Med., 2007, 356, 380-92 and Reich et al., Nat. Rev. DrugDiscov., 2009, 8, 355-356). In addition, an antibody targeting the IL-12and IL-23 pathways underwent clinical trials for treating Crohn'sdisease (Mannon et al., N. Engl. J. Med., 2004, 351, 2069-79).

Many pharmaceutical companies have established JAK targeted drugdevelopment programs, including Pfizer, Vertex, Rigel and Incyte. Pfizerhas progressed CP-690550, which is a potent JAK3 inhibitor. Thiscompound was reported to show efficacy in an animal model of organtransplantation and clinical trials, however the molecule is notselective for JAK3 and also inhibits JAK2 kinase with almostequipotency.

WO2010/142752 and US2010/0317643 disclose compounds having TYK2inhibitory activity. DE102009001438 and DE102009015070 disclosecarbonylamino substituted anilino pyrimidine derivatives as TYK2inhibiters. WO2011/113802 discloses imidazopyridine compounds useful fortreating diseases mediated by TYK2 kinase. US2010/0311743 discloses thecompounds which are inhibitors of protein kinases, particularly JAKfamily kinases. US2010/0256365 discloses compounds which are active onprotein kinases. WO2005/082367 discloses compounds having kinaseinhibitory activity.

WO2005/097129 discloses 6-azaindole compounds having superior IκB kinaseinhibitory activity. US2005/0228000 discloses bicyclic heterocyclesuseful as serine protease inhibitors. US2010/063047 discloses inhibitorsof histamine receptor. WO2009/129335 discloses Inhibitors of histonedeacetylase. WO2005/028434 discloses compounds which are inhibitors ofHSP90. WO2002/098876 dislcoses CAK inhibitors. EP778277 discloses CRFantagonists.

While progress has been made in this field, there is a great need todevelop a novel compound that inhibits protein kinase. In particular, itwould be desirable to develop compounds that inhibit JAK family kinasessuch as JAK1, JAK2, JAK3 and TYK2. Accordingly, the present inventionprovides novel compounds which modulate the JAK pathway and are usefulfor the prevention and/or treatment of auto-immune and/or inflammatorydiseases.

SUMMARY OF THE INVENTION

Accordingly, the present invention provides heterocyclic compound offormula (I), a pharmaceutically acceptable salt thereof, a prodrugthereof or a hydrate thereof, a pharmaceutical composition comprising acompound of formula (I) as an active ingredient, methods of production,and methods of use thereof. Particularly, the present invention providesa compound of formula (I) useful for treating or preventing autoimmuneand inflammatory disease, condition or disorder associated withdysregulation of protein kinases, preferably with Janus Kinase familysuch as JAK1, JAK2, JAK3, TYK2 or combination thereof.

It is evident from the literature that there is no potent compound inthe preclinical or clinical trial having selectivity for TYK2 over otherkinases such as JAK1, JAK2 and JAK3. A TYK2 selective inhibitor wouldnot interfere with the signaling pathways mediated/controlled by othermembers of kinases such as JAK1, JAK2, and JAK3. One drawback of some ofthe current JAK3 inhibitors is that they also have activities towardsother kinases, which also play critical roles to the signaling of manyhematopoietic cytokine and growth factor receptors.

The availability of compounds that selectively inhibit one kinasecompared to other kinases would therefore be desirable. The inventors ofthe present invention have studied heterocyclic compounds (e.g.,azaindole compounds) having excellent Janus kinase inhibitory activity,and are thus useful agents for the treatment or prevention of disease,condition or disorder mediated by Janus kinase. In particular, thecompounds of the present invention have excellent TYK2 inhibitoryactivity over other kinases, and are useful in preventing and/ortreating autoimmune and/or inflammatory disease, condition or disorderselected from, but are not limited to, rheumatoid arthritis (RA),psoriasis, organ transplant rejection, multiple sclerosis (MS),inflammatory bowel disease (IBD), chronic obstructive pulmonary disease(COPD), asthma or cancer.

Thus, one aspect of the present invention provides a compound having thestructure of formula (I),

a pharmaceutically acceptable salt thereof, a prodrug thereof or ahydrate thereof, wherein:A and B independently represent N or CR, with the proviso that both Aand B are not N;R, R′ and R″ independently represent H, (C₁-C₆) alkyl, halogen, —CN,—NR^(a)R^(b), —NR^(a)COR^(b) or —CONR^(a)R^(b), with the proviso that R′represents H, halogen or —NR^(a)COR^(b) when A is N and R″ represents H,halogen or —NR^(a)COR^(b) when B is N;R¹ represents H, (C₁-C₃) alkyl or —COR⁴;R² represents H, (C₁-C₃) alkyl, halo or —CN;R³ represents H, (C₁-C₃) alkyl, halo, —CN or —COR⁴;R⁴ represents optionally substituted phenyl, with the proviso that R¹represents —COR⁴ when A is N and R³ represents —COR⁴ when B is N;R^(a) and R^(b) independently represent H, (C₁-C₈) alkyl, (C₃-C₈)cycloalkyl or OR′″;R^(a) and R^(b) are taken together with the N atom to which they areattached to form 3-8 membered heterocyclyl, optionally containingadditional heteroatom(s) selected from N, O or S, wherein heterocyclylis optionally substituted; and R′″ is H or (C₁-C₃) alkyl.

The present invention may involve one or more of the followingembodiments associated with the compound of formula (I). For example, inone embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof, or ahydrate thereof, wherein A represents N.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein B represents N.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein A represents N, R′ represents H or —NR^(a)COR^(b) andR¹ represents —COR⁴.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein A represents N, R′ represents —NR^(a)COR^(b) and R¹represents —COR⁴.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein B represents N, R″ represents H or —NR^(a)COR^(b) andR³ represents —COR⁴.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein B represents N, R″ represents —NR^(a)COR^(b) and R³represents —COR⁴.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein R¹ represents H or (C₁-C₃) alkyl and R³ represents—COR⁴.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein R¹ represents —COR⁴ and R³ represents H, (C₁-C₃) alkyl,halo or —CN.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein R¹ represents —COR⁴ and R³ represents H.

In another embodiment, there is provided a compound of formula (I), apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof, wherein R¹ represents H and R³ represents —COR⁴.

In yet another embodiment of the present invention, there is provided acompound of formula (I), a pharmaceutically acceptable salt thereof, aprodrug thereof or a hydrate thereof, wherein R⁴ represents a groupselected from

wherein:

R⁷, R⁸ and R⁹ independently represent H, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, alkoxy, halo, —NO₂, —(CH₂)_(q)C(O)NR^(c)R^(d),—(CH₂)_(q)NR^(c)COR^(d), —(CH₂)_(q)NR^(c)CONR^(c)R^(d),—(CH₂)_(q)NR^(c)C(O)OR^(d), —(CH₂)_(q)NR^(c)R^(d),—(CH═CH)—(CH₂)_(s)C(O)OR^(e), —(CH═CH)—(CH₂)_(s)CONR^(c)R^(d),—(CH═CH)—(CH₂)_(s)CN, —(CH═CH)—(CH₂)_(s)R^(e), —(CH₂)_(s)C(O)OR^(e),—(CH)_(r)CN, —(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH₂)_(r)C(O)OR^(e),—(CH)_(r)halo, —S(O)_(p)R^(e), —S(O)_(p)NR^(c)R^(d),—NR^(c)S(O)_(p)R^(d), and wherein alkyl, alkenyl, alkynyl, cycloalkyl,aryl, heteroaryl heterocyclyl are optionally substituted;

R^(c) and R^(d) independently represent H, (C₁-C₈) alkyl, (C₃-C₈)cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,—(CH₂)_(r)OR^(e), —(CH₂)_(r)SR^(e), —(CH₂)_(r)CN, —(CH₂)_(r)halo,—(CH₂)_(r)C(O)OR^(e), —(CH₂)_(r)NR^(c)R^(d), —COR^(e), —S(O)_(p)R^(e) or—(CH₂)_(r)R^(e), wherein alkyl, cycloalkyl, aryl and heteroaryl areoptionally substituted;

R^(c) and R^(d) are taken together with the N atom to which they areattached to form 3-8 membered heterocyclyl, optionally containingadditional heteroatom(s) selected from N, O or S, wherein heterocyclylis optionally substituted;

R^(e) represents H, (C₁-C₆) alkyl, —CF₃, (C₃-C₈) cycloalkyl,heterocyclyl, aryl or heteroaryl; wherein alkyl, cycloalkyl,heterocyclyl, aryl and heteroaryl are optionally substituted;

p represents an integer of 1 or 2;

q represents an integer of 0, 1, 2 or 3;

r represents an integer of 0, 1, 2, 3 or 4; and

s represents an integer of 0, 1 or 2.

In yet another embodiment, the present invention provides a compound offormula (I), a pharmaceutically acceptable salt thereof, a prodrugthereof or a hydrate thereof, wherein R^(a) represents H or (C₁-C₃)alkyl and R^(b) represents H, (C₁-C₃) alkyl, (C₁-C₃) alkoxy or (C₃-C₅)cycloalkyl.

One embodiment of the present invention provides a compound of formula(I) selected from:

-   (2-Chloro-6-fluorophenyl)(1H-pyrrolo[2,3-c]pyridine-3-yl)methanone    (Compound No. 1),-   3,5-Dichloro-N-ethyl-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzamide    (Compound No. 2),-   (4-Amino-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone    (Compound No. 3),-   [2,6-Dichloro-4-(2-methoxypyrimidin-5-yl)phenyl](1H-pyrrolo[2,3-c]pyridin-3-yl)methanone    (Compound No. 4),-   N-[3-(2,6-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 5),-   3,5-Dichloro-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzonitrile    (Compound No. 6),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-methylbenzamide    (Compound No. 7),-   N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide    (Compound No. 8),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-ethylbenzamide    (Compound No. 9),-   (4-Bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone    (Compound No. 10),-   N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 11),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide    (Compound No. 12),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethylbenzamide    (Compound No. 13),-   3,5-Dichloro-N-(2-methoxyethyl)-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzamide    (Compound No. 14),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-propylbenzamide    (Compound No. 15),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(2-methoxyethyl)benzamide    (Compound No. 16),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-(2-methoxyethyl)benzamide    (Compound No. 17),-   N-[3-(2,6-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide    (Compound No. 18),-   N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide    (Compound No. 19),-   3,5-Dichloro-4-({5-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide    (Compound No. 20),-   N-[3-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide    (Compound No. 21),-   N-[3-(4-Bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 22),-   N-{3-[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 23),-   N-[3-(4-Bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide    (Compound No. 24),-   Methyl    3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoate    (Compound No. 25),-   N-[3-(4-Amino-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 26),-   N-{3-[4-(Acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 27),-   N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]propanamide    (Compound No. 28),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(2-hydroxyethoxy)ethyl]benzamide    (Compound No. 29),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-hydroxypropyl)benzamide    (Compound No. 30),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[3-(morpholin-4-yl)propyl]benzamide    (Compound No. 31),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(2,3-dihydroxypropyl)benzamide    (Compound No. 32),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(dimethylamino)ethyl]benzamide    (Compound No. 33),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N[2-(piperidin-1-yl)ethyl]benzamide    (Compound No. 34),-   Methyl    N-[3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycinate    (Compound No. 35),-   N-[3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycine    (Compound No. 36),-   N-[3-(2-Chloro-3,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 37),-   3,5-Dichloro-N-methyl-4-{[7-(propanoylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}benzamide    (Compound No. 38),-   N-[3-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 39),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(dimethylamino)ethyl]benzamide    (Compound No. 40),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(2-hydroxyethoxy)ethyl]benzamide    (Compound No. 41),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(piperidin-1-yl)ethyl]benzamide    (Compound No. 42),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(morpholin-4-yl)ethyl]benzamide    (Compound No. 43),-   4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(pyrrolidin-1-yl)ethyl]benzamide    (Compound No. 44),-   N-[3-(2,4,6-Trichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 45),-   N-{3-[2,6-Dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 46),-   N-{3-[2,6-Dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 47),-   N-{3-[2,6-Dichloro-4-(6-methoxypyridin-3-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 48),-   N-{3-[2,6-Dichloro-4-(6-fluoropyridin-3-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 49),-   N-{3-[2,6-Dichloro-4-(1-methyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 50),-   N-[3-(4-Cyano-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 51),-   Methyl    4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluorobenzoate    (Compound No. 52),-   N-[3-(4-Cyano-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide    (Compound No. 53),-   3,5-Dichloro-N-cyclopropyl-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzamide    (Compound No. 54),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(cyclopropylmethyl)benzamide    (Compound No. 55),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-ethoxypropyl)benzamide    (Compound No. 56),-   N-Butyl-3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzamide    (Compound No. 57),-   N-{3-[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 58),-   4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-(2-fluoroethyl)benzamide    (Compound No. 59),-   4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethyl-3,5-difluorobenzamide    (Compound No. 60),-   4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-methylbenzamide    (Compound No. 61),-   4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-(3-hydroxypropyl)benzamide    (Compound No. 62),-   4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(dimethylamino)ethyl]-3,5-difluorobenzamide    (Compound No. 63),-   4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-ethoxypropyl)-3,5-difluorobenzamide    (Compound No. 64),-   N-{3-[4-(3,5-Dimethyl-1,2-oxazol-4-yl)-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide    (Compound No. 65),-   N-(3-{2,6-Dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide    (Compound No. 66),-   N-(3-{2,6-Dichloro-4-[(ethylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide    (Compound No. 67),-   N-[3-(2,6-Dichlorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 68),-   N-[3-(4-Bromo-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 69),-   N-[3-(2,6-Difluorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide    (Compound No. 70),-   3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide    (Compound No. 71),-   3,5-Dichloro-N-methyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide    (Compound No. 72),-   3,5-Dichloro-N-ethyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide    (Compound No. 73),-   Methyl    [1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate    (Compound No. 74),-   3,5-Dichloro-N-(2-hydroxyethyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide    (Compound No. 75),-   3,5-Dichloro-N-(cyanomethyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide    (Compound No. 76),-   N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 77),-   1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-ethylurea    (Compound No. 78),-   Methyl    [3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]carbamate    (Compound No. 79),-   1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-(2-hydroxyethyl)urea    (Compound No. 80),-   3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-1,1-dimethylurea    (Compound No. 81),-   2-Cyano-N-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]acetamide    (Compound No. 82),-   (2E)-3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enamide    (Compound No. 83),-   (2E)-3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enenitrile    (Compound No. 84),-   N-(Cyclopropylcarbonyl)-N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 85),-   N-[1-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 86),-   N-{1-[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 87),-   N-{1-[2,6-Dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 88)-   N-{1-[2,6-Dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 89),-   [2,6-Dichloro-4-(hydroxymethyl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone    (Compound No. 90),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-hydroxyethyl)benzamide    (Compound No. 91),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-ethylbenzamide    (Compound No. 92),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide    (Compound No. 93),-   N-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-2-fluoroacetamide    (Compound No. 94),-   3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzonitrile    (Compound No. 95),-   N-{1-[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 96),-   N-{1-[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}acetamide    (Compound No. 97),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-methoxyethyl)benzamide    (Compound No. 98),-   N-[1-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide    (Compound No. 99),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide    (Compound No. 100),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2-methoxyethyl)benzamide    (Compound No. 101),-   Methyl    [1-(2-chloro-6-fluorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate    (Compound No. 102),-   N-(1-{2,6-Dichloro-4-[(ethylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide    (Compound No. 103),-   1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-(2-methoxyethyl)urea    (Compound No. 104),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-methylbenzamide    (Compound No. 105),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide    (Compound No. 106),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(propan-2-yl)benzamide    (Compound No. 107),-   Methyl    {1-[2,6-dichloro-4-(ethylcarbamoyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}carbamate    (Compound No. 108),-   N-(1-{2,6-Dichloro-4-[(cyclopropylcarbonyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide    (Compound No. 109),-   N-{1-[4-(Acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 110),-   N-[1-(2,6-Dichloro-4-{[(2-methoxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 111),-   N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)(methyl)    carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 112),-   N-(1-{2,6-Dichloro-4-[(cyclopropylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide    (Compound No. 113),-   N-(1-{2,6-Dichloro-4-[(cyclopropylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide    (Compound No. 114),-   N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 115),-   N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide    (Compound No. 116),-   N-(1-{2,6-Dichloro-4-[(ethylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide    (Compound No. 117),-   3,5-Dichloro-4-[(3-chloro-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-N-ethylbenzamide    (Compound No. 118),-   3,5-Dichloro-4-[(3-chloro-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]benzonitrile    (Compound No. 119),-   N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide    (Compound No. 120),-   Methyl    3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoate    (Compound No. 121)-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(dimethylamino)ethyl]benzamide    (Compound No. 122),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-hydroxypropyl)benzamide    (Compound No. 123),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(2-hydroxyethoxy)ethyl]benzamide    (Compound No. 124),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(morpholin-4-yl)ethyl]benzamide    (Compound No. 125),-   Ethyl    N-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-b-alaninate    (Compound No. 126),-   N-(2-Aminoethyl)-3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide    (Compound No. 127),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(dimethylamino)ethyl]benzamide    (Compound No. 128),-   Ethyl    N-(4-{[4-(acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichlorobenzoyl)-b-alaninate    (Compound No. 129),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide    (Compound No. 130),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-methoxypropyl)benzamide    (Compound No. 131),-   3,5-Dichloro-N-cyclobutyl-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide    (Compound No. 132),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-propylbenzamide    (Compound No. 133),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(3-methoxypropyl)benzamide    (Compound No. 134),-   N-[3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-b-alanine    (Compound No. 135),-   3,5-Dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide    (Compound No. 136),-   N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide    (Compound No. 137),-   3,5-Dichloro-N-ethyl-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide    (Compound No. 138),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(1H-indol-3-yl)ethyl]benzamide    (Compound No. 139),-   3,5-Dichloro-N-methyl-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide    (Compound No. 140),-   Ethyl    N-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alaninate    (Compound No. 141),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(2-oxoimidazolidin-1-yl)ethyl]benzamide    (Compound No. 142),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2,3-dihydroxypropyl)benzamide    (Compound No. 143),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(thiophen-2-yl)ethyl]benzamide    (Compound No. 144),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyridin-4-yl)ethyl]benzamide    (Compound No. 145),-   3,5-Dichloro-N-cyclopropyl-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide    (Compound No. 146),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(pyridin-2-ylmethyl)benzamide    (Compound No. 147),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyrrolidin-1-yl)ethyl]benzamide    (Compound No. 148),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[3-(morpholin-4-yl)propyl]benzamide    (Compound No. 149),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N[2-(piperidin-1-yl)ethyl]benzamide    (Compound No. 150),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(1-hydroxypropan-2-yl)benzamide    (Compound No. 151),-   N-[3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-L-alanine    (Compound No. 152),-   3,5-Dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide    (Compound No. 153),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-fluoroethyl)benzamide    (Compound No. 154),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2,2,2-trifluoroethyl)benzamide    (Compound No. 155),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-ethoxypropyl)benzamide    (Compound No. 156),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2-fluoroethyl)benzamide    (Compound No. 157),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(1H-indol-3-yl)ethyl]benzamide    (Compound No. 158),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[(2R)-1-methoxypropan-2-yl]benzamide    (Compound No. 159),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(pyridin-2-ylmethyl)benzamide    (Compound No. 160),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(pyridin-2-yl)ethyl]benzamide    (Compound No. 161),-   4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[3-(morpholin-4-yl)propyl]benzamide    (Compound No. 162),-   N-(1-{2,6-Dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide    (Compound No. 163),-   N-(1-{2,6-Dichloro-4-[(ethylamino)methyl]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide    (Compound No. 164),-   N-{1-[2,6-Dichloro-4-({[2-(2-oxoimidazolidin-1-yl)ethyl]amino}methyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 165),-   N-{1-[2,6-Dichloro-4-({[3-(morpholin-4-yl)propyl]amino}methyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide    (Compound No. 166),-   N-[1-(2,6-Dichloro-4-{[(3-hydroxypropyl)amino]methyl}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide    (Compound No. 167),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(1H-pyrrol-1-yl)ethyl]benzamide    (Compound No. 168),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyridin-3-yl)ethyl]benzamide    (Compound No. 169),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(cyclopropylmethyl)benzamide    (Compound No. 170),-   3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(piperidin-3-ylmethyl)benzamide    (Compound No. 171),-   N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide    (Compound No. 172),    -   or a pharmaceutically acceptable salt thereof, a prodrug thereof        or a hydrate thereof.

The present invention provides a pharmaceutical composition comprising acompound of formula (I), a pharmaceutically acceptable salt thereof, aprodrug thereof, a hydrate thereof as its active ingredient and one ormore pharmaceutically acceptable excipient(s).

Another aspect of the present invention provides a use of a compound offormula (I) or a pharmaceutically acceptable salt thereof, a prodrugthereof or a hydrate thereof, for the manufacture of a medicament fortreating or preventing disease, condition or disorder responsive to theinhibition of signal transduction pathway mediated at least in part byprotein kinase activity.

In another aspect, there is provided a method for treating or preventinga disease, condition or disorder responsive to the inhibition of signaltransduction pathway mediated at least in part by protein kinaseactivity in a patient comprising the steps of administering to the saidpatient a therapeutically effective amount of a compound of formula (I),a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydratethereof or a pharmaceutical composition thereof.

The present invention also provides a method for treating or preventingautoimmune, inflammatory or proliferative disease, condition ordisorder.

In certain embodiments, the protein kinase is Janus kinase. In anotherembodiment, Janus kinase represents JAK1, JAK2, JAK3, TYK2 orcombination thereof.

In a preferred embodiment, there is provided a method for treating orpreventing a disease, condition or disorder mediated by JAK1, JAK2,JAK3, TYK2 or combination thereof, in a patient comprising the steps ofadministering to the said patient a therapeutically effective amount ofa compound of formula (I), a pharmaceutically acceptable salt thereof,or a pharmaceutical composition thereof.

In yet another embodiment the disease is auto-immune or inflammatorydisease selected from, but not limited to, asthma, rheumatoid arthritis,psoriasis, multiple sclerosis, chronic obstructive pulmonary disease orinflammatory bowel disease.

The present invention provides a compound of formula (I), or apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof for use in a method of treating or preventing disease, conditionor disorder associated with protein kinase.

The present invention also provides processes and intermediatesdisclosed herein that are useful for preparing compounds of formula (I)and salts thereof.

The aforementioned aspects and embodiments, and other aspects, objects,features and advantages of the present invention will be apparent fromthe following detailed description and the appended claims thereof.

DETAILED DESCRIPTION OF THE INVENTION

As used herein the following definitions apply unless clearly indicatedotherwise.

It should be understood that unless expressly stated to the contrary, “acompound of general formula (I)” refers to and includes any and allcompounds described by formula (I), its embodiments, as well assubgenuses, inclusive of all salts, prodrugs and hydrates thereof. Itshould also be noted that the singular forms “a” “an” and “the” includeplural reference unless the context clearly dictates otherwise.

The term “halo” or “halogen” as used herein alone or in combinationrefers to fluorine, chlorine, bromine, and iodine.

The term “alkyl” as used herein alone or in combination refers toalkane-derived radical containing from 1 to 15 carbon atoms thatincludes a straight alkyl or branched alkyl. The straight chain orbranched alkyl group is attached at any available point to produce astable compound. In many embodiments, alkyl is a straight or branchedalkyl group containing from 1-6, 1-4, or 1-3 carbon atoms, such asmethyl, ethyl, propyl, isopropyl, butyl, t-butyl, and the like. A“substituted alkyl” denotes alkyl that is independently substituted,unless indicated otherwise, with one or more, preferably 1, 2, 3, 4 or5, more preferably 1, 2 or 3 substituents, attached at any availableatom to produce a stable compound, wherein the substituents are selectedfrom, but are not limited to, Cl, F, Br, —NO₂, —CN, —OR^(f), —SR^(f),—C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), C(S)OR^(f), (CH)_(r)NR^(f)R^(g),—C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g), —C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g),—NR^(f)C(S)R^(g), —NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h),—NR^(f)S(O)₂R^(g), —NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g),—CONR^(f)R^(g), —OC(O)R^(f), —OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f),—S(O)_(p)NR^(f)R^(g), R^(i) or R^(j).

The term “alkenyl” as used herein alone or in combination refers tostraight or branched hydrocarbon containing 2 to 10 carbon atoms and atleast one, preferably 1-3, more preferably 1-2, most preferably one,carbon to carbon double bond, which may be present either in straightchain or branched chain. Examples of alkenyl include, but are notlimited to, ethenyl, propenyl, isopropenyl, butenyl, and the like. A“substituted alkenyl” denotes alkenyl that is independently substituted,unless indicated otherwise, with one or more, preferably 1, 2, 3, 4 or5, more preferably 1, 2 or 3 substituents, attached at any availableatom to produce a stable compound, wherein the substituents are selectedfrom, but are not limited to, Cl, F, Br, —NO₂, —CN, —OR^(f), —SR^(f),—C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f), —(CH)_(r)NR^(f)R^(g),—C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g), —C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g),NR^(f)C(S)R^(g), —NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h),—NR^(f)S(O)₂R^(g), —NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g),CONR^(f)R^(g), —OC(O)R^(f), —OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f),—S(O)_(p)NR^(f)R^(g), R^(i) or R^(j).

The term “alkynyl” as used herein alone or in combination refers tostraight or branched hydrocarbon containing 2 to 10 carbon atoms and atleast one, preferably one carbon to carbon triple bond, which may bepresent either in straight chain or branched chain. Examples of alkynylinclude, but are not limited to, ethynyl, propynyl, butyryl, and thelike. A “substituted alkynyl” denotes alkynyl that is independentlysubstituted, unless indicated otherwise, with one or more, preferably 1,2, 3, 4 or 5, more preferably 1, 2 or 3 substituents, attached at anyavailable atom to produce a stable compound, wherein the substituentsare selected from, but are not limited to, Cl, F, Br, —NO₂, —CN,—OR^(f), —SR^(f), —C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f),—(CH)_(r)NR^(f)R^(g), —C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g),—C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g), —NR^(f)C(S)R^(g),—NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h), —NR^(f)S(O)₂R^(g),—NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g), —CONR^(f)R^(g), —OC(O)R^(f),—OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f), —S(O)_(p)NR^(f)R^(g), R^(i)or R^(j).

The term “alkoxy” as used herein alone or in combination refers to alkylor substituted alkyl, as defined above, bonded to an oxygen atom.Representative examples of alkoxy group include, but are not limited tomethoxy, ethoxy, tert-butoxy, trifluoromethoxy, etc.

The term “cycloalkyl” as used herein refers to saturated or unsaturatednon-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3to 10, preferably 3 to 8, more preferably 3 to 6 ring members per ring.Examples of cycloalkyl include, but are not limited to, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, adamantly, and the like. A“substituted cycloalkyl” denotes cycloalkyl that is independentlysubstituted, unless indicated otherwise, with one or more, preferably 1,2, 3, 4 or 5, more preferably 1, 2 or 3 substituents, attached at anyavailable atom to produce a stable compound, wherein the substituentsare selected from, but are not limited to, Cl, F, Br, —NO₂, —CN,—OR^(f), —SR^(f), —C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f),—(CH)_(r)NR^(f)R^(g), —C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g),—C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g), —NR^(f)C(S)R^(g),—NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h), —NR^(f)S(O)₂R^(g),—NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g), —CONR^(f)R^(g), —OC(O)R^(f),—OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f), —S(O)_(p)NR^(f)R^(g), R^(i)or R^(j).

The term “heterocycloalkyl” as used herein refers to a saturated orunsaturated non-aromatic mono or polycyclic cycloalkyl group in whichfrom 1 to 3 carbon atoms in the ring are replaced by heteroatom selectedfrom oxygen, sulphur, phosphorus or nitrogen. Heterocycloalkyl is alsointended to include oxidized S or N, such as sulfinyl, sulfonyl, andN-oxide of tertiary ring nitrogen. Heterocycloalkyl is also intended toinclude compounds, in which a ring carbon may be oxo substituted, i.e.,the ring carbon is carbonyl group, such as lacyones and lactams.Heterocycloalkyl is also intended to include fused, bridged and spiroring system. Preferably, heterocycloalkyl rings are optionally fusedwith benzo or 5 to 6 membered heteroaryl ring. The point of attachmentof the heterocycloalkyl ring is at a carbon or nitrogen atom such that astable ring is retained. Examples of heterocycloalkyl include, but arenot limited to, oxiranyl, thiaarnyl, aziridinyl, oxetanyl, thiatanyl,azetidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl,tetrahydropyranyl, pyranyl, tetrahydrothiopyranyl, thiopyranyl,piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl, morpholinyl, thiomorpholinyl,1,4-dithianyl, piperazinyl, 1,4-azathianyl, oxepanyl, thiepanyl,azepanyl, 1,4-dioxepanyl, 1,4-oxathiepanyl, 1,4-oxaazepanyl,1,4-dithiepanyl, 1,4-thieazepanyl, 1,4-azaphosphinanyl, 1,4-diazepanyl,1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl,tetrahydrothiadiazinyl, 1,2-tetrahydrodiazin-2-yl,1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, chromanyl, chromenyl,isooxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl,1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl,7-oxa-1-aza-spiro[4,4]nonanyl, 3-azabicyclo[3.1.0]hexanyl, indolinyl,dihydroindolinyl, octahydro-1H-indolyl,octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[4.1.0]heptanyl,3,4-dihydro-2H-pyranyl, 1,2,3,4-tetrahydropyridinyl,1,2,5,6-tetrahydropyridinyl, or tetrahydro-1H-benzo[d]azepinyl, etc. A“substituted heterocycloalkyl” denotes heterocycloalkyl that isindependently substituted, unless indicated otherwise, with one or more,preferably 1, 2, 3, 4 or 5, more preferably 1, 2 or 3 substituents,attached at any available atom to produce a stable compound, wherein thesubstituents are selected from, but are not limited to, Cl, F, Br, —NO₂,—CN, —OR^(f), —SR^(f), —C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f),—(CH)_(r)NR^(f)R^(g), —C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g),—C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g), NR^(f)C(S)R^(g),—NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h), —NR^(f)S(O)₂R^(g),—NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g), —CONR^(f)R^(g), —OC(O)R^(f),—OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f), —S(O)_(p)NR^(f)R^(g), R^(i)or R^(j).

The term “heterocycloalkylalkyl” as used herein refers to alkyl group,as defined above, having a heterocycloalkyl group, as defined above, asa substituent. Examples include, but are not limited to,piperidinylmethyl, pyrrolidinylethyl, etc.

The term “aryl” as used herein alone or in combination refers tomonocyclic and polycyclic aromatic hydrocarbon ring systems containingthe requisite number of carbon atoms as described above. Representativeexamples include, but not limited to, phenyl, naphhthyl, etc. A“substituted aryl” denotes aryl that is independently substituted,unless indicated otherwise, with one or more, preferably 1, 2, 3, 4 or5, more preferably 1, 2 or 3 substituents, attached at any availableatom to produce a stable compound, wherein the substituents are selectedfrom, but are not limited to, Cl, F, Br, —NO₂, —CN, —OR^(f), —SR^(f),—C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f), —(CH)_(r)NR^(f)R^(g),—C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g), —C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g),—NR^(f)C(S)R^(g), —NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h),—NR^(f)S(O)₂R^(g), —NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g),—CONR^(f)R^(g), —OC(O)R^(f), —OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f),—S(O)_(p)NR^(f)R^(g), R^(i) or R^(j).

The term “aralkyl” as used herein alone or in combination refers toalkyl, as defined above, having aryl group, as defined above, as asubstituent, for example, benzyl, phenylethyl, etc.

The term “heteroaryl” as used herein alone or in combination refers tomonocyclic or polycyclic aromatic ring systems containing requisitenumber of carbon atoms, and at least one heteroatom selected from N, Oor S. polycyclic ring systems may contain aromatic portions, while otherportions of the ring system may be fully saturated or non-aromatic.Representative examples of heteroaryl include, but are not limited topyrrolyl, furanyl, thiophenyl, thienyl, pyrazolyl, imidazolyl,isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3-triazolyl,1,2,4-triazolyl, tetrazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl,1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl,1,2,4-thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,1,2,3-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl,purinyl, 6,7-dihydro-5H-Npyrindinyl, benzo[b]thiophenyl, benzoxazolyl,benzothiazolyl, benzoisothiazolyl, benzoisoxazolyl, benzimidazolyl,benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl,indazolyl, isoquinolinyl, quinolinyl, phthalazinyl, quinoxalinyl,quinazolinyl, benzoxazinyl, and the like. A “substituted heteroaryl”denotes heteroaryl that is independently substituted, unless indicatedotherwise, with one or more, preferably 1, 2, 3, 4 or 5, more preferably1, 2 or 3 substituents, attached at any available atom to produce astable compound, wherein the substituents are selected from, but are notlimited to, Cl, F, Br, —NO₂, —CN, —OR^(f), —SR^(f), —C(O)R^(f),—C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f), —(CH)_(r)NR^(f)R^(g),—C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g), —C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g),—NR^(f)C(S)R^(g), —NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h),—NR^(f)S(O)₂R^(g), —NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g),—CONR^(f)R^(g), —OC(O)R^(f), —OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f),—S(O)_(p)NR^(f)R^(g), R^(i) or R^(j).

The term “heteroarylalkyl” as used herein refers to alkyl group, asdefined above, having a heteroaryl group, as defined above, as asubstituent. Examples include, but are not limited to, pyridinylmethyl,pyrrolidinylethyl, etc.

The term “optionally substituted alkyl, alkenyl, alkenyl, cycloalkyl,aryl and heteroaryl” as used herein refers to alkyl, alkenyl, alkenyl,cycloalkyl, aryl and heteroaryl optionally substituted with one or moresubstituent(s) independently selected from, but are not limited to,halogen, —NO₂, —CN, —OR^(f), —SR^(f), —C(O)R^(f), —C(S)R^(f),—C(O)OR^(f), C(S)OR^(f), —(CH)_(r)NR^(f)R^(g), —C(O)NR^(f)R^(g),—C(S)NR^(f)R^(g), —C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g), —NR^(f)C(S)R^(g),—NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h), —NR^(f)S(O)₂R^(g),—NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g), —CONR^(f)R^(g), —OC(O)R^(f),—OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f), —S(O)_(p)NR^(f)R^(g), R^(i)or R^(j). In a preferred embodiment, one or more substituents areselected from C₁-C₆ alkyl, halogen, —NO₂, —CN, —OR^(f), —C(O)R^(f) or—NR^(f)R^(g), C(O)NR^(f)R^(g), —NR^(f)C(O)R^(g) or heteroaryl.

The variables R^(f), R^(g), R^(h), R^(i) and R^(j) as used in thedescription of optional substituents for alkyl, alkynyl, cycloalkyl,heterocycloalkyl, aryl, and heteroaryl are as follows.

R^(f), R^(g) and R^(h) independently represent H, R^(i) or R^(j). R^(f)and R^(g) or R^(g) and R^(h) along with nitrogen atom to which they areattached form 3-8 membered optionally substituted heterocyclyl group,optionally containing one or more heteroatom(s) selected from N, O or S.

R^(i) represents alkyl, alkenyl, alkynyl or cycloalkyl, wherein alkyl,alkenyl, alkynyl or cycloalkyl is optionally substituted with one ormore, preferably 1, 2 or 3 substitutents selected from, but are notlimited to, halogen, —NO₂, —CN, —OR^(f), —SR^(f), —C(O)R^(f),—C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f), —(CH)_(r)NR^(f)R^(g),—C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g), —C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g),—NR^(f)C(S)R^(g), —NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h),—NR^(f)S(O)₂R^(g), —NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g),—CONR^(f)R^(g), —OC(O)R^(f), OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f)or —S(O)_(p)NR^(f)R^(g), wherein R^(f), R^(g) and R^(h) are as definedhereinbefore.

R^(j) represents aryl, heteroaryl and heterocyclyl wherein aryl,heteroaryl or heterocyclyl is optionally substituted with one or more,preferably 1, 2, 3, 4 or 5, more preferably 1, 2 or 3, most preferably 1or 2 substitutents selected from, but are not limited to, halogen, —NO₂,—CN, —OR^(f), —SR^(f), —C(O)R^(f), —C(S)R^(f), —C(O)OR^(f), —C(S)OR^(f),—(CH)_(r)NR^(f)R^(g), —C(O)NR^(f)R^(g), —C(S)NR^(f)R^(g),—C(NH)NR^(f)R^(g), —NR^(f)C(O)R^(g), —NR^(f)C(S)R^(g),—NR^(f)C(O)NR^(g)R^(h), —NR^(f)C(S)NR^(g)R^(h), —NR^(f)S(O)₂R^(g),—NR^(f)S(O)₂NR^(g)R^(h), —NR^(f)C(O)OR^(g), —CONR^(f)R^(g), —OC(O)R^(f),—OC(S)R^(f), —(CH)_(r)halo, —S(O)_(p)R^(f) or —S(O)_(p)NR^(f)R^(g),wherein R^(f), R^(g) and R^(h) are as defined hereinbefore.

Preferred substituents in the heterocyclic compounds of formula (I)according to the present invention are described hereinafter.

The values for R¹ include, but are not limited to, H, methyl, ethyl,propyl or —COR⁴, wherein R⁴ is phenyl optionally substituted with two ormore substituents independently selected from R⁵, R⁶, R⁷, R⁸ or R⁹.

The values for R² include, but are not limited to, H, methyl, ethyl,propyl or isopropyl.

The values for R³ include, but are not limited to H, methyl, ethyl,propyl, Cl, Br, F or —COR⁴, wherein R⁴ is phenyl optionally substitutedwith two or more substituents selected from R⁵, R⁶, R⁷, R⁸ or R⁹.

R⁵, R⁶, R⁷, R⁸ and R⁹ independently represent H, alkyl, alkenyl,alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,heterocyclyl, heterocyclylalkyl, alkoxy, halo, —NO₂,—(CH₂)_(q)C(O)NR^(c)R^(d), —(CH₂)_(q)NR^(c)COR^(d),—(CH₂)_(q)NR^(c)CONR^(c)R^(d), —(CH₂)_(q)NR^(c)C(O)OR^(d),—(CH₂)_(q)NR^(c)R^(d), —(CH═CH)—(CH₂)_(s)C(O)OR^(e),—(CH═CH)—(CH₂)_(s)CONR^(c)R^(d), —(CH═CH)—(CH₂)_(s)CN,—(CH═CH)—(CH₂)_(s)R^(e), —(CH₂)_(s)C(O)OR^(e), —(CH)_(r)CN,—(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH₂)_(r)C(O)OR^(e), —(CH)_(r)halo,—S(O)_(p)R^(e), —S(O)_(p)NR^(c)R^(d), —NR^(c)S(O)_(p)R^(d), and whereinalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl heterocyclyl areoptionally substituted and R^(c), R^(d), R^(e), p, q, r and s are asdefined hereinbefore.

In one embodiment, R⁵ and R⁶ independently represent, but are notlimited to, H, Cl, Br, F, —CN, —NO₂, —NH₂, —CH₃, —C₂H₅, —OCF₃, —OCH₃,—CH₂OH or —COOH. In a preferred embodiment, R⁵ and R⁶ independentlyrepresent H, Cl, Br, F, —CN, —NO₂, —NH₂, —CH₃ or —OCH₃.

In another embodiment, R⁷ and R⁸ independently represent, but are notlimited to, H, Cl, Br, F, —CN, —NO₂, —NH₂, NHCOCH₃ or NHCOC₂H₅.

In another embodiment, R⁹ represents, but are not limited to, H, Cl, Br,—CN, —NO₂, —NH₂, —CH₃, —C₂H₅, —OCF₃, —OCH₃, —CH₂OH, —COOH, —C(O)OCH₃,—(CH═CH)—COOH, —(CH═CH)—CH₂COOH, —(CH═CH)—CONH₂, —(CH═CH)—CH₂CONH₂,—(CH═CH)CN, —(CH═CH)CH₂CN, —CO(heterocyclyl), —CH₂CH₂CN, —CH₂CN,—(CH═CH)—CONHC₂H₅, —(CH═CH)phenyl, —(CH═CH)CH₂phenyl, —CH₂CH₂C(O)OC₂H₅,—CH₂CH₂CONHC₂H₅, —CH₂CH₂CONH₂, —CH₂CH₂COOH, —CH₂CH₂CN,—(CH₂)₃(morpholinyl), —CH₂NH(CH₂)₃OH or —CH₂NHC₂H₅.

In another embodiment, R⁹ represents, but are not limited to, —CONH₂,—CONHCH₃, —CON(CH₃)₂, —CONHC₂H₅, —CONHC₃H₇, —CONHC(CH₃)₂, —CONHCH₂CH₂OH,—CONHCH₂CH₂OCH₃, —CONHCH₂CN, —CONH(cycloalkyl), —CONHCH₂C(CH₃)₂,—CON(C₂H₅)₂, —CONHCH₂CH₂OCH₂CH₂OH, —CONH(CH₂)₁₋₃(heterocyclyl),—CONH(CH₂)₁₋₃(heteroaryl), —CONHCH₂CH(OH)CH₂OH, —CONHCH₂CH₂N(CH₃)₂,—CONH(CH₂)₁₋₃C(O)OCH₃, —CONH(CH₂)₁₋₃C(O)OC₂H₅, —CONHCH(CH₃)C(O)OC₂H₅,—CONHCH(CH₃)C₃H₇, —CONHCH(CH₃)CH₂OH, —CONHCH(CH₃)COOH,—CONH(CH₂)₁₋₃COOH, —CONHCH(CH₃)CH₂OCH₃, —CONHCH₂(cycloalkyl),—CONH(CH₂)₁₋₃OCH₃, —CONH(CH₂)₁₋₃OC₂H₅, —CONH(CH₂)₃CH₃, —CONHCH₂CH₂F,—CONHCH₂CF₃, —CONHCH₂CH₂NH₂, wherein cycloalkyl, heterocyclyl andheteroaryl are optionally substituted.

In another embodiment, R⁹ represents, but are not limited to, —N(CH₃)₂,—NHCONHC₂H₅, —NHC(O)OCH₃, —NHC(O)O(tert-butyl),—N(benzyl)C(O)O(tert-butyl), —NHCONHCH₂CH₂OH, —NHCONHCH₂CH₂OCH₃,—NHCON(CH₃)₂, —NH(heteroaryl), —NHCH₂phenyl, —NHCOCH₂CN,—NHCO(cycloalkyl), —NHCOCH₂OH, —NHCOCH₃, —NHCOC₂H₅, —NHCOCH₂F,—NHCOCH₂Cl, —NHCOCH₂(heteroaryl), —NH(SO₂)CH₃, —NHC(O)OC(CH₃)₃, —NHCH₃,—NH(cycloalkyl), —NHCON(CH₃)CH₂CH₂OH, —NHCONH(cycloalkyl), —NHCONHC₃H₇,—NHCONHC₂H₅, —N(CH₃)CH₂C(O)OCH₃ or —NCH₃CH₂C(O)OH, wherein cycloalkyl,phenyl, heteroaryl and heterocyclyl are optionally substituted.

In another embodiment, R⁹ represents, but are not limited to,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl,piperazinyl, pyrrolidinyl, azetidinyl, pyrazolyl, imidazolyl,isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyridinyl, pyridazinyl,pyrimidinyl or pyrazinyl ring, wherein the ring is optionallysubstituted with halo, alkyl or alkoxy.

Preferred values for the descriptors R, R′ and R″ include, but are notlimited to, H, Cl, Br, F, —CN, —NH₂, —NHC₂H₅, —NHCH₃, —NH(heteroaryl),—NH(aryl), —NHC(O)OCH₃, —NHCOCH₂Cl, —NHCOCH₂F, —NHCOCH₂CF₃, —CONH₂,—NHCOCH₃, —NHCO-cyclopropyl, —NHCO-cyclobutyl, —NHCO-cyclopentyl,—NHCO-cyclohexyl, —N(CO-cyclopropyl)₂, —NHC(O)OC₂H₅, —NHCONHC₂H₅,—NHCOC(CH₃)₂, —NHCOC(CH₃)₃ or —NH—(C₁-C₉) alkyl, wherein alkyl, aryl andheteroaryl are optionally substituted. In particular, R′ and R″ areselected from, but are not limited, to, H, —NHC(O)OCH₃, —NHC(O)OC₂H₅,—NHCOCH₂Cl, —NHCOCH₂F, —NHCOCH₃, —NHCOC₂H₅, —NHCO-cyclopropyl or—NHCO-cyclobutyl.

According to another preferred embodiment of the present invention,there is provided a compound of formula (I), a pharmaceuticallyacceptable salt thereof, a prodrug thereof or a hydrate thereof, whereinR⁴ represents a group selected from:

wherein:

R⁷ and R⁸ independently represent, but are not limited to, H, Cl, Br,—CN, —NO₂, —NH₂, —NHCOCH₃ or —NHCOC₂H₅;

R⁹ represents H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, alkoxy,halo, —NO₂, —(CH₂)_(q)C(O)NR^(c)R^(d), —(CH₂)_(q)NR^(c)COR^(d),—(CH₂)_(q)NR^(c)CONR^(c)R^(d), —(CH₂)_(q)NR^(c)C(O)OR^(d),—(CH₂)_(q)NR^(c)R^(d), —(CH═CH)—(CH₂)_(s)C(O)OR^(e),—(CH═CH)—(CH₂)_(s)CONR^(c)R^(d), —(CH═CH)—(CH₂)_(s)CN,—(CH═CH)—(CH₂)_(s)R^(e), —(CH₂)_(s)C(O)OR^(e), —(CH)_(r)CN,—(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH₂)_(r)C(O)OR^(e), —(CH)_(r)halo,—S(O)_(p)R^(e), —S(O)_(p)NR^(c)R^(d), —NR^(c)S(O)_(p)R^(d), and whereinalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl heterocyclyl areoptionally substituted; and R^(a), R^(b), R^(c), R^(d), R^(e), p, q, rand s are as defined hereinbefore.

Yet another embodiment of the present invention provides a compoundhaving the structure of formula (IA),

a pharmaceutically acceptable salt thereof, a prodrug thereof or ahydrate thereof, wherein:R and R′ independently represent H, (C₁-C₆) alkyl, halogen, —CN,—NR^(a)R^(b), —NR^(a)COR^(b) or —CONR^(a)R^(b);R″ represents H, halogen or —NR^(a)COR^(b);R¹ and R² are independently represent H or (C₁-C₃) alkyl;R⁵ and R⁶ independently represent H, Cl, Br, F, —CN, —NO₂, —NH₂, —CH₃,—C₂H₅, —OCF₃, —OCH₃, —CH₂OH or —COOH;R⁷ and R⁸ independently represent H, Cl, Br, —CN, —NO₂, —NH₂, —NHCOCH₃or —NHCOC₂H₅;R⁹ represents H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, alkoxy,halo, —NO₂, —(CH₂)_(q)C(O)NR^(c)R^(d), —(CH₂)_(q)NR^(c)COR^(d),—(CH₂)_(q)NR^(c)CONR^(c)R^(d), —(CH₂)_(q)NR^(c)C(O)OR^(d),—(CH₂)_(q)NR^(c)R^(d), —(CH═CH)—(CH₂)_(s)C(O)OR^(e),—(CH═CH)—(CH₂)_(s)CONR^(c)R^(d), —(CH═CH)—(CH₂)_(s)CN,—(CH═CH)—(CH₂)_(s)R^(e), —(CH₂)_(s)C(O)OR^(e), —(CH)_(r)CN,—(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH₂)_(r)C(O)OR^(e), —(CH)_(r)halo,—S(O)_(p)R^(e), —S(O)_(p)NR^(c)R^(d), —NR^(c)S(O)_(p)R^(d), and whereinalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl heterocyclyl areoptionally substituted; and R^(a), R^(b), R^(b), R^(d), R^(e), p, q, rand s are as defined hereinbefore.

Yet another embodiment of the present invention provides a compoundhaving the structure of formula (IB),

R and R″ independently represent H, (C₁-C₆) alkyl, halogen, —CN,—NR^(a)R^(b), —NR^(a)COR^(b) or —CONR^(a)R^(b);R′ represents H, halogen or —NR^(a)COR^(b);R² represents H or (C₁-C₃) alkyl;R³ represents H, halo, —CN or (C₁-C₃) alkyl;R⁵ and R⁶ independently represent H, Cl, Br, F, —CN, —NO₂, —NH₂, —CH₃,—C₂H₅, —OCF₃, —OCH₃, —CH₂OH or —COON.R⁷ and R⁸ independently represent H, Cl, Br, F, —CN, —NO₂, —NH₂,—NHCOCH₃ or —NHCOC₂H₅.R⁹ represents H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, alkoxy,halo, —NO₂, —(CH₂)_(q)C(O)NR^(c)R^(d), —(CH₂)_(q)NR^(c)COR^(d),—(CH₂)_(q)NR^(c)CONR^(c)R^(d), —(CH₂)_(q)NR^(c)C(O)OR^(d),—(CH₂)_(q)NR^(c)R^(d), —(CH═CH)—(CH₂)_(s)C(O)OR^(e),—(CH═CH)—(CH₂)_(s)CONR^(c)R^(d), —(CH═CH)—(CH₂)_(s)CN,—(CH═CH)—(CH₂)_(s)R^(e), —(CH₂)_(s)C(O)OR^(e), —(CH)_(r)CN,—(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH₂)_(r)C(O)OR^(e), —(CH)_(r)halo,—S(O)_(p)R^(e), —S(O)_(p)NR^(c)R^(d), —NR^(c)S(O)_(p)R^(d), and whereinalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl heterocyclyl areoptionally substituted; and R^(a), R^(b), R^(b), R^(d), R^(e), p, q, rand s are as defined hereinbefore.

In certain embodiments, the compound of formula (IA) is represented byfollowing formulae:

wherein R, R′, R¹, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined for formula (IA)and R^(b) represents —(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH)_(r)halo,alkyl or cycloalkyl.

In certain embodiments, the compound of formula (IA) is represented byfollowing formulae:

wherein R, R′, R″, R¹, R², R⁵, R⁶, R⁷ and R⁸ are as defined for formula(I).

In certain embodiments, the compound of formula (IB) is represented byfollowing formulae:

wherein R, R″, R², R³, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined for formula(IB) and R^(b) represents —(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e),—(CH)_(r)halo, alkyl or cycloalkyl.

In certain embodiments, the compound of formula (IB) is represented byfollowing formulae:

wherein R^(a), R^(b), R, R′, R″, R¹, R², R³, R⁵, R⁶, R⁷, R⁸ and R⁹ areas defined for formula (I) and T represents CN or CONH₂.

The compounds of formula (I) including their embodiments, subgenuses andintermediates described herein may be isolated in the form of apharmaceutically acceptable salt. It should be understood that the term“pharmaceutically acceptable salt” as used herein refers to salts thatare chemically and/or physically compatible with other ingredientscomprising a formulation, and/or are physiologically compatible with therecipient thereof. The pharmaceutically acceptable salts are however notlimited to the salts approved by a regulatory authority such as FDA forclinical or therapeutic use in humans. It should be understood that allsalts known to a person of ordinary skill in the art including mixedsalt forms are within the scope of the instant application. Thepharmaceutically salts of the compounds of the present invention can beprepared in situ during the isolation and/or purification of a compound,or by separately reacting the compound with a suitable organic orinorganic acid or base and isolating the salt thus formed. The compoundsof the present invention have a basic group such as an amino group or anacidic group such as carboxylic group and accordingly their salts can beprepared by reacting with an acid or base, respectively. The salts maybe precipitated (with or without the addition of one or more so-solventsand/or anti-solvents) and collected by filtration or the salts may berecovered by evaporation of solvents(s). The salts of the presentinvention may also be formed via a “salt switch” or ion exchange/doubledisplacement reaction. It should also be understood that the salts maybe prepared and/or isolated using a single method or a combination ofmethods.

Representative salts include, but are not limited to, acetate,ascorbate, aspartate, benzoate, besylate, bicarbonate, carbonate,bisulfate, sulfate, borate, camsylate, citrate, edisylate, esylate,formate, fumarate, gluconate, glucuronate, glutamate,hexafluorophosphate, chloride, bromide, iodide, lactate, malate,maleate, malonate, mesylate, methanesulfonate, ethanesulfonate,benzenesulfonate, p-toluenesulfonate, methylsulphate, nicotinate,nitrate, bisulphate, oxalate, palmitate, pamoate, hydrogen phosphate,dihydrogen phosphate, phosphate, stearate, saccharate, succinate,salicylate, tartrate, bitartrate, tannate, tosylate or trifluoroacetate.Other examples of representative salts include alkali or alkaline earthmetal cations such as sodium, lithium, potassium, calcium, magnesium,and the like, as well as non-toxic ammonium, quaternary ammonium andamine cations including, but are not limited to, ammonium,tetramethylammonium, tetraethylammonium, lysine, arginine, benzathine,choline, tromethamine, diolamine, glycine, meglumine, olamine, and thelike.

The term “prodrug” as used herein refers to a compound that istransformed in vivo to yield the parent compound, wherein the in vivotransformation may occur by various mechanisms such as hydrolysis by thegastric acid under the physiological condition or enzymatic hydrolysis.Examples of prodrugs are compounds, wherein the amino group or hydroxylgroup in a compound of the present invention is acylated, alkylated,phosphorylated or sulphonated, glycosylated or wherein the carboxylgroup is esterified or amidated. A prodrug of a compound of formula (I)may be formed in a conventional manner, for example, if a compound offormula (I) contains a carboxylic acid functional group, a prodrug canbe formed by replacement of a hydrogen atom of the acid group with agroup such as alkyl or aryl. Similarly, a prodrug may be formed by anymethods well known in the art.

Discussion regarding prodrugs and their use can be found in, forexample, see Stella et al., “Prodrugs: A Chemical Approach to TargetedDrug Delivery,” Directed Drug Delivery, Borchardt et al., (ed), pp.247-267, Hamana Press (1985); Bioreversible Carriers in Drug Design,Pergamon Press, 1987 (ed. E B Roche, American PharmaceuticalAssociation).

The term “bioavailability” as used herein refers to the systemicavailability of a given amount of a drug administered to a patient. Itis an absolute term that indicates measurement of both the time andtotal amount of drug that reaches the general circulation from anadministered dosage form.

The term “pharmaceutically acceptable” as used herein refers to acompound of formula (I) or pharmaceutical composition thereof issuitable for administration to humans. Preferably, this term meansapproved by a regulatory agencies such as EMEA (Europe) and/or FDAand/or any other National Regulatory Agency for use in animals,preferably humans.

The term “patient” as used herein refers to human subjects and otheranimal subjects. In this context, the terms “subject”, “animal subject”,and the like refer to human such as men and women, and non-humanvertebrates, for example mammals such as non-human primates, sports andcommercial animals, and pets (e.g., canines and felines). Preferably,the patient is human subject.

The term “hydrate” as used herein refers to hydrate formed by theassociation of one or more water molecules to a compound of formula (I).The water molecule may be bounded or freely available on to the surfaceof a compound of formula (I). Representative examples of hydrate, butare not limited to, monohydrate, dehydrate, trihydrate, tetrahydrate,and the like. Certain compounds of the present invention can also existin a solvate form, wherein the term “solvate” refers to association ofsolvent molecules with a compound of formula (I). The solvent may beorganic, inorganic or combination of both. All such solvate forms of acompound of formula (I) are considered to be within the scope of thepresent invention.

The term “therapeutically effective amount” as used herein refers to anamount of a compound of formula (I) sufficient to treat or prevent aspecific disease, disorder, condition or one or more of its symptoms.The amount of a compound which constitutes an effective amount will varydepending on the various factors including for example, the compoundbeing used, the disease state and its severity, the age of the patientto be treated, and the like. The said effective amount can be determinedroutinely by a person of ordinary skill in the art.

The present invention also intends to encompass the metabolites of acompound of formula (I). The term “metabolites” means all moleculesderived from any of the compounds of formula (I) in a cell or organism,preferably mammal. The structure of the metabolites of the compoundsaccording to the present invention will be understood by any personhaving ordinary skill in the art, using the various appropriate methods.

Certain compounds of the present invention may have one or moreasymmetric centers and therefore can exist in a number of stereoisomericand diastereomeric configurations. All such configurations are withinthe scope of the present invention. Where the compound of formula (I)contain asymmetric centers, such compounds can be synthesized and/orisolated as mixtures of enantiomers and/or as individual enantiomers, aswell as diastereomers and mixtures of different diastereomers.

In practice, resolution and isolation of pure enantiomers can beachieved using methods well known in the art. The examples include, butare not limited to, (a) by formation of diastereomeric salts which maybe separated, for example, by crystallization; (b) by formationdiastereomeric derivatives or complexes which may be separated, forexample, by crystallization, gas-liquid or liquid chromatography; (c) byselective reaction of one enantiomer with an enantiomer specificreagent, for example enzymatic esterification; (d) by using an opticallyactive starting material; (e) by asymmetric synthesis using opticallyactive reagents, substrates, catalysts or solvents; or (f) by convertingone stereoisomer into the other by asymmetric transformation orinversion. It will be appreciated and understood by one of ordinaryskill in the art that where the desired stereoisomer is converted intoanother chemical entity by one of the separation procedures describedabove, one or more steps may additionally be required to liberate thedesired enantiomeric form.

Certain compounds of the present invention may have one or more olefinicdouble bonds or other centers of geometric asymmetry. Unless specifiedotherwise, it is intended that both E and Z geometric isomers of suchcompounds are within the scope of the present invention.

The compounds of the present invention have utility over a wide range oftherapeutic applications and may be used to treat or prevent a varietyof diseases, conditions and/or disorders responsive to the inhibition ofsignal transduction pathway mediated at least in part by proteinactivity, in a patient including men and women, as well as a mammal ingeneral. For example, such diseases and disorders include, but are notlimited to, those associated with cardiovascular disease, proliferativedisease, inflammatory disease or autoimmune disease. The term proteinkinase is preferably meant to include Janus kinase, wherein Janus kinaseis selected from JAK1, JAK2, JAK3, TYK2 or combination thereof.

As shown in the specification, the compounds of the present inventionwere tested for their selectivity for TYK2 over other kinases such asJAK1, JAK2 and JAK3. In certain embodiments, the compounds of theinstant invention bind TYK2 more selectively than JAK1, JAK2 or JAK3. Asa result of these findings, the compounds of the present invention areconsidered to be useful for the prevention and/or treatment of diseasesand/or disorders associated with TYK2, for example inflammatory,autoimmune, proliferative diseases (such as cancer), Transplantrejection or Graft-versus-host disease.

Thus, one object of the present invention is to provide a method fortreating or preventing a disease, condition or disorder associated withprotein kinase activity.

Another object of the present invention is to provide a method fortreating or preventing a disease, condition or disorder associated withJanus kinase activity, preferably JAK1, JAK2, JAK3, TYK2 or combinationthereof, and most preferably with TYK2.

According to another object of the present invention, there is provideda method for treating or preventing inflammatory disease, condition ordisorder.

In another object there is provided a method for treating or preventingautoimmune disease, condition or disorder.

In yet another object there is provided a method for treating orpreventing proliferative disease, condition or disorder.

The term “inflammatory disease” as used herein refers to theinflammation of tissues and organs which results from activation of thecytokine family of receptors. The inflammatory diseases or disordersassociated with activation of TYK2 include, but are not limited to, skininflammation, skin inflammation due to radiation exposure, asthma,chronic obstructive pulmonary disease, allergic inflammation and chronicinflammation.

The term “autoimmune disease” as used herein refers to a disease whichis partially provoked by an immune reaction of the body against owncomponents, for example DNA, lipids, protein, and the like. Theautoimmune disease could be organ-specific or non-organ specific.Representative examples of organic-specific include, but are not limitedto, insulin-dependent diabetes (Type I), celiac disease, psoriasis,inflammatory bowel disease, chronic active hepatitis, polycystic ovarysyndrome, pernicious anemia, ankylosing spondylitis, Hashimoto'sthyroiditis and Graves' disease which affects the thyroid gland,Cushing's disease and Addison's disease which affect the adrenal glands,and the like. The non-limiting examples of non-organ specific autoimmunedisease include rheumatoid arthritis, multiple sclerosis, systemic lupuserythmetosus or myasthenia gravis.

The proliferative disease or disorder refers to increased cellmultiplication as observed in myeloproliferative disorders such aspolycythemia vera.

Cancer comprises a group of diseases characterized by uncontrolledgrowth and spread of abnormal cells. Typically, cancers are classifiedas hematological cancers (e.g., leukemias or lymphomas) and solidcancers such as sarcomas and carcinomas (e.g., cancer of the breast,brain, lung, colon, stomach, liver, pancreas, prostate or ovary). Inparticular, cancers in which the JAK-STAT signal transduction pathway isactivated. For example due to activation of TYK2 are expected to respondto treatment with TYK2 inhibitors.

Transplant rejection (allograft transplant rejection) includes, but isnot limited to, acute and chronic allograft rejection following forexample transplantation of kidney, heart, liver, lung, bone marrow, skinand cornea. It is known that T cells play a central role in the specificimmune response of allograft rejection.

Graft-versus-host disease (GVDH) is a major complication in allogenicbone marrow transplantation. It is caused by donor T cells thatrecognize and react to recipient differences in the histocompatibilitycomplex system, resulting in significant morbidity and mortality.

Inflammatory bowel disease (IBD) is characterized by a chronic relapsingintestinal inflammation. It is subdivided into Crohn's disease andulcerative colitis phenotypes. Psoriasis is a chronic inflammatorydermatosis that affects approximately 2% of the population. Multiplesclerosis is an inflammatory and demyelating neurological disease.Rheumatoid arthritis is a chronic progressive, debilitating inflammatorydisease that affects approximately 1% of the world's population.

In certain embodiments, the disease, disorder or condition is selectedfrom, but are not limited to, skin inflammation due to radiationexposure, asthma, chronic obstructive pulmonary disease, allergicinflammation, chronic inflammation, allergic disease, insulin-dependentdiabetes (Type I), celiac disease, psoriasis, inflammatory boweldisease, chronic active hepatitis, polycystic ovary syndrome, perniciousanemia, ankylosing spondylitis, Hashimoto's thyroiditis and Graves'disease which affects the thyroid gland, Cushing's disease and Addison'sdisease which affect the adrenal glands, rheumatoid arthritis, multiplesclerosis, systemic lupus erythmetosus, myasthenia gravis, Crohn'sdisease, myeloproliferative disorders (polycythemia vera), acuteallograft rejection, chronic allograft rejection, Graft-versus-hostdisease, cancer (e.g., breast, ovary, cervix, stomach, lung, melanoma,small cell lung, and the like), stroke, cardiovascular disease,atherosclerosis, retenosis, immunodeficiency disorders, destructive bonedisorders, infectious diseases, CNS disorders, harmone-related disease,and the like.

In particular, the disease, disorder or condition is selected fromasthma, chronic obstructive pulmonary disease, insulin-dependentdiabetes (Type I), psoriasis, inflammatory bowel disease, rheumatoidarthritis, multiple sclerosis, systemic lupus, myeloproliferativedisorders, cancer, and the like.

In a preferred embodiment of the present invention, there is provided amethod for treating or prevention rheumatoid arthritis.

In another preferred embodiment of the present invention, there isprovided a method for treating or preventing psoriasis.

In another preferred embodiment of the present invention, there isprovided a method for treating or preventing multiple sclerosis.

In another preferred embodiment of the present invention, there isprovided a method for treating or preventing chronic obstructivepulmonary disease.

In yet another preferred embodiment of the present invention there isprovided a method for treating or preventing inflammatory bowel disease.

In certain embodiments, the compound of the present invention is about100 fold or about 50 fold or about 10 to 25 fold more selective ininhibiting TYK2 activity over inhibiting JAK1, JAK2 or JAK3. In onepreferred embodiment, the compound of the present invention is more thanabout 100 fold selective in inhibiting TYK2 activity over inhibitingJAK1, JAK2 or JAK3.

The compound alone or in the form of a pharmaceutical composition willtypically be used in therapy for human subjects. However, they may alsobe used to prevent or treat similar indications in other animal subjectsas described herein. Thus, for therapy a suitable dosage form may berequired. Suitable dosage forms will depend upon the use or the route ofadministration. It should be understood that such dosage forms shouldallow the compound to reach target cells. Other factors are well knownin the art, and include considerations such as toxicity and dosage formsthat retard the compound or composition from exerting its effect.Techniques and formulations generally may be found in The Science andPractice of Pharmacy, 21^(st) edition, Lippincott, Willams and Wilkins,Philadelphia, Pa., 2005 (incorporated herein by reference).

Thus, in another object of the present invention, there is provided apharmaceutical composition comprising a compound of formula (I) and oneor more pharmaceutically acceptable excipient(s).

The compound of formula (I), a pharmaceutically acceptable salt thereof,a prodrug thereof or a hydrate thereof, may be administered as aformulation, i.e., pharmaceutical composition, in association with oneor more pharmaceutically acceptable excipient(s). The term “excipient”as used herein refers to any ingredient in the formulation other thanthe compound of formula (I). The examples of an excipient includes, butare not limited to, carrier, vehicle, solvent, adjuvant, lubricant,surfactant, binder, buffer, diluent, flavouring agent, coloring agent,disintegrant, emulsifying agent, suspending agent, plasticizer,solubilizer, filler or bulking agent. The choice of excipient(s) willlargely depend on factors such as the particular mode of administration,the effect of the excipients on solubility, stability, and releaseprofile, and the nature of the dosage form. The compound of formula (I)may be generally referred to as the active ingredient(s) in aformulation or pharmaceutical composition. A pharmaceutical compositionsuitable for the delivery of a compound of formula (I) and methods fortheir preparation will be readily apparent to those skilled in the art.Such compositions and methods for their preparation may be found, forexample, in Remington's Pharmaceutical Sciences, 19^(th) ed., (MackPublishing Company, 1995).

The compounds can be administered by different routes including, forexample intravenous, intraperitoneal, subcutaneous, intramuscular, oral,transmucosal, rectal, transdermal, or inhalant. Oral administration ispreferred. For oral administration, for example, the compounds can beformulated into conventional oral dosage forms such as a tablet, capsule(hard or soft filled), pill, powder, sustain or immediate releaseformulations, solution, suspension; for parenteral injection as asterile solution, suspension or emulsion; for topical administration asan ointment or cream.

The amount of active ingredient(s) and excipient(s) to be present informulation or pharmaceutical composition can be determined by standardprocedures taking into account factors such as the compound IC₅₀, thebiological half life of the compound, the age, size, and weight of thepatient, and the disorder associated with the patient. The importance ofthese and other factors are well known to those of ordinary skill in theart. Generally, a dose will be between about 0.01 and 100 mg/Kg,preferably 0.1 to 50 mg/Kg, even more preferably 0.1 to 20 mg/Kg of thepatient being treated. Multiple doses may be used. The person skilled inthe art would appreciate that the dose is adjusted in accordance withthe methods well know in the therapeutic arts. That is, the maximumtolerable dose can be readily established, and the effective amountproviding a detectable therapeutic benefit to the patient may also bedetermined. Accordingly, while certain dose and administration regimensare exemplified herein, however, these do not in any way limit the doseand administration regimen that may be provided to the patient inpracticing the present invention.

General Methods for Preparation of a Compound of Formula (I)

In general, compounds of the formula (I) can be prepared by followingthe processes described in the methods, schemes and specific examples ofthe present application and/or by additional or alternative processesand procedures known in the art in combination with the knowledge ofordinary skill in the art. It should be understood that the methods setforth in the following descriptions, reaction schemes, methods, andexperimental part are intended for illustrative purposes and are not tobe construed as limiting the scope of the disclosure. Alternativereagents, intermediates, starting materials, synthetic routes andmethods can be used or adapted in practice, particularly in light of thescope of the present disclosure in combination with the knowledge of oneof ordinary skill in the art. Such alternatives and modifications shouldbe understood as being within the spirit and scope of the presentapplication and the claims. Unless otherwise indicated, the variables R,R′, R″, R^(a), R^(b), R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ shown orreferenced in the methods and schemes are defined as above or as definedherein the specification including claims. The compound of formula (I)may be prepared from commercially available starting materials using thegeneral methods illustrated herein below.

It should also be appreciated and understood that where appropriatefunctional groups exist, compounds of methods (1-15) includingintermediates may be further derivatized by using one or more syntheticmethods known in the art including for example oxidation, reduction,substitution, condensation or cleavage reactions. In particular, theintroduction of functional groups such as halo group, nitro group, aminogroup, amide group, urea group, carboxylic group, hydroxyl group oralkoxy group, in the compounds of the present invention may be achievedby following the procedures well known in the art. For example, theprocedures described hereinafter.

Method (1)

A compound of formula (IA) [formula (I), wherein A represents CR, Brepresents N; R³ represents —COR⁴, wherein R⁴ is optionally substitutedphenyl] can be prepared by reacting a compound of formula (a) or saltthereof, with a compound of formula (b) according to the Freidel-Craftsacylation as shown in the reaction Scheme 1.

wherein R, R′, R″, R¹, R², R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined herein.

The reaction is performed using the procedure well known in the art. Inparticular, the reaction is carried out in a chlorinated solvent such asdichloromethane, and in the presence of a metal halide such as aluminiumchloride. The compound of formula (b) can be prepared by heating acidderivative of formula (b) with thionyl chloride in presence or absenceof a suitable chlorinated solvent such as dichloromethane. The compoundof formula (b) can also be prepared by treating acid derivative offormula (b) with oxalyl chloride in presence of a suitable solvent suchas dichloromethane, dimethylformamide or mixture thereof.

Method (2)

A compound of formula (IA-a) [formula IA, wherein R⁹ represents amino]can be prepared from a halo compound of formula (IA-b) [formula IA,wherein R, R′, R″, R¹, R², R⁵, R⁶, R⁷ and R⁸ are as defined herein andR⁹ represents halo such as bromo).

The reaction is performed by reacting compound of formula (IA-b) withmetal azide such as sodium azide and metal iodide such as cuprousiodide, in a suitable protic solvent such as water, methanol, ethanol orisopropanol, or an aprotic solvent such as dimethylformamide ordimethylsulfoxide or a mixture thereof, in the presence of an organicbase, for example, dimethylaminopyridine, N,N-diisopropylethylamine,triethylamine, pyridine or N,N-dimethylethylenediamine, in a temperaturerange of about 75° C. to about 150° C.

Method (3)

A compound of formula (IA-c) [formula IA, wherein R⁹ represents CN] canbe prepared from a halo compound of formula (IA-b).

The cyanation reaction is carried out following procedures well known inthe art. For example, the reaction is performed in an appropriatesolvent such as tetrahydrofuran, dioxane, ether or dimethylformamide inthe presence of metal cyanide such as cuprous cyanide or zinc cyanide.The palladium catalyst such as tris(dibenzylideneacetone)dipalladium(0)and a ligand such as 1,1′-bis(diphenylphosphino)ferrocene are used forthis reaction. Such a palladium catalyzed cyanation reaction isperformed in a temperature range of about 100° C. to about 150° C.

Method (4)

The compound of formula (IA-d) [formula IA, wherein R⁹ representsheteroaryl] can be prepared from a halo compound of formula (IA-b).

The reaction is performed by reacting a compound of formula (IA-b) witha borate ester of formula R⁹B(OH)₂ (wherein R⁹ represents aryl such asphenyl or heteroaryl such as pyrrolyl) or a boronic acid, in anappropriate solvent such as water, acetonitrile, 1,4-dioxane,dimethylformamide, toluene or a mixture thereof, in the presence of apalladium complex such asdichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) and a basesuch as potassium carbonate, cesium carbonate or sodium carbonate. Sucha reaction is optionally performed under heating system well known inthe art including, for example, microwave heating system, in atemperature range of about 80° C. to about 110° C.

Method (5)

The compound of formula (IA-e) [formula IA, wherein R⁹ represents—NHCOR^(b)] can be prepared from an amino compound of formula (IA-a).

The compound of formula (IA-a) is reacted with a compound of formulaR^(b)COCl in an appropriate solvent such as methylene chloride,chloroform or carbon tetrachloride, in the presence of a base such astriethylamine, N,N-diisopropylethylamine, pyridine, 2,6-dialkylpyridine(e.g., 2,6-lutidine or 2,6-di-tert-butylpyridine) to give a compound offormula (IA-e).

Method (6)

The compound of formula (IA-f) [formula IA, wherein R⁹ represents—CONHR^(b)] can be prepared from a compound of formula (IA-g) [formulaIA, wherein R, R′, R″, R¹, R², R⁵, R⁶, R⁷ and R⁸ are as defined hereinand R⁹ represents —COOCH₃).

The compound of formula (IA-f) can be prepared by following any methodswell known in the art including the methods described herein. Forinstant, said compound is prepared by hydrolyzing a compound of formula(IA-g) under basic condition (e.g., sodium hydroxide) in a suitablesolvent such as water, tetrahydrofuran, dioxane or mixture thereof,followed by reacting with an amine compound of formula R^(b)NH₂ inpresence of a coupling agent and a suitable solvent such asdimethylformamide or dimethylsulfoxide.

Method (7)

The compound of formula (IA-h) [formula IA, wherein R⁹ represents—CH₂NHR^(b)] can be prepared from a compound of formula (IA-g) byfollowing the steps (i), (ii) and (iii).

(i) The compound of formula (IA-g) is subjected to reduction using anappropriate reducing agent such as sodium borohydride and a suitablesolvent such as water, tetrahydrofuran, methanol, dioxane or mixturethereof, to give a compound of formula (IA-i) [formula IA, wherein R,R′, R″, R¹, R², R⁵, R⁶, R⁷ and R⁸ are as defined herein and R⁹represents —CH₂OH].

(ii) The compound of formula (IA-i) is brominated using an appropriatebrominating agent such as phosphorous tribromide, in a suitable solventsuch as methylene chloride, chloroform, carbon tetrachloride or mixturethereof, to give a compound of formula (IA-j) [formula IA, wherein R,R′, R″, R¹, R², R⁵, R⁶, R⁷ and R⁸ are as defined herein and R⁹represents —CH₂halo such as —CH₂Br).

(iii) The compound of formula (IA-j) is finally reacted with an aminecompound R^(b)NH₂ in an appropriate solvent such as acetonitrile, in thepresence of a base such as cesium carbonate to give a compound offormula (IA-h).

Method (8)

A compound of formula (IB) [formula (I), wherein A represents N, Brepresents CR, R¹ represents —COR⁴, wherein R⁴ is optionally substitutedphenyl] can be prepared by reacting a compound of formula (d) or saltthereof, with a compound of formula (e) according to the reaction Scheme2.

wherein R, R′, R″, R², R³, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined herein.The reaction (when L is OH) is performed in an appropriate solvent suchas dimethylformamide, dimethylacetamide, ethyl acetate, acetonitrile, inthe presence of a coupling agent and a base such asdimethylaminopyridine (DMAP) or N,N-diisopropylethylamine (DIPEA). Theexamples of coupling agents include, but are not limited to,2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate methanaminium (HATU) or 1-hydroxy-7-azabenzotriazole(HOAt) or mixture thereof.

In Scheme 2, when L is halo such as chloro, the reaction is performed i)in an appropriate solvent such as tetrahydrofuran, ether, dioxane,methylene chloride, chloroform or carbon tetrachloride, in the presenceof a base, for example, N,N-diisopropylethylamine (Hünig's base),triethylamine, diethylamine or pyridine or ii) in an appropriate solventsuch as dimethylformamide or dimethylsulfoxide, in the presence of ametal hydride such as sodium hydride or potassium hydride. Such areaction is performed in a temperature range of 0° C. to 80° C.,preferably from 0° C. to an ambient temperature.

Method (9)

A compound of formula (IB-a) [formula IB, wherein R′ represents—NHCOR^(b)] can be prepared from a compound of formula (IB-b) [formulaIB, wherein R, R″, R², R³, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined and R′represents —NH₂).

The compound of formula (IB-b) is reacted with a compound of formulaR^(b)COCl in an appropriate solvent such as diethyl ether,tetrahydrofuran or dioxane, dichloromethane in the presence of a basesuch as triethylamine, diethylamine, pyridine or diisopropylethylamine,at an ambient temperature, followed by treatment with an inorganic basesuch as potassium carbonate or sodium carbonate, in a suitable solventsuch as methanol or ethanol, at the same temperature.

The compound of formula (IB-b) can be prepared by following any methodswell known in the art including the methods described herein. Forexample, the N-oxidation of a compound of formula (IB, wherein R′ is H),followed by reaction with a compound of formula R′″NH₂ (wherein R′″ isalkyl such as tert-butyl or tert-octyl) in a suitable solvent such aschloroform, dichloromethane or carbon tetrachloride, in the presence ofp-toluenesulfonyl chloride or methanesulfonyl chloride, in a temperaturerange of 0° C. to an ambient temperature gives an intermediate compoundwhich upon treatment with an acid, in a suitable solvent such aschloroform, dichloromethane or carbon tetrachloride gives (IB-b). Theexamples of acids include, but are not limited to, acetic acid,trichloroacetic acid, trifluoroacetic acid or difluoroacetic acid,preferably trifluoroacetic acid. The N-oxidation can be carried out inan appropriate solvent such as chloroform, dichloromethane or carbontetrachloride, in presence of an oxidizing agent such as hydrogenperoxide, peracetic acid, potassium peroxymonosulfate (oxone) ormeta-chloroperbenzoic acid, preferably m-chloroperbenzoic acid, in atemperature range of 0° C. to an ambient temperature. The N-oxideproduct thus formed is halogenated in a temperature range of ambienttemperature to about 70° C. The examples of halogenating agents include,but are not limited to, thionyl chloride, phosphorous trichloride orphosphoryl chloride.

Method (10)

A compound of formula (IB-c) [formula IB, wherein R⁹ represents CN,heteroaryl or —NR^(a)R^(b)] can be prepared from a compound of formula(IB-d) [formula IB, wherein R, R′, R″, R², R³, R⁵, R⁶, R⁷ and R⁸ are asdefined herein and R⁹ represents halo such as bromo).

The compound of formula (IB-d) is subjected to a palladium catalyzedcyanation procedures well known in the art, to give a compound offormula (IB-c1, wherein R⁹ represents CN). For example, the reaction isperformed in an appropriate solvent such as tetrahydrofuran, dioxane orether, in the presence of metal cyanide such as cuprous cyanide or zinccyanide and a base such as potassium carbonate, cesium carbonate orsodium carbonate. The palladium catalyst such astris(dibenzylideneacetone)dipalladium(0) and a ligand such as1,1′-bis(diphenylphosphino)ferrocene are used for this reaction. Such apalladium catalyzed cyanation reaction is performed in a temperaturerange of about 70° C. to about 100° C.

The compound of formula (IB-d) is reacted with borate esters of formulaR⁹B(OH)₂ (wherein R⁹ is heteroaryl such as pyrrolyl) in an appropriatesolvent such as water, acetonitrile, dimethylformamide, toluene or amixture thereof, in the presence of a palladium complex such asdichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) and a basesuch as potassium carbonate, cesium carbonate or sodium carbonate, togive a compound of formula (IB-c2, wherein R⁹ is heteroaryl). Such areaction is performed under heating system well known in the artincluding, for example, microwave heating system, in a temperature rangeof about 75° C. to about 100° C.

The compound of formula (IB-d) is reacted with an amine compound offormula —NR^(a)R^(b) in a suitable solvent such as toluene or xylene, inthe presence of a palladium catalyst and ligand such as4,5-bis(diphenylphosphino)-9,9-dimethylxanthene or2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and a base such aspotassium carbonate, cesium carbonate or sodium carbonate, to give acompound of formula (IB-c3, wherein R⁹ represents —NR^(a)R^(b). Theexamples of palladium catalysts include, but are not limited to,palladium (II) acetate or tris(dibenzylideneacetone) dipalladium (0).Such a palladium catalyzed reaction is performed in the temperaturerange of about 80° C. to about 100° C.

Method (11)

A compound of formula (IB-e) [formula IB, wherein R⁹ represents—(CH═CH)COOH or —(CH═CH)CONR^(a)R^(b)] can be prepared from a compoundof formula (IB-f) [formula IB, wherein R, R′, R″, R², R³, R⁵, R⁶, R⁷ andR⁸ are as defined herein and R⁹ represents —CH═CH-T, wherein T isCOO-ethyl).

The compound of formula (IB-f) is hydrolyzed in an appropriate solventsuch as water, tetrahydrofuran, ether or a mixture thereof, in thepresence of metal hydroxide such as lithium hydroxide, potassiumhydroxide, sodium hydroxide, magnesium hydroxide or calcium hydroxide,and in a temperature range of ambient temperature to about 80° C.,preferably ambient temperature to a give a compound of formula [IB-e1,wherein R⁹ represents —(CH═CH)COOH], which upon reacting with an aminecompound (—NR^(a)R^(b)) in an appropriate solvent such asdimethylformamide or dimethylsulfoxide, in the presence of a couplingagent and optionally in the presence of a base such as triethylamine,N,N-diisopropylethylamine, pyridine, 2,6-dialkylpyridine (e.g.,2,6-lutidine or 2,6-di-tert-butylpyridine) gives a compound of formula[IB-e2, wherein R⁹ represents —(CH═CH)CONR^(a)R^(b)].

A standard coupling agent well known in the art can be used. Inparticular, a coupling agent such as carbonyldiimidazole,dicyclohexyl-carbodiimidazole, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or a combination thereof can be used. Such acoupling reaction can optionally be performed in the presence of acatalyst such as 1-hydroxy-benzotriazole.

Method (12)

The compound of formula (IB-g) [formula IB, wherein R, R′, R″, R², R³,R⁵, R⁶, R⁷ and R⁸ are as defined herein and R⁹ represents —NHCOR^(b)]can be prepared by following the procedures (i), (ii) or (iii).

(i) The compound of formula (IB-c3, wherein R⁹ represents —NR^(a)R^(b);both R^(a) and R^(b) represent H) is subjected to a coupling reactionwith a compound of formula R^(b)COOH in a reaction condition describedin Method (11).

(ii) The compound of formula (IB-c3, wherein R⁹ represents —NR^(a)R^(b);both R^(a) and R^(b) represent H) is reacted with a compound of formulaR^(b)COCl in an appropriate solvent such as methylene chloride,chloroform or carbon tetrachloride, in the presence of a base such astriethylamine, N,N-diisopropylethylamine, pyridine, 2,6-dialkylpyridine(e.g., 2,6-lutidine or 2,6-di-tert-butylpyridine).

(iii) The compound of formula (IB-c3, wherein R⁹ represents—NR^(a)R^(b); both R^(a) and R^(b) represent H) is reacted with phenylchloroformate in an appropriate solvent such as tetrahydrofuran, etheror dioxane, in the presence of a base such as triethylamine,N,N-diisopropylethylamine, pyridine, 2,6-dialkylpyridine (e.g.,2,6-lutidine or 2,6-di-tert-butylpyridine), followed by reaction with acompound of formula R^(b)NH₂ in a suitable solvent such as methanol,ethanol or isopropanol.

Method (13)

A compound of formula (IB-h) [formula IB, wherein R⁹ represents halo,—CN and R′ represents —NR^(a)COR^(b) or —NR^(a)C(O)OR^(b) or both R⁹ andR′ represent —NR^(a)COR^(b)] can be prepared from a compound of formula(IB-i, wherein R, R′, R″, R², R³, R⁵, R⁶, R⁷ and R⁸ are as definedherein and R⁹ represents halo such as bromo).

(i) The compound of formula (IB-h1, wherein R⁹ represents halo and R′represents —NR^(a)C(O)OR^(b)] can be prepared by treating a compound offormula (IB-i1, wherein R⁹ represents halo and R′ represents amino) withphenyl chloroformate as defined herein.

(ii) The compound of formula (IB-h2, wherein R⁹ represents halo and R′represents —NR^(a)COR^(b)] can be prepared by following the standardmethods known in the art.

(iii) The compound of formula (IB-h3, wherein R⁹ represents CN and R′represents —NR^(a)COR^(b)] can be prepared by treating an amine compoundwith a compound of formula R^(b)COCl in a reaction condition asmentioned herein, followed by a palladium catalyzed cyanation procedureswell known in the art including, for example, the use of a combinationof 1,1′-bis(diphenylphosphino)ferrocene andtris(dibenzylideneacetone)dipalladium(0). The palladium catalyzedcyanation is performed in a suitable solvent such as tetrahydrofuran,dioxane or ether, in the presence of a metal cyanide such as cuprouscyanide or zinc cyanide and a base such as potassium carbonate, cesiumcarbonate or sodium carbonate, in a temperature range of about 75° C. toabout 100° C.

(iv) The compound of formula (IB-h4, wherein both R⁹ and R′ represent—NR^(a)COR^(b)] can be prepared by reacting an amine compound with acompound of formula R^(b)COCl in a reaction condition well known in theart, for example, the process described herein.

Method (14)

A compound of formula (IB-j) [formula IB, wherein R⁹ represents—CONR^(a)R^(b)] can be prepared from a compound of formula (IB-k,wherein R, R′, R″, R², R³, R⁵, R⁶, R⁷ and R⁸ are as defined herein andR⁹ represents —COOCH₃). The compound of formula (IB-j) can be preparedby following any methods well known in the art including the methodsdescribed herein, for example Method (6).

Method (15)

The compound of formula (IB-l) [formula IB, wherein R⁹ represents—CH₂NHR^(b)] can be prepared from a compound of formula (IB-k) byfollowing steps as described in Method (7).

One of ordinary skill in the art will appreciate that in some casesprotecting groups may be required during the reaction in any of themethods described herein. The term “protecting group” as used hereinrefers to a group used to mask or block a particular site/functionalgroup in the preparation for a chemical transformation at a differentsite/functional group in a molecule. After a particular target ortransformation is complete or at some specific step later in a syntheticroute, the protecting group can be removed using methods well known inthe art. The introduction, use and removal of protecting group have beendescribed in “Protective Groups in Organic Synthesis”, (3^(rd) Ed., JohnWiley & Sons, 1999). For example, the reaction of a compound of formula(I) and a compound of formula (2) (wherein R, R′, R″, R¹, R², R³, R⁴,R⁵, R⁶, R⁷, R⁸ or R⁹ is NH-protected) is performed in a suitable solventsuch as methylene chloride, chloroform or carbon tetrachloride, in thepresence of a base such as dimethylaminopyridine, and a coupling agentsuch as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.The protecting group is then removed by treating the compound thusformed with an acid such as trifluoroacetic acid in a suitable solventsuch as methylene dichloride. The examples of N-protecting groupsinclude, but are not limited to, acetyl, benzyl, benzyloxycarbonyl ortert-butyloxycarbonyl.

One of ordinary skill in the art will also appreciate that in some casesleaving group may be required during the reaction in any of the methodsdescribed herein. The examples of leaving groups include, but are notlimited to halogen, aryl or alkyl sulfonates, phosphonates, azides and—S(O)₀₋₂R^(h), wherein R^(h) is alkyl, aryl or heteroaryl (whereinalkyl, aryl or heteroaryl are optionally substituted). The person ofordinary skill in the art of organic synthesis will readily identifysuitable leaving group to perform a desired reaction under differentreaction conditions.

During the course of synthetic reactions, the oxidizing agents may berequired, which include, but are not limited to, Dess-Martin reagent,TEMPO (2,2,6,6-Tetramethylpiperidine-N-oxide), DDQ(2,3-Dichloro-5,6-dicyano-1,4-benzoquinone), PDC (PyridiniumDichromate), pyridine.SO₃, chromium trioxide, sodium chlorite,p-nitroperbenzoic acid, magnesium monoperoxyphythalate, sodiumperiodate, potassium periodate, hydrogen peroxide, urea peroxide, alkalimetal borates, cumene hydroperoxide, tert-butyl peroxide, peracids suchas perbenzoic acid, m-chloroperbenzoic acid, o-carboxyperbenzoic acidand the like; sodium metaperiodate, dichromic acid, dichromates such assodium dichromate, potassium dichromate; permanganic acid; permanganatessuch as potassium permanganate, sodium permanganate; and lead salts suchas lead tetraacetate.

Similarly, the reducing agents may also be required, which include, butare not limited to, catalytic reducing agents using hydrogen andtransition metal catalysts (e.g., palladium, platinum or rhodium); amixture of trifluoracetic acid triethylsilane, borane tetrahydrofurancomplex, diborane, borane dimethylsulfide complex, and a combination ofsodium borohydride and boron trifluoride; metal hydrogen complexcompounds such as alkali metal borohydrides (e.g., potassiumborohydride, sodium borohydride, lithium borohydride, zinc borohydrideor sodium triacetoxyborohydride), aluminium lithium hydride; metalhydrides such as sodium hydride; and metal slats such as nickelcompounds, zinc compounds, tin compounds (e.g., tin(II) chloride).

According to the present invention, the solvents, unless otherwiseindicated, include polar and non-polar solvents well known in the artincluding polar aprotic and polar protic solvents. The examples of polarsolvents include, but are not limited to, methanol, ethanol, isopropylalcohol, tert-butanol, n-butanol, acetic acid, formic acid or water, oraprotic solvent such as tetrahydrofuran, acetonitrile, dioxane,methylene chloride, dimethylsulfoxide, acetone, N,N-dimethylformamide,N,N-dimethylacetamide, ethyl acetate, 1,2-dimethoxyethane,1,2-dichloroethane, chloroform or pyridine. Polar solvent also include amixture of water with any of the above, or a mixture of any two or moreof the above solvents. The examples of non-polar solvents include, butare not limited to, toluene, benzene, chlorobenzene, xylenes andhexanes.

According to the present invention, the coupling agents may be requiredwhich include, but are not limited to, tetramethylfluoroformamidiumhexafluorophosphate (TFFH), benzyltriphenylphosphonium dihydrogentrifluoride (PTF), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate methanaminium (HATU) or1-hydroxy-7-azabenzotriazole (HOAt), 1-hydroxybenzotriazole (HOBt),1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI),1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI.HCl),diphenylphosphoryl azide (DPPA), diethylpyrocarbonate (DEPC),pentafluorophenyl diphenylphosphinate (FDDP),(2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU),benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate (BOP), 1-(t-butyldimethylsilyloxy)benzotriazole(TBDMS-OBt) or 1-(t-butyldiphenylsilyloxy)benzotriazole (TBDPS-OBt). Thecoupling agent may be optionally used in combination with one or morebase(s) selected from, but are not limited to,N,N-diisopropylethylamine, diethylamine, triethylamine,dicyclohexylamine, pyridine, dimethylaminopyridine, collidine (e.g.,2,4,6-trimethylpyridine) or lutidine (e.g., 2,3-dimethylpyridine). Thecoupling agent also includes a mixture of any of the above, for example,a mixture of TFFH and HOAt or a mixture of EDCI and HOAt or HOBt.

According to the present invention, the palladium complex, unlessotherwise indicated, includes, but are not limited to,dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II),1,1′-bis(diphenylphosphino)ferrocene-palladium(11)dichloridedichloromethane,dichloro{bis-2-(3,5-dimethylpyrazolyl-1-carbonyl)furan}palladium(II),dichloro{bis-2-(3,5-dimethylpyrazolyl-1-carbonyl)thiophene}palladium(11),dichloro{bis2-(3,5-di-tert-butylpyrazolyl-1-carbonyl)furan}palladium(II),dichloro{bis-2-(3,5-di-tert-butylpyrazolyl-1-carbonyl)thiophene}palladium(II),dichloro{bis-2-(3-methylpyrazolyl-1-carbonyl)-furan}palladium(II),dichloro{bis-2-(pyrazolyl-1-carbonyl)furan}palladium(II),dichloro{bis-2-(3,5-diphenylpyrazolyl-1-carbonyl)furan}palladium(II) ordichloro{bis-2-(3,5-diphenylpyrazolyl-1-carbonyl)thiophene}palladium(II).

In certain embodiments, it is to be understood that in place ofoxidizing agent, reducing agent, coupling agent, solvent and base,optionally indicated in one or more methods described herein, any otheroxidizing agent, reducing agent, coupling agent, solvent and base, asdescribed herein, can also be employed.

In certain embodiments, it is desirable to separate the reactionproducts from one another and/or from starting materials to get thedesired products in the purified forms. Such a separation can beperformed by using techniques well known in the art. For example,multiphase extraction, crystallization from a solvent or solventmixture, distillation, sublimation or chromatography. One skilled in theart will apply the techniques most likely to achieve the desiredpurification.

In certain embodiments, the present invention encompasses isotopicallylabeled compounds of the formula (I). All isotopes of any particularatom or element as specified are contemplated within the scope of thepresent invention. The examples of isotopes that can be incorporatedinto compounds of the present invention include, but are not limited to,isotopes of hydrogen (e.g., ²H or ³H), carbon (e.g., ¹³C or ¹⁴C),nitrogen (e.g., ¹³N or ¹⁵N), oxygen (e.g., ¹⁵O, ¹⁷O or ¹⁸O), phosphorous(e.g., ³²P or ³³P), sulphur (e.g., ³⁵S), halogen (e.g., ¹⁸F, ³⁶Cl, ¹²³Ior ¹²⁵I). Isotopically labeled compounds of formula (I) can be preparedby following the methods (1-15) by using isotopically labeled reagents.Isotopically labeled of the present invention may be useful in compoundand/or substrate tissue distribution assays. Such applications ofisotopically labeled compounds are well known to person skill in theart, and are therefore within the scope of the present invention.

Experimental Procedures

It should be understood that the procedures set forth below are intendedfor illustrative purposes and are not to be construed as limiting thescope of the disclosure. Any modification in the procedures describedherein, other synthetic procedures and modification thereon can beemployed or adapted. All such modifications and alternative proceduresare within the spirit and scope of the present application. In examplesmentioned below, the term intermediate in some cases may refer tostarting material for the synthesis of final compound.

Preparation of Intermediates Intermediate 1: Synthesis of7-chloro-1H-pyrrolo[2,3-c]pyridine

A solution of 2-chloro-3-nitropyridine (1 g, 6.3 mmol) in drytetrahydrofuran (100 mL) was treated with vinyl magnesium bromide (60mL, 60 mmol) at −78° C. in a drop-wise manner under inert atmosphere.The resulting reaction mixture was stirred at the same temperature for 2hours followed by stirring at −20° C. for 8 hours. The reaction wasquenched slowly with aqueous ammonium chloride solution (20 mL),extracted with ethyl acetate (3×50 mL) and the combined organic layerdried over anhydrous sodium sulfate, filtered and concentrated. Thecrude product was purified by silica gel (100-200) column chromatographyusing ethyl acetate and hexane gradient elution to afford7-chloro-1H-pyrrolo[2,3-c]pyridine (0.350 g, 36.45%).

¹H NMR (400 MHz, CHCl₃-d): δ 8.04 (d, J=5.46 Hz, 1H), 7.50 (dd, J=5.46,0.75 Hz, 1H) 7.43 (dd, J=3.11, 2.54 Hz, 1H), 6.64 (dd, J=3.14, 2.07 Hz,1H). MS: 152.98 (M⁺).

7-Bromo-1H-pyrrolo[2,3-c]pyridine (Intermediate 2) was synthesized from2-bromo-3-nitropyridine (18.55%) in an analogous manner.

¹H NMR (400 MHz, CHCl₃-d): δ 7.99-8.06 (m, 1H), 7.48-7.54 (m, 1H),7.41-7.45 (m, 1H), 6.64-6.69 (m, 1H). MS: 197.40 (M⁺).

Intermediate 3: Synthesis of cyclopropanecarboxamide

Ammonia was purged through a well-stirred solution of cyclopropanecarbonyl chloride (1 g, 9.61 mmol) in dichloromethane (10 mL) for 2hours at room temperature. Solvent was removed under vacuum, the residuewas taken up in ethyl acetate and filtered. The filtrate wasconcentrated to afford pure cyclopropanecarboxamide as a crystallinesolid (0.81 g, 100%).

¹H NMR (400 MHz, CHCl₃-d): δ 5.63-5.91 (br. s, 2H), 1.43 (m, 1H), 0.98(dd, J=4.42, 2.98 Hz, 2H), 0.79 (dd, J=7.91, 2.95 Hz, 2H). MS: 85.91(M+1).

Intermediate 4: Synthesis of Cyclobutane Carboxmide

A solution of cyclobutyl carbonyl chloride (5 g, 42.37 mmol) indichloromethane (20 mL) was treated with aqueous ammonia solution (20mL) at −20° C. The resulting reaction mixture was stirred overnight atroom temperature. Volatiles were removed under vacuum. The precipitatedsolid was filtered and dried under vacuum to afford the cyclobutanecarboxamide (3 g, 71.77%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.02-7.16 (m, 1H), 6.65 (br. s., 1H), 2.95(quind, J=8.43, 8.43, 8.43, 8.43, 0.85 Hz, 1H), 1.61-2.18 (m, 6H).

Intermediate 5: Synthesis ofN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclobutanecarboxamide

To a solution of 7-bromo-1H-pyrrolo[2,3-c]pyridine (500 mg, 2.53 mmol)in toluene were added tris (dibenzylidene acetone) dipalladium (116.20mg, 0.126 mmol), Xantphos (32.98 mg, 0.057 mmol), cesium carbonate (896mg, 2.75 mmol), and cyclobutanecarboxamide (251 mg, 2.96 mmol,Intermediate 4). The resulting reaction mixture was heated to 120° C.and stirred for 8 hours. After cooling to room temperature a saturatedaqueous sodium bicarbonate solution (20 mL) was added to the reactionmixture and extracted with ethyl acetate (3×50 mL). The combined organiclayer was dried over anhydrous sodium sulfate, filtered andconcentrated. The crude product was purified by silica gel (100-200)column chromatography to affordN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide (200 mg, 36%yield).

¹H NMR (400 MHz, CHCl₃-d): δ 7.72-7.79 (m, 1H), 7.45-7.54 (m, 1H),7.38-7.45 (m, 1H), 6.58-6.63 (m, 1H), 3.47-3.51 (m, 1H), 2.29-2.51 (m,2H), 1.88-2.14 (m, 2H), 1.21-1.31 (m, 2H). MS: 216.56 (M+1).

The following intermediates were prepared in an analogous manner.

N-(1H-Pyrrolo[2,3-c]pyridin-7-yl)acetamide (Intermediate 6, yield:8.69%) was synthesized from 7-chloro-1H-pyrrolo[2,3-c]pyridine usingacetamide.

¹H NMR (400 MHz, CHCl₃-d): δ 7.81-7.88 (m, 1H), 7.34-7.43 (m, 2H), 6.56(d, J=3.01 Hz, 1H), 2.31 (s, 3H).

N-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide (Intermediate7, yield: 7.59%) was synthesized from 7-chloro-1H-pyrrolo[2,3-c]pyridineusing cyclopropanamide.

¹H NMR (400 MHz, CHCl₃-d): δ 8.01-8.06 (m, 1H), 7.82-7.87 (m, 1H), 7.36(d, J=5.58 Hz, 2H), 6.55 (d, J=2.95 Hz, 1H), 1.59-1.61 (m, 1H), 1.16 (d,J=4.39 Hz, 2H), 0.94-1.00 (m, 2H). MS: 202.22 (M+1).

N-(1H-pyrrolo[2,3-c]pyridin-7-yl)propanamide (Intermediate 8, yield:15%) was synthesized from 7-chloro-1H-pyrrolo[2,3-c]pyridine usingpropanamide.

¹H NMR (400 MHz, DMSO-d6): δ 11.01 (s, 1H), 10.49 (br s, 1H), 7.82 (d,J=5.6 Hz, 1H), 7.69 (d, J=2.4 Hz), 1H), 7.36 (d, J=5.6 Hz, 1H),2.47-2.53 (m, 2H), 1.12-1.16 (t, J=7.2 Hz, 3H). MS: 190.55 (M+1).

Intermediate 9: Synthesis of 4-bromo-2,6-dichlorobenzoic acid Step a:Synthesis of 2,6-dichloro-3-nitrobenzoic acid

2,6-Dichlorobenzoic acid (10 g, 52 mmol) was added portion wise to apreviously stirred mixture of nitric acid (15 mL) and sulfuric acid (30mL) at 55° C. and stirred for 30 minutes followed by stirring at roomtemperature for 0.5 hour. The reaction mixture was poured into crushedice and the precipitated off white solid was filtered, washed withwater, and dried under vacuum to afford 2,6-dichloro-3-nitrobenzoic acid(7 g, 57%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.98 (d, J=8.8 1H), 7.67 (d, J=8.8 1H).

Step b: Synthesis of 3-amino-2,6-dichlorobenzoic acid

2,6-Dichloro-3-nitro-benzoic acid (10 g, 42 mmol, Step a) was added toconcentrated hydrochloric acid (100 mL), followed by stannous chloridedihydrate (38 g, 169 mmol). The reaction mixture was heated at 60° C.for 1 hour. The reaction mixture was diluted with water (500 mL) andextracted with ethyl acetate (2×300 mL). The combined organic layer wasdried over anhydrous sodium sulfate and concentrated under vacuum toafford the crude product (sticky material). The crude material wasdissolved in water (200 mL, turbid solution) and treated slowly withaqueous sodium hydroxide (20%) solution till precipitation whilemaintaining the pH 1-2 (dense precipitate was observed). The precipitatewas filtered and filtrate was extracted with ethyl acetate (2×200 mL)and dried over anhydrous sodium sulfate and concentrated under vacuum toyield 3-amino-2,6-dichloro-benzoic acid as a creamish solid (6 gm, 69%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.11 (d, J=8.8 1H), 6.85 (d, J=8.8 1H).

Step c: Synthesis of 3-amino-4-bromo-2,6-dichlorobenzoic acid

A mixture of 3-amino-2,6-dichlorobenzoic acid (5 g, 24 mmol, Step b) inacetonitrile (50 mL) was treated with N-bromosuccinimide (5.1 g, 29mmol) and the reaction mixture was stirred at 90° C. for 45 minutes.Acetonitrile was removed in vaccuo and the residue was partitionedbetween water (200 mL) and ethyl acetate (200 mL). The organic layer wasseparated and the aqueous layer was again extracted with ethyl acetate(2×100 mL). The combined organics were dried over anhydrous sodiumsulfate and concentrated to afford 3-amino-4-bromo-2,6-dichloro-benzoicacid (5 g, 73%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.49 (s, 1H) and 7.11 (d, J=8.8 1H).

Step d: Synthesis of 4-bromo-2,6-dichlorobenzoic acid

An aqueous solution of sodium nitrite (3.64 g dissolved in 4 mL ofwater, 52 mmol) was added drop wise to the concentrated hydrochloricacid (15 mL) cooled to −10 to −5° C. 3-Amino-4-bromo-2,6-dichlorobenzoicacid (5 g, 17 mmol, Step c) was added to the above solution portion-wisewhile maintaining the temperature around −5° C. The reaction mixture wasstirred at this temperature for about 2 hours. Then hypophosphorous acid(9 mL, 170 moles) was added very slowly over a period of 1 hour at thesame temperature. The reaction mixture was stirred at the sametemperature for about 3 hours and then kept in refrigerator overnight. Aprecipitate was observed at this stage. The reaction mixture was allowedto warm to room temperature and kept for another 2 hours at roomtemperature. The reaction mixture was filtered, the residue was washedwith cold water and dried to obtain 4-bromo-2,6-dichloro benzoic acid asa yellowish solid (2 g, 42%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.69 (s, 2H).

Intermediate 10: Synthesis of 4-bromo-2,6-dichlorobenzoyl chloride

A solution of 4-bromo-2,6-dichlorobenzoic acid (2 g, 7.4 mmol), andthionyl chloride (5.5 mL, 74 mmol) in dichloromethane (30 mL) was heatedunder refluxed for 5 hours. The reaction mixture was cooled to roomtemperature and concentrated under vacuum. The resulting mass was takenup in dichloromethane (20 mL) and concentrated under vacuum. The processwas repeated 2-3 times to remove excess thionyl chloride.4-Bromo-2,6-dichlorobenzoyl chloride (2.2 g, 100%) thus formed was usedas such for the next step.

Intermediate 11: Synthesis of N-(1H-pyrrolo[2,3-c]pyridin-5-yl)acetamideStep a: Synthesis of N-(4-methyl-5-nitropyridin-2-yl) acetamide

A mixture of 4-methyl-5-nitropyridin-2-amine (5 g, 32 mmol) and aceticanhydride (20 mL) was heated at 90° C. for 4 hours. After cooling thesolvent was evaporated under vacuum. The concentrated mass was dissolvedin toluene and evaporated under vacuum. The resulting solid wastriturated with diethyl ether and filtered to affordN-(4-methyl-5-nitropyridin-2-yl) acetamide (5.5 g, 87%).

Step b: Synthesis ofN-{4-[(Z)-2-(dimethylamino)ethenyl]-5-nitropyridin-2-yl}acetamide

To a solution of N-(4-methyl-5-nitropyridin-2-yl)acetamide (1 g, 5 mmol,Step a) in dry dimethylformamide (10 mL), dimethylformamide dimethylacetal (1.5 mL, 11 mmol) was added and the resulting reaction mixturewas heated at 90° C. for 3 hours. The reaction mixture was cooled toroom temperature, toluene was added and evaporated under vacuum followedby triturating with diethyl ether and filtration to affordN-{4-[(Z)-2-(dimethylamino)ethenyl]-5-nitropyridin-2-yl}acetamide (0.8g, 63%).

Step c: Synthesis of N-(1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide

To a solution ofN-{4-[(Z)-2-(dimethylamino)ethenyl]-5-nitropyridin-2-yl}acetamide (0.7g, 3 mmol, Step b) in methanol and dichloromethane (5:1, 120 mL),palladium on carbon (0.4 g) was added followed by addition of aceticacid (7 mL). The reaction mixture was then purged with hydrogen gas andstirred overnight at room temperature. The resulting mixture wasfiltered over celite bed, and the residue was washed with methanol (100mL). The combined filtrate was concentrated under vacuum and purified bysilica gel column chromatography using methanol in dichloromethane (2%)to afford N-(1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (0.35 g, 71%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.43 (br. s., 1H), 10.13 (s, 1H), 8.46 (s,1H), 8.21, (s, 1H), 7.56 (t, J=2.76 Hz, 1H), 6.45 (t, J=1.88 Hz, 1H),2.06 (s, 3H). MS: 176.44 (M+1).

Intermediate 12: Synthesis ofN-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide Step a:Synthesis of N-(4-methyl-5-nitropyridin-2-yl)cyclopropanecarboxamide

An ice-cooled mixture of 4-methyl-5-nitropyridin-2-amine (1 g, 6.5mmol), triethylamine (1.31 g, 13 mmol) in tetrahydrofuran (20 mL) wastreated with cyclopropyl acetyl chloride (0.75 g, 7.1 mmol) drop wise.After complete addition the reaction mixture was stirred at roomtemperature for 1 hour, cooled to 0° C. and added cyclopropyl acetylchloride (0.75 g, 7.1 mmol) followed by stirring at room temperature for1 hour. The solvent was evaporated under vacuum and water (100 mL) waspoured into the reaction mixture and extracted with ethyl acetate (2×150mL). The organic layer was washed with aqueous sodium bicarbonatesolution, dried over anhydrous sodium sulfate and concentrated undervacuum. The residue (1.5 g) was taken-up in methanol and water (4:1, 40mL). Potassium carbonate was added to it and stirred at room temperaturefor 20 hours. The mixture was concentrated under vacuum. Residue wastaken up in water (100 mL) and extracted with ethyl acetate (2×150 mL).The organic layer was dried over anhydrous sodium sulfate andconcentrated under vacuum to get the crude compound, which uponpurification by silica gel column chromatography using methanol indichloromethane (1%) as eluent affordedN-(4-methyl-5-nitropyridin-2-yl)cyclopropanecarboxamide (0.6 g, 52%).

Step b: Synthesis ofN-{4-[(Z)-2-(dimethylamino)ethenyl]-5-nitropyridin-2-yl}cyclopropanecarboxamide

N-{4-[(Z)-2-(dimethylamino)ethenyl]-5-nitropyridin-2-yl}cyclopropanecarboxamidewas prepared in an analogous manner as in intermediate 11, Step b.

Step c: Synthesis ofN-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide:

N-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide was preparedfollowing a procedure similar toN-(1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (Intermediate 11, Step c).

¹H NMR (400 MHz, DMSO-d₆): δ 11.43 (br. s., 1H), 10.41 (s, 1H), 8.47 (s,1H), 8.19 (s, 1H), 7.56 (t, J=2.76 Hz, 1H), 6.43 (td, J=1.82, 0.88 Hz,1H), 1.99 (s, 1H), 0.65-0.88 (m, 4H). MS: 202.51 (M+1).

Intermediate 13: Synthesis of 3,5-dichloro-4-(methoxycarbonyl)benzoicacid Step a: Synthesis of dimethyl2-amino-3,5-dichlorobenzene-1,4-dicarboxylate

Sulfuryl chloride (8.5 mL, 10.5 mmol) was added to a round bottom flaskcontaining diethyl ether (150 mL) at 0° C. Dimethyl2-aminobenzene-1,4-dicarboxylate (10 g, 47.8 mmol) was addedportion-wise while maintaining the temperature at 0° C. After completeaddition, reaction mixture was stirred at room temperature for 15 hours.The reaction mixture was neutralized using saturated aqueous sodiumbicarbonate solution under ice-cooled condition, diluted with water (100mL) and then extracted with ethyl acetate (2×800 mL). The combinedorganic layer was washed with brine, dried over anhydrous sodium sulfateand concentrated under vacuum to afford dimethyl2-amino-3,5-dichlorobenzene-1,4-dicarboxylate as a brownish liquid (12.9g, 97%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.82 (s, 2H), 6.95-7.37 (m, 2H), 3.93 (s,3H), 3.86 (s, 3H). MS: 278.09 (M⁺), 280.07 (M+2).

Step b: Synthesis of dimethyl 2,6-dichlorobenzene-1,4-dicarboxylate

In a round bottom flask containing concentrated sulfuric acid (10 mL)was added ice-cold water (10 mL) while maintaining the temperaturearound 0° C. Sodium nitrite (3.7 g, 53 mmol) was added portion wisefollowed by the drop wise addition of hypophosphorous acid (8 mL). Thiswas followed by drop wise addition of a solution of dimethyl2-amino-3,5-dichlorobenzene-1,4-dicarboxylate (5 g, 17.9 mmol, Step a)in acetic acid (10 mL). The resulting reaction mixture was stirred at 0°C. for 2 hours and then stored in a refrigerator at −10° C. for 15hours. The reaction mixture was stirred at room temperature foradditional 2 hours. The reaction mixture was again cooled to 0° C. andneutralized with aqueous ammonia solution, partitioned with ethylacetate (2×15 mL). The combined organic layer was washed with brine,dried over anhydrous sodium sulfate, filtered and concentrated. Thecrude product was purified by silica gel column chromatography usingethyl acetate in hexane (4%) to yield dimethyl2,6-dichlorobenzene-1,4-dicarboxylate as a pale yellow crystalline solid(3.8 g, 79%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (s, 2H), 3.96 (s, 3H), 3.90 (s, 3H).

Step c: Synthesis of 3,5-dichloro-4-(methoxycarbonyl)benzoic acid:

To the stirred solution of dimethyl2,6-dichlorobenzene-1,4-dicarboxylate (2 g, 7.6 mmol, Step b) intetrahydrofuran and water (1:1, 20 mL), sodium hydroxide (304 mg, 7.6mmol) was added and the reaction mixture was stirred at room temperaturefor 16 hours. The reaction mixture was concentrated under vacuum and theresidue was neutralized using cold hydrochloric acid (1N). Theprecipitated solid was filtered under suction, washed with hexane anddried to afford 3,5-dichloro-4-(methoxycarbonyl)benzoic acid as an whitesolid (1.5 g, 85%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.93 (s, 2H), 3.94 (s, 3H). MS: 247.6(M−2), 249.6 (M).

Intermediate 14: Synthesis of 2,6-dichloro-4-(methylcarbamoyl)benzoylchloride Synthesis of 2,6-dichloro-4-(methylcarbamoyl)benzoyl chloride

A mixture of 2,6-dichloro-4-(methylcarbamoyl)benzoic acid (400 mg, 1.6mmol) and thionyl chloride (1.91 g, 16 mmol) in dichloromethane (10 mL)was stirred at 50° C. for 5 hours. The reaction mixture was concentratedunder rotary evaporator and used as such for next step.

The following intermediates were prepared in an analogous manner usingappropriate starting materials. These intermediates are used as such fornext step.

-   2,6-Dichloro-4-(ethylcarbamoyl)benzene carbonyl chloride    (Intermediate 15).-   2,6-Dichloro-4-(2-methoxyethylcarbamoyl)benzene carbonyl chloride    (Intermediate 16).-   2,6-Dichloro-4-(carbamoyl)benzene carbonyl chloride (Intermediate    17).

Intermediate 18: Synthesis of methyl-4-(chlorocarbonyl)3,5-difluoro-benzoate Step a: Synthesis of methyl-3,5-difluorobenzoate

To a solution of 3,5-difluorobenzoic acid (10 gm, 63.2 mmol) indichloromethane (100 mL) was added oxalyl chloride (11.96 gm, 94.9 mmol)at 0° C. followed by addition of dimethylformamide (2 mL). The resultingreaction mixture was stirred for about 3 hours at room temperature.Methanol (100 mL) was added to the reaction mass and stirring wascontinued further for 20-30 minutes. Solvents were evaporated to obtainan oily mass which was further purified by column chromatography oversilica gel (100-200) using ethyl acetate/hexane gradient elution toafford colorless methyl 3,5-difluorobenzoate (10 gm, 91.91%).

¹H NMR (400 MHz, CHCl₃-d): δ 7.52-7.59 (m, 1H), 6.97-7.06 (m, 1H), 3.94(s, 3H).

Step b: Synthesis of methyl-3,5-difluoro-4-formyl benzoate

To a solution of methyl 3,5-difluorobenzoate (1 gm, 5.8 mmol) in drytetrahydrofuran (20 mL), lithium diisopropylamide (0.621 gm, 5.8 mmol,15% solution in tetrahydrofuran and heptane) was added at −78° C. Theresulting reaction mixture was stirred for about 1 hour.Dimethylformamide (0.51 g, 6.9 mmol) was added drop wise to the reactionmixture and stirring was continued for about 3 hours at −78° C. Thereaction was warm up to room temperature. Saturated aqueous ammoniumchloride solution (20 mL) was added to quench the reaction mass. Theaqueous phase was extracted with ethyl acetate (3×50 mL) and thecombined organic layer dried over anhydrous sodium sulfate, filtered andconcentrated. The crude product was purified by column chromatographyover silica gel (100-200) using ethyl acetate/hexane gradient elution toafford methyl 3,5-difluoro-4-formylbenzoate (0.5 gm, 31.25%).

¹H NMR (400 MHz, CHCl₃-d): δ 10.39 (s, 1H), 7.55-7.83 (m, 2H), 3.98 (s,3H).

Step c: Synthesis of 2,6-difluoro-4-(methoxycarbonyl)benzoic acid

To a solution of 3,5-difluoro-4-formylbenzoate (2.5 gm, 12.5 mmol) indimethylsulfoxide (10 mL) were added potassium dihydrogen phosphate(4.25 gm, 31.2 mmol), sodium chlorite (2.26 gm, 25 mmol), sulfamic acid(1.21 gm, 12.5 mmol) and water (5 mL) in one lot at an ambienttemperature. The resulting reaction mixture was stirred for about 3hours. The reaction mass was diluted with water (100 mL). The aqueousphase was extracted with ethyl acetate (3×100 mL) and the combinedorganic layer dried over anhydrous sodium sulfate, filtered andconcentrated to afford 2,6-difluoro-4-(methoxycarbonyl)benzoic acid (1.6gm, 89.88%).

¹H NMR (400 MHz, DMSO-d6): δ 7.55-7.56 (m, 2H), 3.89 (s, 3H).

Step d: Synthesis of methyl-4-(chlorocarbonyl) 3,5-difluoro-benzoate

To a solution of 2,6-difluoro-4-(methoxycarbonyl)benzoic acid (1.6 gm,7.4 mmol) in dichloromethane (25 mL), oxalyl chloride (2.33 gm, 18.5mmol) was added at 0° C. followed by addition of dimethylformamide (1mL). The resulting reaction mixture was stirred for about 3 hours at anambient temperature. Solvents were evaporated to afford crude solidmethyl 4-(chlorocarbonyl)-3,5-difluorobenzoate (1.6 gm, 94.11% Yield).The resulting product was used as such for next step.

Intermediate 19: Synthesis of 4-cyano-2,6-difluorobenzoyl chloride Stepa: Synthesis of 3,5-difluoro-4-formylbenzonitrile

To a solution of 3,5-difluorobenzonitrile (1 gm, 7.1 mmol) in drytetrahydrofuran (20 mL), lithium diisopropylamide (0.769 gm, 7.1 mmol)was added at −78° C. The resulting reaction mixture was stirred forabout 1 hour. Dimethylformamide (0.62 g, 8.5 mmol) was added dropwise tothe reaction mixture and stirring was continued for about 45 minutes.Acetic acid (1.5 mL) and water (40 mL) were added to the cold solutionof reaction mixture. The aquoeus phase was extracted with diethyl ether(4×50 mL). The combined organic layer was dried over anhydrous sodiumsulfate, filtered and concentrated. The crude product was purified bysilica gel (100-200) column chromatography using hexane and ethylacetate as gradient system to afford pure3,5-difluoro-4-formylbenzonitrile (0.5 gm, 31.25%).

¹H NMR (400 MHz, DMSO-d6): δ 10.20 (s, 1H), 7.91-8.04 (m, 2H).

Step b: Synthesis of 4-cyano-2,6-difluoro benzoic acid

To a solution of 3,5-difluoro-4-formylbenzonitrile (0.2 g, 1.1 mmol) indimethylsulfoxide (10 mL), were added a aqueous solution of potassiumdihydrogen phosphate (0.41 g, 2.9 mmol in 0.4 mL of water), sodiumchlorite (0.216 g, 2.3 mmol in 4 mL of water) in one lot at an ambienttemperature. The resulting reaction mixture was stirred for about 1hour. The reaction mass was diluted with water (100 mL). The aquoeusphase was extracted with ethyl acetate (3×100 mL). The combined organiclayer dried over anhydrous sodium sulfate, filtered and concentrated toafford 4-cyano-2,6-difluorobenzoic acid (200 mg, 91.32%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.95 (d, J=7.53 Hz, 2H).

Step c: Synthesis of 4-cyano-2,6-difluorobenzoyl chloride

A mixture of 4-cyano-2,6-difluorobenzoic acid (0.3 gm, 0.5 mmol) andthionyl chloride (5 mL) were refluxed for about 3 hours. The reactionmixture was cooled to ambient temperature, and concentrated under vacuumat 50° C. to afford 4-cyano-2,6-difluorobenzoyl chloride (0.3 gm,91.18%).

The resulting product was used as such for further reaction.

Intermediate 20: Synthesis of 4-bromo-2,6-difluorobenzoic acid

To a solution of 1-bromo-3,5-difluorobenzene (1 g, 5.2 mmol) in drytetrahydrofuran (50 mL), was added lithium diisopropylamide (0.557 g,5.2 mmol) at −78° C. The resulting reaction mixture was stirred at anambient temperature for about 1.5 hours. A cooled reaction mixture waspoured onto dry ice and left for about 20 minutes, followed by mixingwith aqueous hydrochloric acid (6N, 10 mL). The acidic aqueous phase wasextracted with ethyl acetate (3×100 mL). The combined organic layerdried over anhydrous sodium sulfate, filtered and concentrated to afford4-bromo-2,6-difluorobenzoic acid (800 mg, 66.66%).

¹H NMR (400 MHz, DMSO-d₆): Shift 13.80-14.46 (m, 1H), 7.59-7.67 (m, 2H).

Intermediate 21: Synthesis ofN-(2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide Stepa: Synthesis of 7-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine

7-Chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine was preparedfollowing the method described in US 2010/0292262.

¹H NMR (400 MHz, DMSO-d6): δ 8.29 (d, J=3.76 Hz, 1H), 8.17 (d, J=5.02Hz, 1H), 7.93 (dd, J=1.13, 8.41 Hz, 2H), 7.73-7.79 (m, 2H), 7.67 (d,J=8.28 Hz, 2H), 7.08 (d, J=3.51 Hz, 1H). MS: 292.96 (M+1).

Step b: Synthesis of7-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine

7-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine wasprepared following the method described in Synthesis 2005 No. 20 pp3581-3588.

¹H NMR (400 MHz, CHCl₃-d): δ 8.14 (d, J=5.02 Hz, 1H), 7.84-7.86 (m, 2H),7.60-7.66 (m, 1H), 7.49-7.56 (m, 2H), 7.30 (d, J=5.02 Hz, 1H), 6.49 (d,J=1.00 Hz, 1H), 2.75 (d, J=1.25 Hz, 3H). MS: 307.35 (M+1).

Step c: Synthesis of 7-chloro-2-methyl-1H-pyrrolo[2,3-c]pyridine

To a solution of7-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine (220 mg,0.71 mmol) in ethanol (10 mL), a solution of sodium hydroxide (10%, 6mL) was added and the reaction mixture was stirred at room temperaturefor about 16 hours. The solvent was removed under vacuum. The residuewas taken up in ethyl acetate washed with water and brine, dried overanhydrous sodium sulfate & concentrated under vacuum to give7-chloro-2-methyl-1H-pyrrolo[2,3-c]pyridine (110 mg, 92% yield).

¹H NMR (400 MHz, CHCl₃-d): δ 8.47 (br. s, 1H), 7.97 (d, J=5.27 Hz, 1H),7.35 (d, J=5.52 Hz, 1H), 6.30 (dd, J=1.00, 2.01 Hz, 1H), 2.48 (d, J=0.75Hz, 3H). MS: 167.14 (M+1).

Step d: Synthesis ofN-(2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide

To a solution of 7-chloro-2-methyl-1H-pyrrolo[2,3-c]pyridine (1.1 g, 06mmol) in toluene were added tris (dibenzylidene acetone) dipalladium(302 mg, 0.3 mmol), Xantphos (0.286 g, 0.49 mmol), cesium carbonate (4.3g, 13.2 mmol), and cyclopropanecarboxamide (0.842 g, 9 mmol). Theresulting reaction mixture was heated to 110° C. and stirred for about 4hours. The reaction mixture cooled to room temperature diluted withwater and extracted with ethyl acetate. The combined organic layer wasdried over anhydrous sodium sulfate, filtered and concentrated. Thecrude product was purified by silica gel (100-200) column chromatographyto affordN-(2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide (0.45g, 40% yield).

¹H NMR (400 MHz, CHCl₃-d): δ 11.01 (brs, 1H), 10.3 (brs, 1H), 7.75 (d,J=5.52 Hz, 1H), 7.23 (d, J=5.77 Hz, 1H), 6.24 (s, 1H), 2.43 (s, 3H),1.86 (m, 1H), 1.14-1.25 (m, 2H), 0.94-1.12 (m, 2H). MS: 216.06 (M+1).

Intermediate 22: Synthesis of 1H-pyrrolo[3,2-c]pyridine Step a:Synthesis of 3-methylpyridine 1-oxide

3-Methylpyridine (20 g, 21.5 mmol) was added into a round bottom flaskcontaining acetic acid (60 mL). The mixture was treated with ice-cooledhydrogen peroxide (19 mL, 50% solution, 27.6 mmol) and the resultingreaction mixture was heated at 70° C. for 20 hours. The reaction mixturewas concentrated under vacuum and the residue was treated with aqueoussodium hydroxide solution (40%) while maintaining the temperature at 0°C. The mixture was then extracted with dichloromethane. The combinedorganic layer was washed with brine, dried over anhydrous sodium sulfateand concentrated under vacuum to get 3-methylpyridine 1-oxide (24 g,100%) as oil.

¹H NMR (400 MHz, DMSO-d₆): δ 8.09-8.15 (m, 1H), 8.05 (dd, J=6.37, 0.78Hz, 1H), 7.27-7.34 (m, 1H), 7.18 (dt, J=7.81, 0.74 Hz, 1H), 2.51 (m,3H).

Step b: Synthesis of 3-methyl-4-nitropyridine 1-oxide

3-Methylpyridine 1-oxide (2 g, 18.3 mmol, Step a) was added slowly tothe round bottom flask containing sulfuric acid (7 mL, 128 mmol). Themixture was cooled to 0° C. and nitric acid (5.7 mL, 128 mmol) was addeddrop wise. The resulting reaction mixture was heated at 90-100° C. for 2hours. The reaction mixture was poured onto crushed ice and sodiumcarbonate was added portion wise. The aqueous phase was extracted withchloroform. The combined organic layer was washed with brine, dried overanhydrous sodium sulfate and concentrated under vacuum to get3-methyl-4-nitropyridine 1-oxide (1.4 g, 50%).

¹H NMR (400 MHz, CHCl₃-d): δ 8.09-8.17 (m, 2H), 8.02 (d, J=7.09 Hz, 1H),2.62 (s, 3H).

Step c: Synthesis of(E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine

To the stirred solution of 3-methyl-4-nitropyridine 1-oxide (600 mg, 3.8mmol, Step b) in dimethylformamide was added dimethylformamide anddimethylamine (1.14 mL, 8.5 mmol) drop wise at room temperature. Aftercomplete addition, the reaction mixture was stirred at 90° C. for 15hours. The reaction mixture was poured on cold water and theprecipitated solid was filtered, washed with water and dried to get(E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine (470 mg,50%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.68 (d, J=1.88 Hz, 1H), 7.82-7.92 (m, 2H),7.61 (dd, J=7.22, 1.94 Hz, 1H), 5.84 (d, J=13.30 Hz, 1H), 2.98 (br. s.,6H).

Step d: Synthesis of 1H-pyrrolo[3,2-c]pyridine

To a suspension of(E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine (400 mg, Stepc) in methanol was added palladium on carbon (50 mg, 10% wet) and thereaction mixture was stirred under hydrogen atmosphere for 2 hours. Thereaction mixture was filtered through celite and the filtrate wasconcentrated to get 1H-pyrrolo[3,2-c]pyridine (98 mg, 44%) as off-whitesolid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.83 (s, 1H) and 11.50 (br. s., 1H), 8.15(d, J=5.71 Hz, 1H), 7.29-7.56 (m, 2H), 6.55-6.59 (m, 1H).

Intermediate 23: Synthesis of benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate Step a: Synthesis ofbenzyl 1H-pyrrolo[3,2-c]pyridine-1-carboxylate

To a stirred solution of 1H-pyrrolo[3,2-c]pyridine (500 mg, 4.2 mmol) indichloromethane (6 mL), triethylamine (1.2 mL, 8.4 mmol) was added. Themixture was cooled to 0° C. and benzyl chloroformate (1.6 mL, 50%solution in dichloromethane, 4.6 mmol) was added drop wise. Aftercomplete addition, the reaction mixture was stirred at room temperaturefor about 1 hour. On completion, the reaction was quenched by additionof saturated aqueous sodium bicarbonate solution and the organic layerwas separated, washed with brine, dried over anhydrous sodium sulfateand concentrated under vacuum to afford benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (1 g, 100%) as viscousliquid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.93 (d, J=1.00 Hz, 1H), 8.45 (d, J=5.77Hz, 1H), 7.56 (dd, J=8.06, 1.47 Hz, 1H), 7.97 (d, J=5.71 Hz, 1H), 7.82(d, J=3.76 Hz, 1H), 7.32-7.48 (m, 4H), 6.89 (dd, J=3.76, 0.82 Hz, 1H),5.51 (s, 2H).

Step b: Synthesis of benzyl 1H-pyrrolo[3,2-c]pyridine-1-carboxylate5-oxide

A stirred suspension of benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (1 g, 3.9 mmol, Step a))in a mixture of dichloromethane and dimethyl ether (10:1 mL) was treatedportion wise with 3-chloroperoxybenzoic acid (0.85 g, 4.9 mmol) followedby stirring at room temperature for 4 hours. The reaction wasneutralized with saturated aqueous sodium bicarbonate solution. Theorganic layer was separated, dried over anhydrous sodium sulfate andconcentrated to yield benzyl 1H-pyrrolo[3,2-c]pyridine-1-carboxylate5-oxide (1 g, 99%).

Step c: Synthesis of benzyl4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

A solution of benzyl 1H-pyrrolo[3,2-c]pyridine-1-carboxylate 5-oxide(500 mg, 1.9 mmol, Step b) in chloroform was treated dropwise with2,4,4-trimethylpentan-2-amine (1.57 mL, 8.5 mmol) and stirred for about15 minutes. The mixture was cooled to 0° C. followed by the portion wiseaddition of p-toluenesulphonyl chloride (745 mg, 4.2 mmol). The reactionmixture was then stirred at room temperature for 1 hour, diluted withdichloromethane and washed with saturated sodium bicarbonate solution.The organic layer was separated, dried over anhydrous sodium sulfate andconcentrated under vacuum to yield viscous oil. The crude product waspurified by silica gel (100-200 mesh) column chromatography using ethylacetate in hexane (1.5%) as eluent to yield benzyl4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(390 mg, 43%) as a pale yellow solid.

¹H NMR (400 MHz, CHCl₃-d): δ 7.95 (d, J=5.90 Hz, 1H), 7.27-7.50 (m, 7H),6.37 (dd, J=3.76, 0.56 Hz, 1H), 5.44 (s, 2H), 4.42 (s, 1H), 1.96 (s,2H), 1.59 (s, 6H), 0.99 (s, 9H).

Step d: Synthesis of benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

Trifluoroacetic acid (10 ml) was added drop wise to an ice-cooledsuspension of benzyl4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(5 g, 9.7 mmol, Step c) in dichloromethane (30 mL). The reaction mixturewas stirred at room temperature for 4 hours. Upon completion, thereaction mixture was concentrated under vacuum and the residue wasstirred in excess aqueous ammonia solution. The precipitated solid wasfiltered under suction, washed with water and dried to yield benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (2.5 g, 95%) asoff-white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 7.77 (d, J=6.40 Hz, 1H), 7.66 (d, J=3.76Hz, 1H), 7.51-7.56 (m, 2H), 7.36-7.48 (m, 3H), 7.30 (d, J=6.34 Hz, 1H),7.19 (br. s., 2H), 6.98-7.03 (m, 1H).

Intermediate 24: Synthesis ofN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide

To a stirred solution of benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (1 g, 3.5 mmol) intetrahydrofuran was added triethylamine (1 mL, 7 mmol). The mixture wascooled to −10° C. and cyclopropanecarbonyl chloride (0.53 mL, 5.3 mmol)was added drop wise. The reaction mixture was stirred at roomtemperature for 1 hour, followed by concentration under vacuum to removetetrahydrofuran. The residue was dissolved in ethyl acetate and organiclayer was washed with water, dried over anhydrous sodium sulfate andconcentrated to give the crude mixture of benzyl4-[bis(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylateand benzyl4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate.The mixture was treated with a saturated potassium carbonate solution inmethanol and stirred at room temperature followed by removal of methanolunder vacuum at the same temperature. The residue was treated drop wisewith saturated aqueous sodium bicarbonate solution and the precipitatedsolid was filtered, washed with water and dried to yieldN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide (0.5 g, 69%) asa pale yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ 7.91 (d, J=5.96 Hz, 1H), 7.43 (br. s., 1H),7.30 (d, J=5.96 Hz, 1H), 6.74 (br. s., 1H), 2.10-2.20 (m, 1H), 0.84-0.93(m, 4H). MS: 201.1 (M⁺).

N-(1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide (Intermediate 25) wasprepared from benzyl 4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate inan analogous manner using acetyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 9.57 (d, J=0.76 Hz, 1H), 8.40 (d, J=0.82Hz, 1H), 7.55 (d, J=9.03 Hz, 2H), 7.37 (d, J=8.97 Hz, 2H), 2.23 (s, 3H).

N-(1H-pyrrolo[3,2-c]pyridin-4-yl)propanamide (Intermediate 26) wasprepared from benzyl 4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate inan analogous manner using propanoyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 9.5 (s, 1H), 8.40 (d, J=0.82 Hz, 1H), 7.55(d, J=9.03 Hz, 2H), 7.37 (d, J=8.97 Hz, 2H), 2.43-2.55 (m, 2H),1.15-1.23 (t, J=7.2 Hz, 3H).

Intermediate 27: Synthesis of methyl1H-pyrrolo[3,2-c]pyridin-4-ylcarbamate Step a: Synthesis of benzyl4-[(methoxycarbonyl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

A well stirred mixture of a solution of benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (464 mg, 1.74 mmol) andtriethylamine (0.49 mL, 3.47 mmol) in tetrahydrofuran was cooled to −10°C. and treated drop wise with methyl carbonochloridate (0.15 mL, 1.92mmol). The reaction mixture was stirred at room temperature for 30minutes followed by removal of volatiles under vacuum. The residue wasdissolved in ethyl acetate and organic layer was washed with water,dried over anhydrous sodium sulfate and concentrated to yield benzyl4-[(methoxycarbonyl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (278mg, 49.13%).

MS: 325.33 (M⁺).

Step b: Synthesis of methyl 1H-pyrrolo[3,2-c]pyridin-4-ylcarbamate

To a stirred solution of benzyl4-[(methoxycarbonyl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (264mg, 0.82 mmol, Step a) in ethanol (10 mL) was added catalytic amount ofpalladium on carbon (10% wet). The reaction mixture was stirred under anatmosphere of hydrogen gas (atmospheric pressure) for 1 hour. Thereaction mixture was filtered over celite and the residue washed withethanol. The filtrate was concentrated to yield methyl1H-pyrrolo[3,2-c]pyridin-4-ylcarbamate as a white powder (141 mg,90.75%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.49 (br. s., 1H), 9.55-10.05 (m, 1H),7.86 (d, J=5.77 Hz, 1H), 7.33 (dd, J=2.42, 3.04 Hz, 1H), 7.17 (d, J=5.71Hz, 1H), 6.59 (td, J=1.05, 2.04 Hz, 1H), 3.67 (s, 3H). MS: 191.19 (M⁺).

Intermediate 28: Synthesis of 2,6-dichloro-4-(methylcarbamoyl)benzoicacid Step a: Synthesis of methyl2,6-dichloro-4-(methylcarbamoyl)benzoate

A solution of 3,5-dichloro-4-(methoxycarbonyl)benzoic acid (400 mg, 1.6mmol) in dimethylformamide and dichloromethane was treated with oxalylchloride (0.16 ml, 1.9 mmol) drop wise at room temperature followed bystirring at same temperature for 30 minutes. The reaction mixture wasconcentrated under vacuum. The residue was dissolved in dichloromethane,cooled to 0° C. and methylamine hydrochloride (118 mg, 1.7 mmol) wasadded followed by the drop wise addition of triethylamine (0.33 ml, 2.4mmol) at the same temperature. The reaction mixture was allowed to warmto room temperature, stirred for 1 hour and concentrated under vacuum.The residue was treated with ice-cooled aqueous sodium bicarbonatesolution (5%). The precipitated solid was filtered, washed with water,and dried to yield methyl 2,6-dichloro-4-(methylcarbamoyl)benzoate (340mg, 70%) as a pale yellow solid.

Step b: Synthesis of 2,6-dichloro-4-(methylcarbamoyl)benzoic acid

A well stirred mixture of methyl2,6-dichloro-4-(methylcarbamoyl)benzoate (280 mg, 1 mmol, Step a) andanhydrous lithium iodide (429 mg, 3.2 mmol) in pyridine (3 mL) washeated under reflux for 3 hours. The reaction mixture was concentratedunder vacuum to remove pyridine. The residue was acidified usingice-cooled dilute hydrochloric acid solution and partitioned with ethylacetate. The combined organic layer was washed with brine, dried oversodium sulfate, and concentrated under vacuum to obtain a solid thatupon triturating with cold diethyl ether yielded pure2,6-dichloro-4-(methylcarbamoyl)benzoic acid (200 mg, 75%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (d, J=4.58 Hz, 1H), 7.93 (s, 2H), 2.79(d, J=4.58 Hz, 3H). MS: 248.2 (M⁺).

The following intermediates (starting materials) were prepared in ananalogous manner using the appropriate amines.

2,6-Dichloro-4-(ethylcarbamoyl)benzoic acid (Intermediate 29)

¹H NMR (400 MHz, DMSO-d₆): δ 8.74 (s, 1H), 7.95 (s, 2H), 3.24-3.31 (m,2H), 1.13 (t, J=7.23 Hz, 3H). MS: 262.00 (M⁺).

4-Carbamoyl-2,6-dichlorobenzoic acid (Intermediate 30)

¹H NMR (400 MHz, DMSO-d₆): δ 8.23 (s, 1H), 7.97 (s, 3H), 7.77 (s, 1H).MS: 234.23 (M⁺).

2,6-Dichloro-4-[(2-hydroxyethyl)carbamoyl]benzoic acid (Intermediate 31)

¹H NMR (400 MHz, DMSO-d₆): δ 8.75 (t, J=5.52 Hz, 1H), 7.96 (s, 2H), 4.76(s, 1H), 3.51 (d, J=4.71 Hz, 2H). MS: 278.18 (M⁺).

2,6-Dichloro-4-[(2-methoxyethyl)carbamoyl]benzoic acid (Intermediate 32)

¹H NMR (400 MHz, DMSO-d₆): δ 8.75-8.90 (m, 1H), 7.97 (s, 2H), 3.40-3.50(m, 5H), 3.29-3.38 (m, 2H). MS: 292.14 (M⁺).

2,6-Dichloro-4-(dimethylcarbamoyl)benzoic acid (Intermediate 33)

¹H NMR (400 MHz, DMSO-d₆): δ 7.60 (s, 2H), 2.98 (s, 3H), 2.89 (s, 3H).

2,6-Dichloro-4-[(cyanomethyl)carbamoyl]benzoic acid (Intermediate 34)

¹H NMR (400 MHz, DMSO-d₆): δ 9.52 (t, J=5.36 Hz, 1H), 7.99 (s, 2H), 4.36(d, J=5.40 Hz, 2H).

2,6-Dichloro-4-[(2-methylpropyl)carbamoyl]benzoic acid (Intermediate 35)

¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (s, 1H), 7.95 (s, 2H), 3.09 (t, J=6.38Hz, 2H), 1.77-1.92 (m, 1H), 0.89 (d, J=6.69 Hz, 6H). MS: 290.16 (M⁺).

2,6-dichloro-4-(cyclopropylcarbamoyl)benzoic acid (Intermediate 36)

¹H NMR (400 MHz, DMSO-d₆): δ 8.69 (d, J=4.11 Hz, 1H), 7.92 (s, 2H), 2.86(dd, J=7.52, 3.54 Hz, 1H), 0.67-0.75 (m, 2H), 0.54-0.63 (m, 2H). MS:274.19 (M⁺).

2,6-Dichloro-4-(morpholin-4-ylcarbonyl)benzoic acid (Intermediate 37)

¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (s, 2H), 3.50-3.70 (m, 6H). MS: 304.14(M+).

-   2,6-Dichloro-4-(propan-2-ylcarbamoyl)benzoic acid (Intermediate 38)    and 2,6-dichloro-4-(piperidin-1-ylcarbonyl)benzoic acid    (Intermediate 39).

Intermediate 40: Synthesis of 2,6-dichloro-4-cyanobenzoic acid Step a:Synthesis of methyl 2,6-dichloro-4-cyanobenzoate

To a solution of methyl 4-carbamoyl-2,6-dichlorobenzoate (100 mg, 0.4mmol) in pyridine (2 mL) trifluoro-acetic anhydride (0.11 ml, 0.8 mmol)was added drop wise at 0° C. The reaction mixture was allowed to warm toroom temperature and stirred for 1 hour. The contents were poured intoice cold water and the precipitated solid was filtered, washed withwater and dried to yield methyl 2,6-dichloro-4-cyanobenzoate (55 mg,88%) as an off-white solid.

Step b: Synthesis of 2,6-dichloro-4-cyanobenzoic acid

A suspension of methyl 2,6-dichloro-4-cyanobenzoate (620 mg, 2.6 mmol)in pyridine (5 mL) was treated with anhydrous lithium iodide (1000 mg, 8mmol). The resulting reaction mixture was stirred at reflux for 1 hourand concentrated under vacuum to remove pyridine. The residue wasacidified with hydrochloric acid (2N) under ice-cold condition to adjustthe pH between 2 to 3. The precipitated solid was filtered, washed withwater and dried to yield 2,6-dichloro-4-cyanobenzoic acid (380 mg, 86%)as a pale brown solid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.23 (s, 2H).

Intermediate 41: Synthesis of 2,6-dichloro-4-(hydroxymethyl)benzoic acidStep a: Synthesis of methyl 2,6-dichloro-4-(hydroxymethyl)benzoate

A solution of dimethyl 2,6-dichlorobenzene-1,4-dicarboxylate (2.3 g, 8.7mmol) in tetrahydrofuran (10 mL) was treated with sodium borohydride(0.496 g, 13 mmol) and heated to refluxing temperature. The reactionmixture was then treated drop wise with methanol (1 mL) and continuedrefluxing for about 2 hours. The reaction mixture was warmed to roomtemperature and quenched with saturated aqueous ammonium chloridesolution followed by partitioning with ethyl acetate. The combinedorganic layer was washed with brine, dried over sodium sulfate, filteredand concentrated. The crude product was purified by silica gel columnchromatography using ethyl acetate in hexane (10%) as an eluant to yieldmethyl 2,6-dichloro-4-(hydroxymethyl)benzoate as a colorless liquid (1.6g, 80%).

Step b: Synthesis of 2,6-dichloro-4-(hydroxymethyl)benzoic acid

A suspension of methyl 2,6-dichloro-4-(hydroxymethyl)benzoate (5.3 g, 22mmol) in pyridine (20 mL) was treated with anhydrous lithium iodide (9g, 67 mmol). The resulting reaction mixture was heated to reflux for 5hours, cooled to room temperature and concentrated under vacuum. Theresidue was diluted with water and acidified with dilute hydrochloricacid (pH 2-3) and partitioned with ethyl acetate. The combined organiclayer was washed with brine, dried over sodium sulfate, concentrated andthe residue obtained upon triturating with diethyl ether afforded2,6-dichloro-4-(hydroxymethyl)benzoic acid as a pale yellow solid (3.5g, 70%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.44 (s, 2H), 4.52 (d, J=5.15 Hz, 2H), 5.50(t, J=5.71 Hz, 1H).

Intermediate 42: Synthesis of 4-bromo-2,6-dichlorobenzoic acid Step a:Synthesis of 2,6-dichloro-3-nitro-benzoic acid

2,6-Dichloro-benzoic acid (10 g, 52 mmol) was treated with a previouslystirred mixture of nitric acid (15 mL) and sulfuric acid (30 mL) at 55°C. for 30 minutes followed by stirring at room temperature for 30minutes. The reaction mixture was poured in ice cold water (1 L) and thesolid obtained was filtered and dried to afford the product (9 gm). Thefiltrate was extracted with ethyl acetate (2×200 mL). The combinedorganic layer was dried over anhydrous sodium sulphate and concentratedto dryness to yield more product (2 gm). (11 g, 88%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.98 (d, J=8.8 1H), 7.67 (d, J=8.8 1H).

Step b: Synthesis of 3-amino-2,6-dichloro-benzoic acid

2,6-Dichloro-3-nitro-benzoic acid (10 g, 42 mmol, Step a) was added toconcentrated hydrochloric acid (100 mL) followed by stannous chloridedihydrate (38 g, 169 mmol). The reaction mixture was heated at 60° C.for 1 hour. The reaction mixture was diluted with water (500 mL) andextracted with ethyl acetate (2×300 mL). The combined organic layer wasdried over anhydrous sodium sulphate and concentrated under vacuum toafford the sticky material. The sticky material (crude product) wasdissolved in water (turbid solution, 200 mL) and treated slowly withaqueous sodium hydroxide (20%) solution till precipitation whilemaintaining the pH 1-2 (dense precipitate was observed). The precipitatewas filtered and the filtrate was extracted with ethyl acetate (2×200mL) and dried over anhydrous sodium sulphate and concentrated undervacuum to yield 3-amino-2,6-dichlorobenzoic acid as a creamish solid (6gm, 69%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.11 (d, J=8.8 1H), 6.85 (d, J=8.8 1H).

Step c: Synthesis of 3-amino-4-bromo-2,6-dichloro-benzoic acid

A mixture of 3-amino-2,6-dichloro-benzoic acid (5 g, 24 mmol, Step b) inacetonitrile (50 mL) was treated with N-bromosuccinimide (5.1 g, 29mmol) and the reaction mixture was stirred at 90° C. for 45 minutes.Acetonitrile was removed under vacuum and the residue was partitionedbetween water (200 mL) and ethyl acetate (200 mL). Organic layer wasseparated and the aqueous layer was again extracted with ethyl acetate(2×100 mL). The combined organic layer was dried over anhydrous sodiumsulphate and concentrated to yield 3-amino-4-bromo-2,6-dichloro-benzoicacid (5 g, 73%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.49 (s, 1H), 7.11 (d, J=8.8 1H).

Step d: Synthesis of 4-bromo-2,6-dichloro-benzoic acid

An aqueous solution of sodium nitrite (3.64 g, dissolved in 4 mL ofwater, 52 mmol) was added drop wise to the concentrated hydrochloricacid (15 mL), cooled to −10° C. to −5° C.3-Amino-4-bromo-2,6-dichloro-benzoic acid (5 g, 17 mmol, Step c) wasadded to the above solution portion-wise while maintaining thetemperature at about −5° C. The reaction mixture was stirred at the sametemperature for about 2 hours. Hypophosphorous acid (9 mL, 170 mmol) wasadded very slowly over a period of 1 hour at the same temperature. Thereaction mixture was stirred at the same temperature for about 3 hoursand kept in refrigerator overnight. A precipitate was observed at thisstage. The reaction mixture was allowed to warm to room temperature andkept for another 2 hours at the same temperature. The reaction mixturewas filtered, the residue was washed with cold water and dried to yield4-bromo-2,6-dichloro-benzoic acid as a yellowish solid (2 g, 42%).

¹H NMR (400 MHz, MeOH-d₄): δ 7.69 (s, 2H).

Intermediate 43: Synthesis of(2,6-dichloro-phenyl)-(5-oxy-pyrrolo[3,2-c]pyridin-1-yl)-methanone

To a stirred solution of(2,6-dichloro-phenyl)-pyrrolo[3,2-c]pyridin-1-yl-methanone (221 mg, 0.76mmol) in dichloromethane (5.0 mL) was added m-chloroperbezoic acid (296mg, 1.72 mmol) in 2 portions at 0° C. After stirring at room temperaturefor 2 hours, saturated sodium bicarbonate solution was added, andextracted with dichloromethane. The organic layer was dried overmagnesium sulfate and concentrated. The residue was purified by flashchromatography (linear gradient: 0 to 5%, methanol in chloroform) togive (2,6-dichloro-phenyl)-(5-oxy-pyrrolo[3,2-c]pyridin-1-yl)-methanone(204 mg, 0.66 mmol, 87%) as a white solid.

¹H NMR (CDCl₃): δ 8.57 (d, J=1.4 Hz, 1H), 8.47 (d, J=7.5 Hz, 1H), 8.29(dd, J=7.5, 1.4 Hz, 1H), 7.48 (m, 3H), 6.99 (d, J=4.0 Hz, 1H), 6.61 (d,J=4.0 Hz, 1H).

Intermediate 44: Synthesis of 3-chloro-1H-pyrrolo[3,2-c]pyridine

A solution of 1H-pyrrolo[3,2-c]pyridine (200 mg, 1.69 mmol) indichloromethane (10 ml) was treated with N-chlorosuccinimide (339 mg,2.5 mmol) and stirred at room temperature for 5 hours. The reactionmixture was diluted with dichloromethane and washed with aqueous sodiumhydrogen carbonate solution, brine, dried over anhydrous sodium sulfateand concentrated. Purification from silica gel column chromatographyusing methanol and dichloromethane gradient afforded3-chloro-1H-pyrrolo[3,2-c]pyridine (98 mg, 40%).

¹H NMR (400 MHz, MeOH-d₄): δ 8.75-8.80 (m, 1H), 8.19-8.24 (m, 1H),7.42-7.47 (m, 2H). MS: 152.28 (M⁺).

Intermediate 45: Synthesis of N-(3-chloro-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide Step a: Synthesis of3-chloro-1H-pyrrolo[3,2-c]pyridine

A solution of 1H-pyrrolo[3,2-c]pyridine (200 mg, 1.69 mmol) indichloromethane (10 mL) was treated with N-chlorosuccinimide (332 mg,2.5 mmol) and stirred at room temperature for about 5 hours. Thereaction mixture was diluted with dichloromethane and washed with aq.sodium hydrogen carbonate solution, brine, dried over anhydrous sodiumsulphate and concentrated. Purification by silica gel (100-200) columnchromatography using methanol and dichloromethane gradient as eluentafforded 3-chloro-1H-pyrrolo[3,2-c]pyridine (103 mg, 40%).

¹H NMR (400 MHz, MeOH-d₄): δ 8.75-8.80 (m, 1H), 8.19-8.24 (m, 1H),7.42-7.47 (m, 2H). MS: 152.58 (M⁺).

Step b: Synthesis of benzyl3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

To a stirred solution of 3-chloro-1H-pyrrolo[3,2-c]pyridine (1 g, 6.55mmol) in dichloromethane (10 mL), triethylamine (2.3 ml, 16.38 mmol) wasadded. The mixture was cooled to 0° C. and benzyl chloroformate (2.3 mL,50% solution in dichloromethane, 9.83 mmol) was added drop wise. Aftercomplete addition, the reaction mixture was stirred at room temperaturefor about 1 hour. On completion, the reaction was quenched by additionof saturated aq. sodium bicarbonate solution and the organic layer wasseparated, washed with brine, dried over anhydrous sodium sulfate andconcentrated under vacuum to afford benzyl3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (2.42 g, 100%) asviscous liquid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.90 (d, J=1.00 Hz, 1H), 8.57 (d, J=5.77Hz, 1H), 8.09 (s, 1H), 8.01 (dd, J=1.00, 5.77 Hz, 1H), 7.53-7.62 (m,2H), 7.26-7.50 (m, 3H), 5.51 (s, 2H). MS: 286.72 (M⁺).

Step c: Synthesis of benzyl3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 5-oxide

A stirred suspension of benzyl3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (2.4 g, 8.37 mmol) indichloromethane (20 mL) was treated portion wise with3-chloroperoxybenzoic acid (2.165 g, 12.55 mmol) followed by stirring atroom temperature for about 1.5 hours. The reaction was neutralized withsaturated aq. sodium bicarbonate solution. The organic layer wasseparated, dried over anhydrous sodium sulfate and concentrated toafford benzyl 3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 5-oxide(2.45 g, 99%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.56 (d, J=1.00 Hz, 1H), 8.22 (d, J=5.77Hz, 1H), 8.19 (s, 1H), 7.87-7.92 (m, 3H), 7.68-7.74 (m, 1H), 7.29-7.33(m, 2H), 5.49 (s, 2H). MS: 302.72 (M⁺).

Step d: Synthesis of benzyl3-chloro-4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

A solution of benzyl 3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate5-oxide (2.6 g, 8.53 mmol) in chloroform was treated dropwise with2,4,4-trimethylpentan-2-amine (6.026 mL, 37.54 mmol) and stirred forabout 15 minutes. The mixture was cooled to 0° C. followed by theportion wise addition of p-toluenesulphonyl chloride (3.578 g, 18.77mmol). The reaction mixture was then stirred at room temperature forabout 1 hour, diluted with dichloromethane and washed with saturated aq.sodium bicarbonate solution. The organic layer was separated, dried overanhydrous sodium sulfate and concentrated under vacuum to get viscousoil. The crude product was purified by silica gel column chromatographyusing ethyl acetate and hexane (1%) to yield benzyl3-chloro-4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(610.8 mg, 43%) as a pale yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ 7.90 (d, J=5.77 Hz, 1H), 7.75 (s, 1H),7.50-7.57 (m, 2H), 7.36-7.47 (m, 3H), 7.22 (d, J=5.77 Hz, 1H), 5.46 (s,2H), 1.96 (s, 2H), 1.53 (s, 6H), 0.93 (s, 9H). MS: 413.95 (M⁺).

Step e: Synthesis of benzyl4-amino-3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

Trifluoroacetic acid (1.5 mL) was added drop wise to an ice-cooledsuspension of benzyl3-chloro-4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(610 mg) in dichloromethane (10 mL). The reaction mixture was stirred atroom temperature for about 4 hours. Upon completion, the reactionmixture was concentrated under vacuum and the residue was stirred inexcess aqueous ammonia solution. The precipitated solid was filteredunder suction, washed with water and dried to afford benzyl4-amino-3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (354.8 mg, 95%)as an off-white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 7.84 (d, J=6.02 Hz, 1H), 7.74 (s, 1H), 7.53(d, J=6.78 Hz, 1H), 7.36-7.48 (m, 2H), 7.36-7.47 (m, 3H), 7.26 (d,J=6.02 Hz, 1H), 7.07 (br. s., 2H), 5.46 (s, 2H). MS: 301.73 (M⁺).

Step f: Synthesis ofN-(3-chloro-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide

Benzyl 4-amino-3-chloro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (350 mg,1.16 mmol) was stirred in tetrahydrofuran and triethylamine (0.32 mL,2.3 mmol) was added. The mixture was cooled to −10° C. andcyclopropanecarbonyl chloride (0.2 mL, 1.73 mmol) was added drop wise.The reaction mixture was stirred at room temperature for about 1 hour,followed by concentration under vacuum to remove tetrahydrofuran. Theresidue was dissolved in ethyl acetate and organic layer was washed withwater, dried over anhydrous sodium sulfate and concentrated to give thecrude mixture of benzyl 4-[bis(cyclopropylcarbonyl) amino]-3-chlorolH-pyrrolo[3,2-c]pyridine-1-carboxylate and benzyl4[(cyclopropylcarbonyl)amino]-3-chloro1H-pyrrolo[3,2-c]pyridine-1-carboxylate.The mixture was treated with saturated potassium carbonate solution inmethanol (1 mL) and stirred at room temperature. After completion,methanol was removed under vacuum at room temperature. The residue wastreated drop wise with saturated aq. sodium bicarbonate solution and theprecipitated solid was filtered, washed with water and dried to obtainN-(3-chloro-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide (176mg, 69%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 11.81 (br. s., 1H), 10.21 (s, 1H), 8.18 (d,J=5.77 Hz, 1H), 8.00 (d, J=5.77 Hz, 1H), 7.71 (s, 1H), 7.52 (s, 1H),7.26-7.34 (m, 1H), 1.82-2.01 (m, 1H), 0.75-0.84 (m, 4H). MS: 235.67(M⁺).

EXAMPLES Example 1 Synthesis of(2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone

1H-Pyrrolo[2,3-c]pyridine (0.5 g, 4.2 mmol) was added to a stirredsuspension of aluminium chloride (2.82 g, 21.1 mmol) in drydichloromethane (100 mL) and the mixture was stirred at room temperaturefor 1 hour. This was followed by drop-wise addition of 2,6-dichlorobenzoyl chloride (4.42 g, 21.1 mmol). The resulting reaction mixture wasstirred at room temperature for 8 hours. Methanol (25 mL) was addedcautiously to quench the reaction mass followed by concentration undervacuum.

The resulting residue was neutralized using aqueous sodium bicarbonatesolution followed by partitioning with ethyl acetate (3×100 mL). Thecombined organic layer was dried over anhydrous sodium sulfate, filteredand concentrated. Purification by silica gel column chromatography usingethyl acetate and hexane gradient as eluent afforded(2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone (0.5 g,41.66%).

¹H NMR (400 MHz, CHCl₃-d): δ 9.81 (s, 1H), 8.71 (br. s., 1H), 8.36 (d,J=6.34 Hz, 1H), 8.11 (s, 1H), 7.39-7.47 (m, 3H). MS: 291.06 (M+1).

The following compounds were prepared in an analogous manner(2-Chloro-6-fluorophenyl)(1H-pyrrolo[2,3-c]pyridine-3-yl)methanone wasprepared from 1H-Pyrrolo[2,3-c]pyridine and 2-chloro-6-fluoro benzoylchloride (Compound No. 1).

¹H NMR (400 MHz, DMSO-d₆): δ 12.73 (br. s., 1H), 8.88 (d, J=1.00 Hz,1H), 8.36 (d, J=5.52 Hz, 1H), 8.11 (s, 1H), 7.93 (br. s., 1H), 7.61 (td,J=8.28, 6.27 Hz, 1H), 7.49 (d, J=8.28 Hz, 1H), 7.38-7.45 (m, 1H). MS:275.1 (M+1).

3,5-Dichloro-N-ethyl-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzamidewas prepared from 1H-Pyrrolo[2,3-c]pyridine and2,6-dichloro-4-(ethylcarbamoyl)benzene carbonyl chloride (Compound No.2).

¹H NMR (400 MHz, DMSO-d₆): δ 12.83 (br. s., 1H), 8.89 (s, 1H), 8.81 (t,J=5.02 Hz, 1H), 8.36 (d, J=4.77 Hz, 1H), 8.16 (br. s., 1H), 8.04 (s,2H), 3.30-3.41 (m, 2H), 1.16 (t, J=7.15 Hz, 3H). MS: 361.90 (M⁺), 363.87(M+2).

N-[3-(2,6-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamidewas similarly synthesized fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide and2,6-dichloro benzoyl chloride (Compound No. 5).

¹H NMR (400 MHz, DMSO-d₆): δ 11.85-11.96 (m, 1H), 11.06-11.19 (m, 2H),8.11 (d, J=5.14 Hz, 1H), 7.54-7.66 (m, 3H), 2.08-2.19 (m, 1H), 0.88-0.96(m, 4H). MS: 373.87 (M+1).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-methylbenzamidewas similarly synthesized from N-(1H-pyrrolo[2,3-c]pyridin-7-yl)acetamide and 2,6-dichloro-4-(methylcarbamoyl)benzene carbonyl chloride(Compound No. 7).

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.80 (d, J=4.27 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.03 (s, 2H), 7.93(br. s., 1H), 2.83 (d, J=4.52 Hz, 3H), 2.19 (s, 3H). MS: 404.84 (M⁺),406.82 (M+2).

N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamidewas prepared analogously using N-(1H-pyrrolo[2,3-c]pyridin-7-yl)acetamide and 2-chloro-6-fluoro benzoyl chloride (Compound No. 8).

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (br. s., 1H), 10.76 (br. s., 1H),8.12 (d, J=5.27 Hz, 1H), 7.89 (s, 1H), 7.85 (br. s., 1H), 7.61 (td,J=8.28, 6.27 Hz, 1H), 7.50 (d, J=8.03 Hz, 1H), 7.43 (t, J=8.66 Hz, 1H),2.01 (s, 3H). MS: 331.9 (M⁺), 333.88 (M+2).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-ethylbenzamidewas prepared from N-(1H-pyrrolo[2,3-c]pyridin-7-yl) acetamide and2,6-dichloro-4-(ethylcarbamoyl)benzene carbonyl chloride (Compound No.9).

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.81 (t, J=5.40 Hz, 1H), 8.13 (d, J=4.77 Hz, 1H), 8.04 (s, 2H), 7.93(br. s., 1H), 3.30-3.36 (m, 2H), 2.19 (s, 3H), 1.16 (t, J=7.28 Hz, 3H).MS: 418.82 (M⁺), 420.80 (M+2).

(4-Bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone wasprepared from 1H-Pyrrolo[2,3-c]pyridine and 4-bromo-2,6-dichloro benzoylchloride (Compound No. 10).

¹H NMR (400 MHz, DMSO-d₆): δ 12.87 (br.s, 1H), 8.82-8.87 (m, 1H),8.12-8.35 (m, 3H), 8.18 (br.s, 1H), 7.97 (s, 2H). MS: 371 (M+1), 372.9(M+2).

N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamidewas similarly synthesized fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide and2-chloro-6-fluoro benzoyl chloride (Compound No. 11).

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (br. s., 1H), 11.14 (s, 1H), 8.13 (d,J=5.27 Hz, 1H), 7.82 (d, J=2.76 Hz, 2H), 7.61 (d, J=6.27 Hz, 1H), 7.50(d, J=8.03 Hz, 1H), 7.43 (s, 1H), 2.07-2.19 (m, 1H), 0.87-0.97 (m, 4H).MS: 358.15 (M⁺), 360.15 (M+2).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamidewas similarly synthesized fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide and2,6-dichloro-4-(methylcarbamoyl)benzene carbonyl chloride (Compound No.12).

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (br. s., 1H), 11.11 (br. s., 1H),8.79 (d, J=4.52 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.02 (s, 2H), 7.85(br. s., 1H), 2.81 (d, J=4.4 Hz, 3H), 2.07-2.12 (m, 1H), 0.88-0.96 (m,4H). MS: 431.11 (M⁺), 433.13 (M+2).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethylbenzamidewas similarly synthesized fromN-(1-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide and2,6-dichloro-4-(ethylcarbamoyl)benzene carbonyl chloride (Compound No.13).

¹H NMR (400 MHz, DMSO-d₆): δ 11.96 (br. s., 1H), 11.12 (br. s., 1H),8.81 (t, J=5.40 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.04 (s, 2H), 7.85(br. s., 1H), 3.29-3.36 (m, 2H), 2.09-2.17 (m, 1H), 1.16 (t, J=7.28 Hz,3H), 0.87-0.96 (m, 4H). MS: 445.15 (M⁺), 447.13 (M+2).

3,5-Dichloro-N-(2-methoxyethyl)-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzamidewas prepared from 1H-Pyrrolo[2,3-c]pyridine and2,6-dichloro-4-(2-methoxyethylcarbamoyl)benzene carbonyl chloride(Compound No. 14).

¹H NMR (400 MHz, DMSO-d₆): δ 12.79 (br. s., 1H), 8.88 (s, 2H), 8.36 (d,J=5.02 Hz, 1H), 8.15 (br. s., 1H), 8.06 (s, 2H), 3.45-3.52 (m, 4H), 3.33(s., 3H). MS: 392.63 (M⁺), 394.64 (M+2).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-propylbenzamidewas prepared from N-(1H-pyrrolo[2,3-c]pyridin-7-yl) acetamide and2,6-dichloro-4-(1-propylcarbamoyl)benzene carbonyl chloride (CompoundNo. 15).

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.79 (t, J=5.52 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.04 (s, 2H), 7.92(dd, J=6.15, 3.39 Hz, 1H), 3.22-3.30 (m, 2H), 2.19 (s, 3H), 1.53-1.61(m, 2H), 0.92 (t, J=7.40 Hz, 3H). MS: 433.75 (M⁺), 435.74 (M+2).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(2-methoxyethyl)benzamidewas prepared analogously usingN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide and2,6-dichloro-4-(2-methoxyethylcarbamoyl)benzene carbonyl chloride(Compound No. 16).

¹H NMR: (400 MHz, DMSO-d₆): δ 11.95 (br. s., 1H), 11.11 (s, 1H),8.85-8.93 (m, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.06 (s, 2H), 7.85 (d,J=9.79 Hz, 1H), 3.45-3.51 (m, 4H), 3.29 (s, 3H), 2.08-2.17 (m, 1H),0.86-0.97 (m, 4H). MS: 475.75 (M⁺), 477.72 (M+2).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-(2-methoxyethyl)benzamidewas prepared analogously using N-(1H-pyrrolo[2,3-c]pyridin-7-yl)acetamide and 2,6-dichloro-4-(2-methoxyethylcarbamoyl)benzene carbonylchloride (Compound No. 17).

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.84-8.93 (m, 1H), 8.13 (d, J=5.27 Hz, 1H), 8.06 (s, 2H), 7.94 (br. s.,1H), 3.45-3.51 (m, 4H), 3.29 (s, 3H), 2.19 (s, 3H). MS: 449.81 (M⁺),451.78 (M+2).N-[3-(2,6-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamidewas prepared using N-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide and 2,6-dichloro benzoyl chloride (Compound No. 18).

¹H NMR (400 MHz, DMSO-d₆): δ 12.53 (br. s., 1H), 10.65 (s, 1H), 8.77(br. s., 1H), 8.57 (d, J=1.00 Hz, 1H), 7.94 (br. s., 1H), 7.57-7.64 (m,2H), 7.50-7.57 (m, 1H), 1.98-2.07 (m, 1H), 0.73-0.87 (m, 4H). MS: 374.70(M⁺), 376.70 (M+2).

N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamidewas prepared using N-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide and 2-chloro-6-fluoro benzoyl chloride (Compound No. 19).

¹H NMR (400 MHz, DMSO-d₆): δ 12.56 (br. s., 1H), 10.66 (s, 1H), 8.79(br. s., 1H), 8.58 (s, 1H), 8.00 (s, 1H), 7.54-7.63 (m, 1H), 7.47 (d,J=8.03 Hz, 1H), 7.40 (t, J=8.53 Hz, 1H), 1.94-2.07 (m, 1H), 0.74-0.89(m, 4H). MS: 358.75 (M+1).

3,5-Dichloro-4-({5-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamidewas prepared using N-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide and 2,6-dichloro-4-(methylcarbamoyl)benzene carbonylchloride (Compound No. 20).

¹H NMR (400 MHz, DMSO-d₆): δ 12.61 (br. s., 1H), 10.67 (br. s., 1H),8.74-8.77 (m, 1H), 8.58 (s, 1H), 8.01 (s, 2H), 7.85-7.95 (m, 1H), 2.83(d, J=4.27 Hz, 3H), 2.02 (br. s., 1H), 0.75-0.88 (m, 4H). MS: 431.70(M+1), 433.69 (M+2).

N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]propanamidewas synthesized using N-(1H-pyrrolo[2,3-c]pyridin-7-yl)propanamide and2-chloro-6-fluoro benzoyl chloride (Compound No. 28).

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (br. s., 1H), 10.73 (s, 1H), 8.12 (d,J=5.27 Hz, 1H), 7.87 (br. s., 1H), 7.85 (br. s., 1H), 7.61 (td, J=8.22,6.40 Hz, 1H), 7.38-7.53 (m, 2H) 2.45-2.54 (m, 2H merged with DMSO), 1.14(t, J=7.53 Hz, 3H). MS: 346.79 (M+1), 348.81 (M+3).

N-[3-(2-Chloro-3,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamidewas prepared using N-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide and 2-chloro-3,6-difluorobenzoyl chloride (Compound No. 37).

¹H NMR (400 MHz, CDCl₃-d1): δ 12.14 (br. s., 1H), 9.13 (br. s., 1H),8.11-8.33 (m, 2H), 7.56 (s, 1H), 7.21-7.26 (m, 1H), 7.07-7.12 (m, 1H),2.17 (m, 1H), 0.98-1.03 (m, 2H), 1.14-1.62 (m, 2H). MS: 376.83 (M+1).

N-[3-(2,4,6-Trichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(Compound No. 45) was prepared usingN-(1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropane carboxamide and2,4,6-trichlorobenzoyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 12.12 (br. s., 1H), 11.25 (br. s., 1H),8.13 (d, J=5.27 Hz, 1H), 7.98 (br. s., 1H), 7.88 (s, 2H), 7.80 (s, 1H),2.09-2.17 (m, 1H), 0.89-0.98 (m, 4H). MS: 469.15 (M+1).

3,5-Dichloro-4-({5-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethylbenzamide

¹H NMR (400 MHz, DMSO-d₆): δ 12.60 (br. s., 1H), 10.67 (br. s., 1H),8.79 (t, J=5.52 Hz, 1H), 8.57 (d, J=1.25 Hz, 1H), 8.03 (s, 2H),3.29-3.37 (m, 2H), 2.02 (br. s., 1H), 1.16 (t, J=7.15 Hz, 3H), 0.72-0.88(m, 4H).

Example 2 Synthesis of(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone(Compound No. 3)

A mixture of4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone (50mg, 0.13 mmol, Compound No. 28), sodium azide (85 mg, 0.54 mmol), copperiodide (7.7 mg, 0.04 mmol) and N,N′-dimethyl ethylenediamine (19 mg,0.24 mmol) in dimethylsulfoxide (2 mL) was heated at 100° C. for 24hours. The reaction mixture was cooled to room temperature and treatedcautiously with saturated aqueous ammonium chloride solution (10 mL)followed by partitioning with ethyl acetate (3×50 mL). The combinedorganic layer was dried over anhydrous sodium sulfate, filtered andconcentrated. The crude product was purified by silica gel (100-200)column chromatography to afford pure(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone(11.2 mg, 26.82%).

¹H NMR (400 MHz, CHCl₃-d+DMSO-d₆): δ 8.71-8.77 (m, 1H), 8.28-8.35 (m,1H), 7.76-8.15 (m, 1H), 7.55-7.65 (m, 1H), 6.69 (s, 2H). MS: 306.06(M⁺).

Example 3 Synthesis of[2,6-dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl](1H-Pyrrolo[2,3-c]pyridin-3-yl)methanone

A mixture of(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone (50mg, 0.135 mmol),[1-(tert-butoxycarbonyl)-3,5-dimethyl-1H-pyrazol-4-yl]boronic acid (52mg, 0.162 mmol), potassium carbonate (55 mg, 0.4 mmol), water (0.5 mL)and 1,1′bis(diphenylphosphino)ferrocene]dichloropalladium (II) (11 mg,0.0135 mmol) in 1,4 dioxane (2 mL) was heated at 100° C. for 2 hours ina sealed vial. The reaction mixture was cooled to room temperature,diluted with water (10 mL) and extracted with ethyl acetate (2×50 mL).The combined organic layer was dried over anhydrous sodium sulfate andconcentrated under vacuum. The resulting crude mass was purified bypreparative thin layer chromatography using methanol in dichloromethane(10%) to afford[2,6-dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl](1H-pyrrolo[2,3-c]pyridin-3-yl)methanone(0.012 g, 23%).

¹H NMR (400 MHz, DMSO-d₆): δ 12.69 (br. s., 1H), 12.51 (br. s., 1H),8.88 (s, 1H), 8.36 (d, J=5.27 Hz, 1H), 8.15 (br. s., 1H), 7.71-8.05 (m,1H), 7.49 (s, 2H), 2.29 (s., 6H). MS: 385.01 (M⁺), 387.03 (M+2).

The following compound was prepared from4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone byan analogous procedure using appropriate starting material.

[2,6-Dichloro-4-(2-methoxypyrimidin-5-yl)phenyl](1H-pyrrolo[2,3-c]pyridin-3-yl)methanone(Compound No. 4).

¹H NMR (400 MHz, DMSO-d₆): δ 12.76 (br. s., 1H), 9.11 (s, 2H), 8.88 (s,1H), 8.37 (br. s., 1H), 8.15 (br. s., 1H), 8.08 (s, 2H), 4.00 (s, 3H).MS: 400.86 (M+1).

Example 4 Synthesis of3,5-dichloro-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzonitrile(Compound No. 6)

A mixture of(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone(100 mg, 0.27 mmol) in dimethylformamide (3 mL) was treated with zinccyanide (25.2 mg, 0.21 mmol), tris(dibenzylideneacetone)dipalladium (0)(6.21 mg, 0.006 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (5.6 mg,0.01 mmol) followed by heating at 130° C. for 16 hours. The reactionmixture was diluted with ethyl acetate, filtered over celite, and thefiltrate was concentrated under vacuum. The crude compound was purifiedby LC-MS to afford3,5-dichloro-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzonitrile (2mg, 2%).

¹H NMR (400 MHz, CHCl₃-d): δ 8.61 (s, 1H) 8.41 (m, 1H), 8.21 (m, 1H),7.48-7.56 (m, 3H). MS: 316.62 (M+1).

Example 5 Synthesis ofN-{3-[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 23)

A mixture ofN-[3-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(0.1 g, 0.2 mmol) and (3,5-dimethyl-1,2-oxazol-4-yl)boronic acid (0.037g, 0.26 mmol) was taken in a vial. To the reaction mixture, 1,4dioxane(3 mL), potassium carbonate (0.091 g, 0.6 mmol) and water (0.5 mL) wereadded. The whole reaction mixture was stirred with argon gas for aboutfive minutes. Finallydichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) (0.018 g,0.02 mmol) was added to the reaction mixture, the vial was sealedproperly and heated at 90° C. for about 4 hours. The reaction mixturewas cooled to room temperature, followed by addition of water (25 mL),extracted with ethyl acetate (2×50 mL). The organic layer was dried overanhydrous sodium sulphate and concentrated under vacuum to get thecrude. The crude was purified by preparative thin layer chloromatographyusing methanol (6%) in dichloromethane to obtainN-{3-[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(0.015 g, 15%).

¹H NMR (400 MHz, CHCl₃-d): δ 12.16 (br. s., 1H), 9.18 (br. s., 1H), 8.11(d, J=5.02 Hz, 1H), 7.99-8.08 (m, 1H), 7.61 (br. s., 1H), 7.29 (s, 2H),2.49 (s, 3H), 2.34 (s, 3H), 1.75 (dt, J=7.65, 3.70 Hz, 1H), 1.12-1.19(m, 2H), 0.89-1.01 (m, 2H). MS: 469.78 (M⁺), 471.79 (M+2).

N-{3-[2,6-Dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 46) was analogously synthesized fromN-[3-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamideand [1-(tert-butoxycarbonyl)-3,5-di methyl-1H-pyrazol-4-yl]boronic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 12.68 (br. s., 1H), 11.91 (br. s., 1H),11.14 (br. s., 1H), 8.12 (d, J=5.27 Hz, 1H), 7.88 (br. s., 1H), 7.50 (s,2H), 2.29 (s, 6H), 2.12-2.17 (m, 1H), 0.88-0.97 (m, 4H). MS: 408.8 (M⁺)and 410.8 (M+2).

Example 6 Synthesis ofN-{3-[2,6-dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 47)

A mixture ofN-[3-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(108 mg, 0.23 mmol), pyrimidin-5-yl-boronic acid (42 mg, 0.34 mmol),potassium carbonate (95.22 mg, 0.69 mmol), water (0.5 mL) anddichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) (34.8 mg,0.047 mmol) in 1,4 dioxane (3 mL) was heated overnight at 100° C. in asealed vial. The reaction mixture was cooled to room temperature,diluted with water (10 mL) and extracted with ethyl acetate (2×50 mL).The combined organic layer was dried over anhydrous sodium sulphate andconcentrated under vacuum. The resulting crude mass was purified bypreparative thin layer chloromatography using 10% methanol indichloromethane to affordN-{3-[2,6-dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7yl}cyclopropanecarboxamide (15 mg, 14.01%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (br. s., 1H), 11.13 (s, 1H), 9.32 (s,2H), 9.28 (s, 1H), 8.18 (s, 2H), 8.14 (d, J=5.02 Hz, 1H), 7.88 (br. s.,1H), 2.09-2.17 (m, 1H), 0.88-0.96 (m, 4H). MS: 451.09 (M⁺).

The following compound was synthesized following a similar procedureusingN-[3-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide and an appropriate boronic acids.

N-{3-[2,6-Dichloro-4-(6-methoxypyridin-3-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 48)

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (br. s., 1H), 11.13 (s, 1H), 8.68 (d,J=2.26 Hz, 1H), 8.23 (d, J=2.51 Hz, 1H), 8.21 (d, J=2.76 Hz, 1H), 8.13(d, J=5.02 Hz, 1H), 7.98 (s, 2H), 7.86 (br. s., 1H), 6.97 (d, J=8.78 Hz,1H), 3.93 (s, 3H), 1.98-2.13 (m, 1H), 0.86-0.98 (m, 4H). MS: 481.14(M⁺).

N-{3-[2,6-Dichloro-4-(6-fluoropyridin-3-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 49)

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (br. s., 1H), 11.13 (s, 1H), 8.76 (d,J=2.26 Hz, 1H), 8.45-8.54 (m, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.07 (s,2H), 7.84-7.90 (m, 1H), 7.37 (dd, J=2.76, 8.53 Hz, 1H), 2.01-2.15 (m,1H), 0.87-0.96 (m, 4H). MS: 469.12 (M⁺).

N-{3-[2,6-Dichloro-4-(1-methyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide.(Compound No. 50)

¹H NMR (400 MHz, DMSO-d₆): δ 11.90 (br. s., 1H), 11.11 (s, 1H), 8.41 (s,1H), 8.11 (s, 2H), 7.83-7.89 (m, 4H), 3.89 (s, 3H), 2.04-2.19 (m, 1H),0.86-0.97 (m, 4H). MS: 454.15 (M⁺).

N-{3-[4-(3,5-Dimethyl-1,2-oxazol-4-yl)-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 65)

¹H NMR (400 MHz, DMSO-d₆): δ 11.96 (br. s., 1H), 11.14 (br. s., 1H),8.15 (d, J=5.27 Hz, 1H), 8.02 (s, 1H), 7.94 (d, J=5.27 Hz, 1H), 7.40 (d,J=8.28 Hz, 2H), 3.35 (s, 3H), 2.33 (s, 3H), 2.04-2.13 (m, 1H), 0.87-0.98(m, 4H). MS: 436.41 (M+).

Example 7 Synthesis ofN-{3-[4-(acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide.(Compound No. 27) Step a: Synthesis ofN-[3-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(Compound No. 22)

Aluminium chloride (4.3 g, 32.2 mmol) was added to a solution ofN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide (0.65 g, 3.2mmol) in dichloromethane (100 mL) under Argon atmosphere. The mixturewas stirred at room temperature under inert atmosphere for about 1 hour,followed by drop wise addition of 4-bromo-2,6-dichlorobenzoyl chloride(4.6 g, 15.9 mmol) in dichloromethane (20 mL). After complete additionthe reaction mixture was stirred at room temperature for about 16 hours.Methanol (100 mL) was poured in the reaction mixture and stirred well.Solvent was evaporated under vacuum, water (250 mL) was added andextracted with ethyl acetate (3×200 mL). The organic layer was washedwith aqueous sodium bicarbonate (10%) solution. The organic layer wasdried over anhydrous sodium sulfate and concentrated under vacuum. Thecrude product was purified by silica gel (100-200 mesh) columnchromatography using 2% methanol in dichloromethane as an eluant toaffordN-[3-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(0.8 g, 54%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (br. s., 1H), 11.10 (s, 1H), 8.13 (d,J=5.52 Hz, 1H), 7.97 (s, 2H), 7.90 (br. s., 1H), 2.12 (br. s., 1H),0.88-0.97 (m, 4H). MS: 452.64 (M−1), 454.65 (M+1), 456.64 (M+3).

Step b: Synthesis ofN-[3-(4-amino-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(Compound No. 26)

N-[3-(4-Bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(0.5 g, 1.1 mmol) was taken in a reaction vial, followed by addition ofsodium azide (0.286 g, 4.4 mmol), cuprous iodide (0.063 g, 0.3 mmol),N,N′-dimethylethane-1,2-diamine (0.058 g, 0.6 mmol) anddimethylsulfoxide (12 mL). The vial was sealed properly and heated at110° C. for overnight. The reaction mixture was cooled to roomtemperature and water (100 mL) was added, extracted with ethyl acetate(3×150 mL). The organic layer was dried over anhydrous sodium sulfateand concentrated under vacuum. The crude product was purified by silicagel (100-200 mesh) column chromatography using 2% methanol indichloromethane to afford pureN-[3-(4-amino-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(0.23 g, 47%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.79 (br. s., 1H), 11.10 (s, 1H), 8.08 (d,J=5.27 Hz, 1H), 7.73 (br. s., 1H), 6.67 (s, 2H), 5.97 (s, 2H), 2.13 (m,1H), 0.81-0.99 (m, 4H). MS: 389.87 (M⁺), 391.88 (M+2).

Step c: Synthesis ofN-{3-[4-(acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide

To a solution ofN-[3-(4-amino-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(0.2 g, 0.5 mmol) in dichloromethane (10 mL), pyridine (0.081 g, 1 mmol)was added followed by addition of acetyl chloride (0.044 g, 0.56 mmol)at 0° C. After stirring at 0° C. for about 0.5 hour, the reaction waskept at room temperature for about 2 hours. Dichloromethane wasevaporated; water (50 mL) was added to the reaction mixture, extractedwith ethyl acetate (2×100 mL). The organic layer was dried overanhydrous sodium sulfate and concentrated under vacuum. The crudeproduct was purified by silica gel (100-200 mesh) column chromatography.Elution with 2.5% methanol in dichloromethane affordedN-{3-[4-(acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(0.06 g, 27%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.89 (br. s., 1H), 11.11 (s, 1H), 10.44(s, 1H), 8.11 (d, J=5.27 Hz, 1H), 7.65-7.98 (m, 4H), 2.02-2.18 (m, 4H),0.87-0.98 (m, 4H). MS: 431.87 (M⁺), 433.89 (M+2).

Example 8 Synthesis ofN-[3-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(Compound No. 39)

N—OH-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide (1 g, 4.9 mmol)was added to a stirred suspension of aluminium chloride (3.30 g, 24.8mmol) in dry dichloromethane (100 mL) and the mixture was stirred atroom temperature for about 1 hour, followed by drop-wise addition of2,6-dichloro-4-cyanobenzoyl chloride (1.16 g, 4.9 mmol). The resultingreaction mixture was stirred at room temperature for about 8 hours.Methanol (25 mL) was added cautiously to quench the reaction massfollowed by concentration under vacuum. The resulting residue was takenup in water followed by partitioning with ethyl acetate. The combinedorganic layer was dried over anhydrous sodium sulfate, filtered andconcentrated. The crude product was purified by silica gel (100-200)column chromatography using ethyl acetate and hexane gradient elution toaffordN-[3-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7yl]cyclopropanecarboxamide (0.75 g, 37.87%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (br. s., 1H), 11.10 (s, 1H),8.28-8.33 (m, 2H), 8.14 (d, J=5.52 Hz, 1H), 7.89-8.04 (m, 2H), 2.07-2.18(m, 1H), 0.83-0.98 (m, 4H).

The following compounds were prepared in an analogous manner:

N-[3-(4-Cyano-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide (Compound No. 51) was prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide and4-cyano-2,6-difluorobenzoyl chloride.

¹H NMR (400 MHz, DMSO-d6): δ 12.03 (br. s., 1H), 10.93-11.23 (m, 1H),8.16 (d, J=5.27 Hz, 1H), 8.07 (d, J=3.26 Hz, 1H), 8.01-8.05 (m, 2H),7.93 (d, J=5.52 Hz, 1H), 2.01-2.22 (m, 1H), 0.88-0.97 (m, 4H). MS:367.19 (M⁺).

Methyl4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluorobenzoate(Compound No. 52) was prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide andmethyl-4(chlorocarbonyl) 3,5-difluoro benzoate.

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 11.13 (s, 1H), 8.15 (d,J=5.27 Hz, 1H), 8.00 (s, 1H), 7.92 (d, J=5.02 Hz, 1H), 7.79 (d, J=7.28Hz, 2H), 3.93 (s, 3H), 2.02-2.2 (m, 1H), 0.84-0.99 (m, 4H). MS: 400.19(M⁺).

N-[3-(4-Cyano-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide(Compound No. 53) was prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)acetamide and 4-cyano-2,6-difluorobenzoyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 12.10 (br. s., 1H), 10.76 (br. s., 1H),8.10-8.21 (m, 2H), 8.00-8.07 (m, 2H), 7.94 (dd, J=1.88, 5.40 Hz, 1H),2.14-2.22 (m, 3H). MS: 341.08 (M⁺).

N-[3-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide(Compound No. 21) was prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)acetamide and 4-cyano-2,6-dichlorobenzoyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.74 (br. s., 1H),8.30 (s, 1H), 8.13 (s, 1H), 8.07 (s, 2H), 2.18 (s, 3H). MS: 371.76(M+1).

N-[3-(4-Bromo-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide (Compound No. 69) was prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropane carboxamide and4-bromo-2,6-difluorobenzoyl chloride

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (br.s, 1H), 11.13 (br.s, 1H),8.13-8.15 (m, 1H), 8.02 (s, 1H), 7.89-7.97 (m, 1H), 7.70 (d, J=7.03 Hz,2H), 2.09-2.18 (m, 1H), 0.94 (br. s., 4H). MS: 419.86 (M⁺), 421.85(M+2).

Methyl3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoate(Compound No. 25) was analogously prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide andmethyl-4(chlorocarbonyl) 3,5-dichloro benzoate.

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (br. s., 1H), 11.11 (s, 1H), 8.13 (d,J=5.02 Hz, 1H), 8.08 (s, 2H), 7.87-7.90 (m, 2H), 3.93 (s, 3H), 2.07-2.16(m, 1H), 0.88-0.95 (m, 4H). MS: 432.88 (M⁺).

3,5-Dichloro-N-methyl-4-{[7-(propanoylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}benzamide(Compound No. 38) was similarly prepared fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)propanamide and2,6-dichloro-4-(methylcarbamoyl)benzene carbonyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.72 (br. s., 1H),8.81 (d, J=4.52 Hz, 1H), 8.12 (d, J=4.77 Hz, 1H), 8.03 (s, 2H), 7.95 (d,J=7.03 Hz, 1H), 2.83 (d, J=4.52 Hz, 3H), 2.54 (qt, 2H merged with DMSO),1.14 (t, J=7.53 Hz, 3H). MS: 419.84 (M⁺), 421.84 (M+2).

N-[3-(4-Bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide(Compound No. 24) was analogously synthesized fromN-(1H-pyrrolo[2,3-c]pyridin-7-yl)acetamide and4-Bromo-2,6-dichlorobenzoyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.74 (br. s., 1H),8.12 (d, J=5.27 Hz, 1H), 7.97 (s, 2H), 7.70-7.90 (m, 2H), 2.19 (s, 3H).MS: 428.64 (M+1).

N-[3-(2-Chloro-4-cyano-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide.

¹H NMR (400 MHz, DMSO-d₆): δ 11.81 (br. s., 1H), 11.09 (br. s., 1H),8.10 (d, J=5.52 Hz, 1H), 7.73-7.88 (m, 2H), 7.60 (s, 1H), 7.26 (s, 1H),2.02-2.13 (m., 1H), 0.81-1.02 (m, 4H). MS: 383.05 (M+1).

Example 9 Synthesis of3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N4-[2,3-dihydroxypropyl]benzamide(Compound No. 32)

Step a: Synthesis of3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoicacid

A mixture of methyl3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoate,(30 mg, 0.06 mmol) and sodium hydroxide (27 mg, 0.06 mmol) were stirredin tetrahydrofuran and water (1:1, 6 mL) solution for about 2 hours,followed by slowly addition of aqueous hydrochloric acid till pH 4-5.The precipitated product was filtered and dried under vacuum to afford3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoicacid (20 mg, 62.5%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.44-8.52 (m, 1H), 8.12 (d, J=6.27 Hz, 1H),8.06 (s, 2H), 2.24-2.35 (m, 1H), 0.90-1.20 (m, 4H). MS: 416.89 (M⁻).

The following compound was prepared in a similar fashion starting fromN-[3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycineethyl ester.

N-[3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycine(Compound No. 36)

¹H NMR (400 MHz, DMSO-d6): δ 12.83 (br. s, 1H), 12.05 (br s., 1H),11.08-11.52 (m, 1H), 9.25 (t, J=5.77 Hz, 1H), 8.13 (d, J=5.52 Hz, 1H),8.08 (s, 2H), 8.00 (br. s., 1H), 3.95-4.01 (m, 2H), 2.09-2.17 (m, 1H),0.89-0.99 (m, 4H). MS: 474.96 (M⁺).

Step b: Synthesis of3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N+2,3-dihydroxypropyl)benzamide

To a solution of3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoicacid (50 mg, 0.11 mmol) in dimethylformamide (3 mL),1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (27.4 mg, 0.14 mmol),1-hydroxybenzotriazole (19.37 mg, 0.14 mmol) and 3-aminopropane-1,2-diol(13 mg, 0.14 mmol) were added in one lot at room temperature. Theresulting reaction mixture was stirred at room temperature for about 5hours. Saturated aquoues sodium bicarbonate solution (20 mL) was addedto quench the reaction mass. The aquoues phase was extracted with ethylacetate and the combined organic layer dried over anhydrous sodiumsulfate, filtered and concentrated. The crude product was purified bysilica gel (100-200) column chromatography using ethyl acetate andhexane gradient elution to afford3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(2,3-dihydroxypropyl)benzamide (30 mg, 51.72%).

¹H NMR (400 MHz, MeOH-d₄): δ 8.11 (d, J=5.02 Hz, 1H), 7.98 (s, 2H), 7.77(br. s., 1H), 5.49 (s, 1H), 3.81-3.90 (m, 1H), 3.52-3.62 (m, 3H),3.37-3.47 (m, 1H), 1.96-2.05 (m, 1H), 1.05-1.11 (m, 2H), 0.92-1.00 (m,2H). MS: 490 (M⁺).

The following compounds were analogously prepared by treating3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoicacid with appropriate amines.

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(2-hydroxyethoxy)ethyl]benzamide(Compound No. 29)

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (br. s., 1H), 11.11 (br. s., 1H),8.88 (br. s., 1H), 8.13 (br. s., 1H), 8.05 (s, 2H), 7.86 (br. s., 1H),4.62 (br. s., 1H), 3.42-3.61 (m, 8H), 2.12 (br. s., 1H), 0.86-0.98 (m,4H). MS: 505.93 (M⁺).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-hydroxypropyl)benzamide(Compound No. 30).

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (br. s., 1H), 11.12 (br. s., 1H),8.79 (br. s., 1H), 8.13 (br. s., 1H), 8.04 (s, 2H), 7.85 (br. s., 1H),4.51 (br. s., 1H), 3.50 (d, J=7.53 Hz, 2H), 2.12 (br. s., 1H), 1.62-1.77(m, 2H), 0.83-0.99 (m, 4H). MS: 475.89 (M⁺).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[3-(morpholin-4-yl)propyl]benzamide(Compound No. 31)

¹H NMR (400 MHz, DMSO-d₆): 811.95 (br. s., 1H), 11.12 (s, 1H), 8.82 (t,J=5.40 Hz, 1H), 8.13 (d, J=4.77 Hz, 1H), 8.03 (s, 2H), 7.85 (br. s.,1H),), 3.58 (t, J=4.39 Hz, 4H), 2.36 (d, J=5.02 Hz, 5H), 2.07-2.16 (m,1H), 1.71 (quin, J=7.03 Hz, 2H), 0.85-0.97 (m, 4H). MS: 545.04 (M+1).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(dimethylamino)ethyl]benzamide(Compound No. 33)

¹H NMR (400 MHz, DMSO-d₆): δ 11.88-12.04 (m, 1H), 11.12 (br. s., 1H),8.83 (br. s., 1H), 8.13 (d, J=5.02 Hz, 1H), 8.05 (s, 2H), 7.81-7.89 (m,1H), 3.40-3.51 (m, 2H), 2.58-2.63 (m, 2H), 2.33 (s., 6H), 2.02-2.14 (m,1H), 0.84-0.98 (m, 4H). MS: 489 (M+1).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(piperidin-1-yl)ethyl]benzamide(Compound No. 34)

¹H NMR (400 MHz, DMSO-d6): δ 11.88-12.02 (m, 1H), 11.12 (br. s., 1H),8.10-8.20 (m, 1H), 8.04 (s, 2H), 7.79-7.91 (m, 1H), 3.44-3.58 (m, 2H),3.38 (d, J=7.03 Hz, 1H), 2.55-2.74 (m, 2H), 2.08-2.17 (m, 1H), 2.06-2.20(m, 1H), 1.59 (br. s., 3H), 1.39-1.50 (m, 2H), 1.09 (t, J=7.03 Hz, 1H),0.80-1.01 (m, 4H), 0.80-0.99 (m, 4H). MS: 529.05 (M+1).

MethylN-[3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycinate(Compound No. 35)

¹H NMR (400 MHz, DMSO-d₆): δ 11.96 (br. s., 1H), 11.11 (br. s., 1H),9.35 (t, J=5.77 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.07 (s, 2H),7.85-7.95 (m, 1H), 4.08 (d, J=5.77 Hz, 2H), 3.69 (s, 3H), 2.12 (br. s.,1H), 0.87-0.97 (m, 4H). MS: 490.07 (M+1).

4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-(2-fluoroethyl)benzamide(Compound No. 59)

¹H NMR (400 MHz, DMSO-d₆): δ 11.13 (s, 1H), 9.02 (t, J=5.65 Hz, 1H),8.15 (d, J=5.27 Hz, 1H), 7.98 (s, 1H), 7.91 (d, J=5.02 Hz, 1H), 7.76 (d,J=8.03 Hz, 2H), 4.63 (t, J=5.02 Hz, 1H), 4.51 (t, J=5.02 Hz, 1H), 3.65(q, J=5.19 Hz, 1H), 3.58 (q, J=5.27 Hz, 1H), 2.08-2.17 (m, 1H),0.88-0.98 (m, 4H). MS: 431.13 (M+1).

4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethyl-3,5-difluorobenzamide(Compound No. 60)

¹H NMR (400 MHz, DMSO-d6): δ 11.98 (br. s., 1H), 11.13 (s, 1H), 8.76 (t,J=5.52 Hz, 1H), 8.15 (d, J=5.52 Hz, 1H), 7.97 (s, 1H), 7.91 (d, J=5.27Hz, 1H), 7.73 (d, J=8.03 Hz, 2H), 2.08-2.17 (m, 1H), 1.15 (t, J=7.28 Hz,3H), 0.87-0.97 (m, 4H). MS: 413.13 (M+1).

4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-methylbenzamide(Compound No. 61)

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (br. s., 1H), 11.13 (s, 1H),8.74-8.75 (d, J=8 Hz, 1H), 8.14-8.15 (d, J=5.2 Hz, 1H), 7.96 (UnresolvedS, 1H), 7.90 (d, J=5.2 Hz, 1H), 7.69-7.71 (m, 2H), 2.83 (d, J=4.52 Hz,3H), 2.08-2.17 (m, 1H), 0.88-0.97 (m, 4H). MS: 399.1 (M⁺).

4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-(3-hydroxypropyl)benzamide(Compound No. 62)

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (br. s., 1H), 11.13 (s, 1H), 8.74 (t,J=5.52 Hz, 1H), 8.15 (d, J=5.27 Hz, 1H), 7.97 (s, 1H), 7.91 (d, J=5.27Hz, 1H), 7.73 (d, J=8.03 Hz, 2H), 4.51 (br. s., 1H), 3.48 (d, J=3.01 Hz,2H), 3.36-3.40 (m, 2H), 2.09-2.17 (m, 1H), 1.71 (quin, J=6.71 Hz, 2H),0.87-0.97 (m, 4H). MS: 443.15 (M+1).

4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(dimethylamino)ethyl]-3,5-difluorobenzamide(Compound No. 63)

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (br. s., 1H), 11.13 (br. s., 1H),8.73 (t, J=5.52 Hz, 1H), 8.15 (d, J=5.52 Hz, 1H), 7.98 (s, 1H), 7.91 (d,J=5.02 Hz, 1H), 7.73 (d, J=8.28 Hz, 2H), 3.41 (q, J=6.53 Hz, 2H), 2.24(s, 6H), 2.10-2.18 (m, 1H), 0.88-0.98 (m, 4H). MS: 456.26 (M+1).

4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-ethoxypropyl)-3,5-difluorobenzamide(Compound No. 64)

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (br. s., 1H), 11.13 (s, 1H), 8.75 (t,J=5.52 Hz, 1H), 8.15 (d, J=5.52 Hz, 1H), 7.97 (s, 1H), 7.91 (d, J=5.27Hz, 1H), 7.72 (d, J=8.03 Hz, 2H), 3.39-3.46 (m, 4H), 3.34-3.39 (m, 2H),2.02-2.13 (m, 1H), 1.78 (q, 2H), 1.12 (t, J=7.03 Hz, 3H), 0.87-0.98 (m,4H). MS: 471.23 (M+1).

3,5-Dichloro-N-cyclopropyl-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzamide(Compound No. 54)

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (br. s., 1H), 11.11 (s, 1H), 8.76 (d,J=4.04 Hz, 1H), 8.12 (d, J=4.80 Hz, 1H), 8.01 (s, 2H), 7.83 (br. s.,1H), 2.89 (dt, J=3.66, 7.26 Hz, 1H), 2.12 (d, J=4.29 Hz, 1H), 0.86-0.98(m, 4H), 0.52-0.79 (m, 4H). MS: 457.12 (M+1).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(cyclopropylmethyl)benzamide(Compound No. 55)

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (br.s., 1H), 11.11 (br.s., 1H), 8.92(m, 1H), 8.12 (m, 1H), 8.06 (s, 2H), 7.85 (br.s., 1H), 3.16-3.20 (m,2H), 2.09-2.18 (m, 1H), 0.86-0.98 (m, 5H), 0.46-0.49 (m, 2H), 0.25-0.27(m, 2H). MS: 471.13 (M⁺).

3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-ethoxypropyl)benzamide(Compound No. 56)

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (br. s., 1H), 11.11 (br. s., 1H),8.79 (m, 1H), 8.13 (d, J=4.80 Hz, 1H), 8.03 (s, 2H), 7.84 (br. s., 1H),3.41-3.43 (m, 4H), 2.12 (br. s., 1H), 1.79 (m, 2H), 1.09-1.13 (m, 3H),0.87-0.98 (m, 4H). MS: 503.14 (M+1).

N-Butyl-3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzamide(Compound No. 57)

¹H NMR (400 MHz, DMSO-d₆): δ 11.96 (br. s., 1H), 11.13 (br. s., 1H),8.78 (t, J=5.27 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.04 (s, 1H),7.91-7.98 (m, 1H), 7.79-7.90 (m, 1H), 3.03-3.11 (m, 1H), 2.13 (br. s.,1H), 1.53 (td, J=7.03, 14.56 Hz, 2H), 1.36 (td, J=7.31, 14.74 Hz, 2H),1.20-1.31 (m, 2H), 0.79-0.99 (m, 7H). MS: 473.19 (M⁺).

Example 104-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(2-hydroxyethoxy)ethyl]benzamide(Compound No. 41)

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichlorobenzoicacid (0.1 g, 0.25 mmol) was taken in a reaction vial. To it2-(2-aminoethoxy)ethanol (0.029 g, 2.8 mmol),1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.073 g, 3.8 mmol),1-hydroxybenzotriazole (0.051 g, 3.8 mmol) and dimethylformamide (2 mL)were added. The whole reaction mixture was stirred at room temperaturefor overnight. Water (20 mL) was added to the reaction mixture,extracted with ethyl acetate (3×50 mL). The organic layer was dried overanhydrous sodium sulfate and concentrated under vacuum to get the crudemass which was purified by flash column chromatography to get4-{[7-(acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(2-hydroxyethoxy)ethyl]benzamide(0.035 g, 29%).

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.87 (t, J=5.27 Hz, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.05 (s, 2H), 7.94(br. s., 1H), 4.62 (br. s., 1H), 3.55-3.60 (m, 2H), 3.45-3.54 (m, 6H),2.19 (s, 3H). MS: 480.07 (M+1), 482.07 (M+3).

The following compounds were synthesized following a similar procedurewhile using appropriate amines.

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(dimethylamino)ethyl]benzamide(Compound No. 40)

¹H NMR (400 MHz, DMSO-d₆): δ 12.01 (br. s., 1H), 10.75 (br. s., 1H),8.77 (t, J=5.43 Hz, 1H), 8.13 (d, J=4.55 Hz, 1H), 8.04 (s, 2H), 7.94(br. s., 1H), 3.38-3.43 (m, 2H), 2.43 (t, J=6.69 Hz, 2H), 2.20 (s, 6H),2.01-2.19 (m, 3H). MS: 463.12 (M+1).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(piperidin-1-yl)ethyl]benzamide(Compound No. 42)

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.74-8.82 (m, 1H), 8.13 (d, J=5.02 Hz, 1H), 8.03 (s, 2H), 7.94 (br. s.,1H), 3.37 (br. s., 4H), 2.45 (br. s., 4H), 2.19 (s, 3H), 1.36-1.56 (m,6H). MS: 503.18 (M+1), 505.18 (M+3).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(morpholin-4-yl)ethyl]benzamide(Compound No. 43)

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (br. s., 1H), 10.75 (br. s., 1H),8.79 (t, J=5.52 Hz, 1H), 8.13 (d, J=4.77 Hz, 1H), 8.01-8.07 (m, 2H),7.94 (br. s., 1H), 3.58 (t, J=4.52 Hz, 4H), 2.43 (br. s., 4H), 2.19 (s,3H). MS: 505.16 (M+1), 507.16 (M+3).

4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(pyrrolidin-1-yl)ethyl]benzamide(Compound No. 44)

¹H NMR (400 MHz, DMSO-d₆): δ 12.01 (br. s., 1H), 10.76 (br. s., 1H),8.88 (br. s., 1H), 8.13 (d, J=5.27 Hz, 1H), 8.06 (s, 2H), 7.93 (br. s.,1H), 3.47 (d, J=6.02 Hz, 2H), 2.56-2.86 (m, 6H), 2.19 (s, 3H), 1.75 (br.s., 4H). MS: 489.13 (M+1), 491.15 (M+3).

Example 11 Synthesis ofN-(3-{2,6-dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide(Compound No. 66) Step a: Synthesis ofN-{3-[2,6-dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(Compound No. 58)

To a solution of methyl3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoate(100 mg, 2.31 mmol) in 1,4-dioxane and water (3:1), sodium borohydride(27 mg, 6.944 mmol) was added portion wise over a period of about 15minutes, followed by heating the reaction mixture at 60° C. untilstarting material was consumed (approximately 3 hours) The reactionmixture was cooled to room temperature and quenched by the addition ofsaturated aq. ammonium chloride solution and extracted with ethylacetate. Organic layer was separated, washed with brine, dried oversodium sulfate and concentrated under vacuum. Purification by silica gel(100-200) column chromatography using dichloromethane and methanolgradient as eluent affordedN-{3-[2,6-dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide (20 mg, 22%).

¹H NMR (400 MHz, DMSO-d6): δ 11.91 (br.s, 1H), 11.12 (br.s, 1H),8.05-8.11 (m, 1H), 7.66-7.82 (m, 1H), 7.53 (s, 2H), 5.57 (m, 1H),4.59-4.66 (m, 2H), 2.13 (m, 1H), 0.89-0.93 (m, 4H). MS: 403.97 (M⁺).

Step b—Synthesis ofN-{3-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide

To a solution ofN-{3-[2,6-dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(900 mg, 2.23 mmol) in dichloromethane and carbon tetrachloride (2:1) at0° C., phosphorus tribromide (1200 mg, 0.42 mL, 4.455 mmol) was addeddrop wise over a period of few minutes, stirred the mixture at 0° C. toroom temperature. On completion, the reaction was quenched by addingsaturated solution of sodium bicarbonate and extracted withdichloromethane. Organic layer was separated, washed with brine, driedover sodium sulfate and concentrated under vacuum. Purification bysilica gel (100-200) column chromatography using dichloromethane andmethanol gradient as eluent affordedN-{3-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(330 mg, 33%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (br.s, 1H), 11.12 (br.s, 1H),8.11-8.12 (m, 1H), 7.79 (m, 1H), 7.73 (s, 2H), 4.77 (s, 2H), 1.95-2.13(m, 1H), 0.85-0.93 (m, 4H). MS: 467.81 (M+1).

Step c: Synthesis ofN-(3-{2,6-dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide

To a solution ofN-{3-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide(50 mg, 0.11 mmol) in acetonitrile, cesium carbonate (70 mg, 0.21 mmol)was added and stirred at same temperature. Methyl amine (6.8 mg, 0.21mmol) was added at 0° C. The reaction mixture was then stirred at roomtemperature for 3 h. On completion, the reaction mixture was dilutedwith water and extracted with ethyl acetate, organic layer wasseparated, washed with brine, dried over sodium sulfate and concentratedunder vacuum. Purification by silica gel (100-200) column chromatographyusing dichloromethane and methanol gradient as eluent affordedN-(3-{2,6-dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide(7.2 mg, 16%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.13 (br. s., 1H), 8.11 (d, J=5.02 Hz,1H), 7.75 (br. s., 2H), 7.62 (s, 2H), 3.86-3.95 (m, 2H), 2.37-2.43 (m,3H), 2.13 (d, J=5.02 Hz, 1H), 0.9-0.92 (m, 4H). MS: 415.08 (M⁺).

The following compound was synthesized in a similar fashion by treatingN-{3-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide with ethylamine

N-(3-{2,6-Dichloro-4-[(ethylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide(Compound No. 67).

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (br.s., 1H), 11.12 (br.s., 1H),8.02-8.16 (m, 1H), 7.70-7.83 (m, 2H), 7.59 (s, 2H), 3.82 (s, 2H),2.3-2.52 (m, 2H, merged), 2.07-2.20 (m, 1H), 1.07 (t, J=7.15 Hz, 3H),0.85-0.98 (m, 4H). MS: 431.22 (M⁺).

Example 12 Synthesis ofN-[3-(2,6-dichlorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(Compound No. 68)

N-(2-Methyl-1H-pyrrolo[2,3-c]pyridin-7yl)cyclopropanecarboxamide (100mg, 0.46 mmol) was added to a stirred suspension of aluminium chloride(620 mg, 4.65 mmol) in dry dichloromethane (5 mL) and the mixture wasstirred at room temperature for about 1 hour under argon atmosphere.This was followed by drop wise addition of a solution of2,6-dichlorobenzoyl chloride (194 mg, 0.93 mmol) in dichloromethane andstirring overnight at room temperature. After completion, methanol (10mL) was added cautiously to quench the reaction mass followed byconcentration under vacuum. The residual mass was diluted with water andextracted with ethyl acetate. The combined organic layer was neutralizedusing aq. sodium bicarbonate solution, washed with brine, dried overanhydrous sodium sulfate and concentrated. Purification by silica gel(100-200) column chromatography using dichloromethane and methanolgradient as eluent affordedN-[3-(2,6-dichlorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(70 mg, 39%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.11-8.14 (m, 1H), 7.53-7.55 (m, 1H),7.43-7.51 (m, 3H), 2.87-2.92 (m, 1.5H), 2.1-2.15 (m, 1H), 2.02-2.09 (m,1.5H), 0.89-0.98 (m, 4H). MS: 388.2 (M⁺), 390.04 (M+2).

Example 13 Synthesis ofN-[3-(2,6-difluorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(Compound No. 70)

To a solution of 2,6-difluorobenzoic acid (176 mg, 1.15 mmol) in drydichloromethane, was added thionyl chloride (5 mL) and heated at 100° C.for about 3 hours. The reaction mass was concentrated under vacuum. Theresidual mass was dissolved in dry dichloromethane (3 mL) and added to awell stirred solution ofN-(2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide (120mg, 0.55 mmol) in aluminium chloride (743 mg, 5.57 mmol) drop wise. Theresulting reaction mixture was stirred overnight at room temperature.After completion, methanol (10 mL) was added cautiously to quench thereaction mass followed by concentration under vacuum. The reaction masswas diluted with water and extracted with ethyl acetate. The combinedorganic layer was neutralized using aq. sodium bicarbonate solution,washed with brine, dried over anhydrous sodium sulfate, andconcentrated. Purification by silica gel (100-200) column chromatographyusing dichloromethane and methanol gradient as eluent affordedN-[3-(2,6-difluorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide(80 mg, 42%).

¹H NMR (400 MHz, DMSO-d₆) δ: 11.80 (br. s., 1H), 10.91 (br. s., 1H),7.96 (d, J=5.52 Hz, 1H), 7.57-7.74 (m, 1H), 7.24-7.35 (m, 2H), 7.03 (br.s., 1H), 2.47 (s, 3H), 1.99-2.11 (m, 1H), 0.86-0.97 (m, 4H). MS: 356.13(M+1)

Example 14 Synthesis of3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide(Compound No. 71)

To a solution of 2,6-dichloro-4-(methylcarbamoyl)benzoic acid (276 mg,1.1 mmol) in dry dichloromethane, was added thionyl chloride (5 mL) andheated at 100° C. for about 3 hours. The mixture was concentrated undervacuum. The residue was dissolved in dry dichloromethane (3 mL) andadded to the stirred solution ofN-(2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide (120mg, 0.55 mmol) in aluminium chloride (743 mg, 5.57 mmol) drop wise. Theresulting reaction mixture was stirred overnight at room temperature.After completion, methanol (10 mL) was added cautiously to quench thereaction mass followed by concentration under vacuum. The reaction masswas diluted with water and extracted with ethyl acetate. The combinedorganic layer was washed with aq. sodium bicarbonate solution, brine,dried over anhydrous sodium sulfate, and concentrated. Purification bysilica gel (100-200) column chromatography using dichloromethane andmethanol gradient as eluent afforded3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide(70 mg, 29%).

¹H NMR (400 MHz, DMSO-d₆): δ 11.74 (br,s., 1H), 10.91 (br.s., 1H), 8.82(dd, J=4.52, 16.56 Hz, 1H), 8.00-8.11 (m, 2H), 2.78-2.91 (m, 3H), 2.07(d, J=4.77 Hz, 1H), 1.99 (d, J=2.26 Hz, 3H), 0.85-0.97 (m, 4H). MS:445.1 (M+1).

Example 15 Synthesis of methyl[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate(Compound No. 74)

A solution of(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)(2,6-dichlorophenyl)methanone (50mg, 0.16 mmol) and triethylamine (0.013 mL, 0.18 mmol) in anhydroustetrahydrofuran was cooled to 0° C. and treated drop wise with methylchloroformate (0.05 mL, 0.33 mL) and stirred at room temperature for 2hours. The reaction mixture was poured onto cold water and theprecipitated solid was filtered off, washed with hexane and dried toafford methyl[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate (35 mg,60%).

¹H NMR (400 MHz, MeOH-d₄): δ 8.28 (d, J=5.27 Hz, 2H), 7.61 (s, 3H), 7.05(d, J=3.89 Hz, 1H), 6.91 (d, J=3.83 Hz, 1H), 3.80 (s, 3H). MS: 364 (M⁺).

Example 16 Synthesis ofN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide(Compound No 172)

To an ice-cooled solution of(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)(2,6-dichlorophenyl) methanone(50 mg, 0.16 mmol) and triethylamine (0.05 ml, 0.32 mmol) intetrahydrofuran (5 mL) was added acetyl chloride (0.01 ml, 0.15 mmol)drop wise and stirred at room temperature for about 1 hour. Ethylacetate was added and washed with saturated aqueous sodium hydrogencarbonate solution, dried over anhydrous sodium sulfate andconcentrated. The residue was taken up in methanol (5 mL), potassiumcarbonate (50 mg) was added and stirred for 10 minutes. The solvent wasremoved on a rotary evaporator at 20° C. and the residue was dissolvedin dichloromethane, washed with water and brine, dried and concentratedto afford the crude product. Purification by silica gel columnchromatography using ethyl acetate and dichloromethane gradient aseluent yieldedN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide (45mg, 81%).

¹H NMR (400 MHz, DMSO-d₆): δ 10.62 (s, 1H), 8.35 (d, J=5.65 Hz, 1H),8.21 (d, J=5.58 Hz, 1H), 7.66-7.79 (m, 3H), 7.21 (d, J=3.89 Hz, 1H),6.79 (d, J=3.70 Hz, 1H), 2.17 (s, 3H). MS: 348.05 (M⁺).

The following compound was prepared following similar method while usingappropriate starting material:

N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 77)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.36 (d, J=5.65 Hz, 1H),8.21 (d, J=5.65 Hz, 1H), 7.64-7.77 (m, 3H), 7.17 (d, J=3.89 Hz, 1H),6.72 (d, J=3.45 Hz, 1H), 2.01-2.10 (m, 1H), 0.85 (d, J=6.21 Hz, 4H). MS:374.07 (M⁺).

Example 17 Synthesis of3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide(Compound No. 93)

A well stirred mixture of 2,6-dichloro-4-(ethylcarbamoyl)benzoic acid(84.6 mg, 0.42 mmol), 1-hydroxy-7-azabenzotriazole (77 mg, 0.57 mmol),N,N-dimethyl aminopyridine (22 mg, 0.11 mmol) and2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate methanaminium (216 mg, 0.57 mmol) inN,N-dimethylaniline was treated withN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide (100 mg, 0.38mmol) and N,N-diisopropylethylamine (0.1 ml, 0.95 mmol). The reactionwas stirred overnight at room temperature. The contents were dilutedwith water and extracted with ethyl acetate. The combined organicportion was washed with brine, dried over anhydrous sodium sulfate,filtered and concentrated. The crude product was purified by silica gelcolumn chromatography using methanol in dichloromethane (3%) as eluentto yield3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide(45 mg, 26%) as an off white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.86 (t, J=5.36 Hz, 1H),8.37 (d, J=5.65 Hz, 1H), 8.21 (d, J=6.27 Hz, 1H), 8.12 (s, 2H), 7.28 (d,J=3.89 Hz, 1H), 6.72 (d, J=3.89 Hz, 1H), 3.35 (q, 2H, merged), 2.00-2.10(m, 1H), 1.15 (t, J=7.22 Hz, 3H), 0.85 (d, J=6.15 Hz, 4H). MS: 444.86(M⁺).

The following compounds were prepared in an analogous manner usingappropriately substituted starting materials.

3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzonitrile(Compound No. 95) was prepared using 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-cyanobenzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 9.00 (d, J=1.07 Hz, 1H), 8.61 (d, J=5.65Hz, 1H), 8.43 (s, 2H), 8.33 (dt, J=5.62, 0.89 Hz, 1H), 7.52 (d, J=3.89Hz, 1H), 6.98 (dd, J=3.86, 0.72 Hz, 1H). MS: 315.89 (M⁺).

N-[1-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide(Compound No. 99) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide and2,6-dichloro-4-cyanobenzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.60 (s, 1H), 8.40 (s, 2H), 8.35 (d,J=5.65 Hz, 1H), 8.19 (d, J=5.65 Hz, 1H), 7.36 (d, J=3.95 Hz, 1H), 6.81(d, J=3.89 Hz, 1H), 2.17 (s, 3H). MS: 373.06 (M⁺).

3,5-Dichloro-N-methyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide(Compound No. 72) was prepared using 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-(methylcarbamoyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆) δ: 9.00 (s, 1H), 8.85 (d, J=4.64 Hz, 1H), 8.61(d, J=5.58 Hz, 1H), 8.35 (d, J=5.65 Hz, 1H), 8.11 (s, 2H), 7.42 (d,J=3.83 Hz, 1H), 6.95 (dd, J=3.83, 0.69 Hz, 1H), 2.84 (d, J=4.58 Hz, 3H).MS: 348.11 (M⁺).

3,5-Dichloro-N-ethyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide(Compound No. 73) was prepared using 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-(ethylcarbamoyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆) δ: 9.00 (s, 1H), 8.87 (s, 1H), 8.60 (d, J=5.65Hz, 1H), 8.35 (d, J=5.58 Hz, 1H), 8.13 (s, 2H), 7.43 (d, J=3.89 Hz, 1H),6.95 (dd, J=3.83, 0.75 Hz, 1H), 1.16 (t, J=7.22 Hz, 3H). MS: 362.09(M⁺).

3,5-Dichloro-N-(2-hydroxyethyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide(Compound No. 75) was prepared using 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-[(2-hydroxyethyl)carbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 9.00 (d, J=0.94 Hz, 1H), 8.86 (t, J=5.55Hz, 1H), 8.61 (d, J=5.58 Hz, 1H), 8.32-8.38 (m, 1H), 8.15 (s, 2H), 7.42(d, J=3.83 Hz, 1H), 6.95 (dd, J=3.89, 0.69 Hz, 1H), 4.80 (t, J=5.65 Hz,1H), 3.54 (q, J=5.92 Hz, 2H), 3.36-3.40 (m, 2H). MS: 378.20 (M⁺).

3,5-Dichloro-N-(cyanomethyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide(Compound No. 76) was prepared using 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-[(cyanomethyl)carbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 9.64 (t, J=5.43 Hz, 1H), 9.00 (d, J=0.75Hz, 1H), 8.61 (d, J=5.65 Hz, 1H), 8.35 (d, J=5.58 Hz, 1H), 8.16 (s, 2H),7.45 (d, J=3.89 Hz, 1H), 6.96 (dd, J=3.86, 0.66 Hz, 1H), 4.41 (d, J=5.40Hz, 2H).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide(Compound No. 100) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide and2,6-dichloro-4-carbamoyl benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.37 (d, J=5.65 Hz, 1H),8.33-8.35 (m, 1H), 8.21 (d, J=5.96 Hz, 1H), 8.15 (s, 2H), 7.78-7.89 (m,1H), 7.29 (d, J=3.89 Hz, 1H), 6.72 (d, J=3.95 Hz, 1H), 1.95-2.10 (m,1H), 0.83-0.95 (m, 4H). MS: 416.91 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide(Compound No. 107) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide and2,6-dichloro-4-(methyl carbamoyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.84 (d, J=4.45 Hz, 1H),8.37 (d, J=5.65 Hz, 1H), 8.21 (d, J=5.65 Hz, 1H), 8.11 (s, 2H), 7.28 (d,J=3.95 Hz, 1H), 6.72 (d, J=3.89 Hz, 1H), 2.84 (d, J=4.52 Hz, 3H),2.01-2.11 (m, 1H), 0.85 (d, J=6.09 Hz, 4H). MS: 430.82 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-hydroxyethyl)benzamide(Compound No. 91) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide and2,6-dichloro-4-[(2-hydroxyethyl)carbamoyl]benzoic acid.

¹H NMR (400 MHz, MeOH-d₄): δ 8.34 (s, 2H), 8.05 (s, 2H), 7.01 (d, J=3.95Hz, 1H), 6.80 (d, J=3.89 Hz, 1H), 3.75 (t, J=5.65 Hz, 2H), 3.49-3.58 (m,2H), 2.02-2.15 (m, 1H), 0.89-0.95 (m, 4H). MS (m/z): 461.00 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-methoxyethyl)benzamide(Compound No. 98) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide and2,6-dichloro-4-[(2-methoxyethyl)carbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.89-8.99 (m, 1H), 8.37 (d,J=5.65 Hz, 1H), 8.21 (d, J=5.27 Hz, 1H), 8.14 (s, 2H), 7.30 (d, J=3.89Hz, 1H), 6.72 (d, J=3.95 Hz, 1H), 3.48 (s, 3H), 3.28 (s, 3H), 2.01-2.09(m, 1H), 0.85-1.01 (m, 4H). MS (m/z): 474.93 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(propan-2-yl)benzamide(Compound No. 106) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide and2,6-dichloro-4-[(propan-2-yl)carbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.62 (d, J=7.40 Hz, 1H),8.37 (d, J=5.58 Hz, 1H), 8.21 (d, J=5.52 Hz, 1H), 8.14 (s, 2H), 7.27 (d,J=3.89 Hz, 1H), 6.72 (d, J=3.58 Hz, 1H), 4.07-4.17 (m, 1H), 2.04-2.33(m, 1H), 1.20 (d, J=6.59 Hz, 6H), 0.85-0.95 (m, 4H). MS (m/z): 458.84(M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-methylbenzamide(Compound No. 105) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide and2,6-dichloro-4-(methylcarbamoyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.60 (s, 1H), 8.84 (d, J=4.64 Hz, 1H),8.36 (d, J=5.65 Hz, 1H), 8.20 (d, J=5.58 Hz, 1H), 8.11 (s, 2H), 7.30 (d,J=3.89 Hz, 1H), 6.78 (d, J=3.83 Hz, 1H), 2.84 (d, J=4.52 Hz, 3H), 2.16(s, 3H). MS (m/z): 404.84 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-ethylbenzamide(Compound No. 92) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide and2,6-dichloro-4-(ethylcarbamoyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.60 (s, 1H), 8.86 (t, J=5.33 Hz, 1H),8.36 (d, J=5.65 Hz, 1H), 8.20 (d, J=5.58 Hz, 1H), 8.13 (s, 2H), 7.30 (d,J=3.89 Hz, 1H), 6.78 (d, J=3.83 Hz, 1H), 3.3 (q, 2H, merged), 2.16 (s,3H), 1.16 (t, J=7.22 Hz, 3H). MS (m/z): 419.08 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2-methoxyethyl)benzamide(Compound No. 101) was prepared usingN-(1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide and2,6-dichloro-4-[(2-methoxyethyl)carbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.60 (s, 1H), 8.93-8.96 (m, 1H), 8.36 (d,J=5.65 Hz, 1H), 8.20 (d, J=6.15 Hz, 1H), 8.15 (s, 2H), 7.32 (d, J=3.89Hz, 1H), 6.78 (d, J=3.89 Hz, 1H), 3.45-3.55 (m, 4H), 3.28 (s, 3H), 2.16(s, 3H). MS (m/z): 448.88 ((M⁺).

Methyl{1-[2,6-dichloro-4-(ethylcarbamoyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}carbamate(Compound No. 108) was prepared using methyl1H-pyrrolo[3,2-c]pyridin-4-ylcarbamate and2,6-dichloro-4-[ethylcarbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.24 (s, 1H), 8.86 (t, J=5.43 Hz, 1H),8.33 (d, J=5.71 Hz, 1H), 8.11-8.20 (m, 3H), 7.32 (d, J=3.95 Hz, 1H),6.85-6.88 (m, 1H), 3.70 (s, 3H), 3.34-3.41 (m, 2H) and 1.16 (t, J=7.22Hz, 3H). MS (m/z): 435.27 (M⁺).

3,5-Dichloro-4-[(3-chloro-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-N-ethylbenzamideCompound No. 118) was prepared using 3-chloro-1H-pyrrolo[3,2-c]pyridineand 2,6-dichloro-4-[ethylcarbamoyl]benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.97-9.00 (m, 1H), 8.84-8.89 (m, 1H),8.71-8.75 (m, 1H), 8.38-8.43 (m, 1H), 8.13 (s, 2H), 7.94 (s, 1H), 3.36(q, 2H, merged) and 1.05-1.26 (m, 3H). MS (m/z): 396.66 (M⁺).

3,5-Dichloro-4-[(3-chloro-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]benzonitrile(Compound No. 119) was prepared using 3-chloro-1H-pyrrolo[3,2-c]pyridineand 2,6-dichloro-4-cyanobenzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.97-9.02 (m, 1H), 8.71-8.77 (m, 1H), 8.45(s, 3H), 7.99-8.03 (m, 1H). MS (m/z): 350.59 (M⁺).

3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide wasprepared using 1H-pyrrolo[3,2-c]pyridine and 2,6-dichloro-4-carbamoylbenzoic acid.

¹H NMR (400 MHz, MeOH-d₄): δ 8.93 (d, J=0.94 Hz, 1H), 8.54-8.58 (m, 1H),8.46-8.52 (m, 1H), 8.09 (s, 2H), 7.23 (d, J=3.83 Hz, 1H), 6.90 (dd,J=3.83, 0.63 Hz, 1H). MS: 334.07 (M⁺).

3,5-Dichloro-N-cyclopropyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamidewas prepared using 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-(cycloproylcarbamoyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 9.00 (d, J=1.00 Hz, 1H), 8.81 (d, J=4.20Hz, 1H), 8.60 (d, J=5.58 Hz, 2H), 8.31-8.37 (m, 1H), 8.10 (s, 2H), 7.40(d, J=3.83 Hz, 1H), 6.94 (dd, J=3.86, 0.72 Hz, 2H), 2.86-2.94 (m, 1H),0.72-0.78 (m, 2H), 0.59-0.64 (m, 2H). MS: 374.21 (M⁺)

Example 18 Synthesis ofN-{1-[2,6-dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(Compound No. 96)

To a stirred solution of 2,6-dichloro-4-(hydroxymethyl)benzoic acid (219mg, 0.99 mmol), 1-hydroxy-7-azabenzotriazole (202 mg, 1.48 mmol),dimethylaminopyridine (60 mg, 0.49 mmol) and2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate methanaminium (567 mg, 1.48 mmol) inN,N-dimethylaniline,N-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide (200 mg, 0.99mmol) was added followed by N,N-diisopropylethylamine (0.25 ml, 1.48mmol). The reaction mixture was stirred at room temperature for 15hours. The contents were diluted with water and extracted with ethylacetate. The combined organic layer was washed with brine, dried overanhydrous sodium sulfate, filtered and concentrated. The crude compoundwas purified by silica gel column chromatography using methanol indichloromethane (3%) as eluent to yieldN-{1-[2,6-dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(45 mg, 11%).

¹H NMR (400 MHz, DMSO-d₆): δ 8.36 (d, J=5.58 Hz, 1H), 8.20 (d, J=5.65Hz, 1H), 7.63 (s, 2H), 7.16 (d, J=3.89 Hz, 1H), 6.71 (d, J=3.95 Hz, 1H),5.65 (t, J=5.77 Hz, 1H), 4.62 (d, J=5.84 Hz, 2H), 2.02-2.08 (m, 1H),0.85 (d, J=6.21 Hz, 4H). MS (m/z): 404.07 (M⁺).

The following compounds were prepared in a similar manner usingappropriately substituted starting materials.

[2,6-Dichloro-4-(hydroxymethyl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone(Compound No. 90) was synthesized from N-(1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-(hydroxymethyl)benzoic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 9.00 (s, 1H), 8.59 (d, J=5.62 Hz, 1H), 8.34(d, J=5.68 Hz, 1H), 7.63 (s, 2H), 7.30 (d, J=3.79 Hz, 1H), 6.93 (d,J=3.79 Hz, 1H), 5.65 (t, J=5.78 Hz, 1H), 4.63 (d, J=5.75 Hz, 2H). MS(m/z): 321.18 (M⁺).

N-{[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}acetamide(Compound No. 97) was synthesized from N-(1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide and 2,6-dichloro-4-(hydroxymethyl)benzoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.59 (s, 1H), 8.35 (d, J=5.65 Hz, 1H),8.20 (d, J=5.65 Hz, 1H), 7.63 (s, 2H), 7.18 (d, J=3.89 Hz, 1H), 6.77 (d,J=3.64 Hz, 1H), 5.65 (t, J=5.80 Hz, 1H), 4.62 (d, J=5.84 Hz, 2H), 2.16(s, 3H). MS (m/z): 378.04 (M⁺).

Example 19 Synthesis of[2,6-dichloro-4-(pyridin-3-yl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone

A mixture of(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone(0.05 g, 0.135 mmol),[1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.011 g,0.0135 mmol), potassium carbonate (0.055 g, 0.40 mmol),pyridine-3-boronic acid (1.1 equiv) and water (0.5 mL) in acetonitrile(2.5 mL) was heated in a sealed vial under microwave irradiation at 110°C. for 25 minutes. Acetonitrile was removed under vacuum and the residuewas diluted with water (25 mL) and extracted with ethyl acetate (2×25mL). The combined organic layer was washed with water, dried overanhydrous sodium sulphate and concentrated to give crude product whichwas purified by silica gel column chromatography using ethyl acetate andhexane as eluent to yield[2,6-dichloro-4-(pyridin-3-yl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone.

¹H NMR (400 MHz, MeOH-d₄): δ 8.88-8.96 (m, 2H), 8.65 (dd, J=4.93, 1.47Hz, 1H), 8.53-8.58 (m, 1H), 8.51 (d, J=5.71 Hz, 1H), 8.21-8.26 (m, 1H),7.99 (s, 2H), 7.61 (dd, J=7.97, 4.89 Hz, 1H), 7.30 (d, J=3.76 Hz, 1H),6.91 (d, J=3.76 Hz, 1H). MS (m/z): 368.02 (M⁺).

The following compounds were prepared in an analogous manner using(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone andappropriate boronic acid or bispinacolatoboranes as starting materials.

N-{1-[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(Compound No. 87) was synthesized in an analogous manner fromN-[1-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]-N-(cyclopropylcarbonyl)cyclopropanecarboxamideand (3,5-dimethyl-1,2-oxazol-4-yl) boronic acid.

¹H NMR (400 MHz, MeOH-d₄): δ 8.35 (s, 2H), 7.63 (s, 2H), 7.18-7.22 (m,1H), 6.79 (d, J=3.89 Hz, 1H), 2.50 (s, 3H), 2.34 (s, 3H), 1.93-2.00 (m,1H), 0.99-1.06 (m, 2H), 0.91-0.97 (m, 2H). MS (m/z): 468.92 (M⁺).

N-{1-[2,6-Dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(Compound No. 88) was synthesized in an analogous manner fromN-[1-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]-N-(cyclopropylcarbonyl)cyclopropanecarboxamideand [1-(-tert-butoxycarbonyl)-3,5-dimethyl-1H-pyrazol-4-yl]boronic acid.

¹H NMR (400 MHz, MeOH-d₄): δ 8.35 (s, 2H), 7.53 (s, 2H), 7.18 (d, J=3.89Hz, 1H), 6.79 (d, J=3.76 Hz, 1H), 2.19 (s, 6H), 1.97 (tt, J=8.06, 4.24Hz, 1H), 1.03 (t, J=3.61 Hz, 2H), 0.91-0.97 (m, 2H). MS (m/z): 467.98(M⁺).

N-{1-[2,6-Dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(Compound No. 89) was synthesized in an analogous manner fromN-[1-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]-N-(cyclopropylcarbonyl)cyclopropanecarboxamideand pyrimidin-5-yl-boronic acid.

¹H NMR (400 MHz, MeOH-d₄): δ 9.25 (s, 1H), 9.20 (s, 2H), 8.35 (s, 2H),8.05 (s, 2H), 7.20 (d, J=3.89 Hz, 1H), 6.79 (d, J=3.89 Hz, 1H),1.92-2.01 (m, 1H), 0.99-1.06 (m, 2H), 0.91-0.97 (m, 2H). MS (m/z):451.99 (M⁺).

[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone

¹H NMR (400 MHz, methanol-d₄): δ 8.93 (s, 1H), 8.48-8.57 (m, 2H), 7.64(s, 2H), 7.31 (d, J=3.89 Hz, 1H), 6.91 (d, J=3.89 Hz, 1H), 2.51 (s, 3H),2.34 (s, 3H). MS: 386.15 (M⁺).

[2,6-Dichloro-4-(pyrimidin-5-yl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆): δ 9.30-9.33 (m, 3H), 9.01 (d, J=1.00 Hz, 1H),8.61 (d, J=5.65 Hz, 1H), 8.35-8.39 (m, 1H), 8.30 (s, 2H), 7.45 (d,J=3.83 Hz, 1H), 6.97 (dd, J=0.69, 3.83 Hz, 1H). MS: 369.21 (M⁺).

Example 20 Synthesis of1-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-ethylurea(Compound No. 78) Step a: Synthesis of(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone

A mixture of(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone(200 mg, 0.54 mmol), sodium azide (105 mg, 1.62 mmol), copper (II)iodide (30 mg, 0.16) and N,N′-dimethylethane-1,2-diamine (26 mg, 0.32moles) in ethanol (2 mL) and water (0.5 mL) was heated in a sealed vialat 90° C. for 16 hours. The reaction mixture was concentrated to removeethanol and the residue was diluted with water (50 mL) and extractedwith ethyl acetate (2×50 mL). The combined organic portion was driedover anhydrous sodium sulphate and concentrated under vacuum to give thecrude product which was purified by silica gel column chromatographyusing ethyl acetate and hexane as eluent to yield(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone (75mg, 45%).

(4-Amino-2,6-dichlorophenyl){4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}methanonewas synthesized from(4-bromo-2,6-dichlorophenyl){4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}methanonefollowing an analogous procedure.

Step b: Synthesis of1-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-ethylurea

A mixture of(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone(100 mg, 0.33 mmol, Step a) in anhydrous tetrahydrofuran (5 mL) wastreated with phenyl chloroformate (74 mg, 0.49 mmol), and pyridine (38mg, 0.49 mmol) and stirred at room temperature for 1 hour.Tetrahydrofuran was removed under vacuum; the residue was diluted withwater (25 mL) followed by partitioning with ethyl acetate (2×25 mL). Thecombined organic layer was washed with water (30 mL), dried overanhydrous sodium sulphate and stripped of solvent to give the crudecarbamate which was dissolved in ethanol (5 mL) treated with ethyl amine(1.65 mL, 2M solution in tetrahydrofuran, 3.3 mmol) and heated at 80° C.for 4 hours. Ethanol was removed under vacuum and residue was dilutedwith water (25 mL) and extracted with ethyl acetate (2×25 mL). Thecombined organic layer was washed with water (30 mL), dried overanhydrous sodium sulphate and concentrated to give the crude productwhich was purified by silica gel column chromatography using ethylacetate and hexane gradient as an eluent to yield pure1-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-ethylurea(25 mg).

¹H NMR (400 MHz, MeOH-d₄): δ 8.88 (s, 1H), 8.43-8.52 (m, 2H), 7.64 (s,2H), 7.17 (d, J=3.83 Hz, 1H), 6.84 (d, J=3.83 Hz, 1H), 3.23 (q, J=7.24Hz, 2H), 1.15 (t, J=7.22 Hz, 3H). MS (m/z): 377.15 (M⁺)

The following compounds were prepared by treating4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone withappropriate amines in an analogous manner.

1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-(2-hydroxyethyl)urea(Compound No. 80)

¹H NMR (400 MHz, MeOH-d₄): δ 8.90 (s, 1H), 8.45-8.54 (m, 2H), 7.67 (s,2H), 7.20 (d, J=3.60 Hz, 1H), 6.86 (d, J=3.22 Hz, 1H), 3.65 (t, J=5.31Hz, 2H), 3.28-3.36 (m, 2H). MS (m/z): 393.04 (M⁺).

1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-(2-methoxyethyl)urea(Compound No. 104)

¹H NMR (400 MHz, MeOH-d₄): δ 8.90 (s, 1H), 8.45-8.55 (m, 2H), 7.66 (s,2H), 7.20 (d, J=3.83 Hz, 1H), 6.86 (d, J=3.76 Hz, 1H), 3.47-3.53 (m,2H), 3.36-3.43 (m, 5H). MS (m/z): 406.98 (M⁺).

3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-1,1-dimethylurea(Compound No. 81)

¹H NMR (400 MHz, DMSO-d₆): δ 8.97 (d, J=19.26 Hz, 2H), 8.58 (d, J=5.56Hz, 1H), 8.33 (d, J=5.68 Hz, 1H), 7.89 (s, 2H), 7.35 (d, J=3.79 Hz, 1H),6.92 (d, J=3.60 Hz, 1H), 2.97 (s, 6H). MS (m/z): 377.05 (M⁺).

Example 21 Synthesis of2-cyano-N[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]acetamide(Compound No. 82)

To a solution of(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone (60mg, 0.19 mmol) in dimethylformamide (1 mL) was added cyanoacetic acid(25 mg, 0.29 mmol), hydroxybenzotriazole (39.73 mg, 0.29 mmol),1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (56.17 mg, 0.29 mmol) andN,N-diisopropylethyl amine (0.06 mL, 0.31 mmol) in the same order. Thereaction mixture was stirred at room temperature for 20 hours. Thereaction mixture was poured onto water (10 mL) and extracted with ethylacetate (2×50 mL). The combined organic layer was washed with saturatedaqueous solution of sodium bicarbonate, dried over anhydrous sodiumsulphate, filtered and the solvent was removed under rotary evaporator.The product was purified by silica gel column chromatography usingdichloromethane and methanol (1.5-2%) as eluant to yield2-cyano-N-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]acetamide(8.7 mg, 12%).

¹H NMR (400 MHz, DMSO-d₆): δ 10.92 (s, 1H), 8.94-9.01 (m, 1H), 8.56-8.61(m, 1H), 8.31-8.35 (m, 1H), 7.83 (s, 2H), 7.40 (br. s., 1H), 6.83-6.93(m, 1H), 4.04 (s, 2H). MS (m/z): 373.20 (M⁺).

The following compounds were prepared in a similar manner from(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone andappropriate starting materials.

N-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-2-fluoroacetamide(Compound No. 94) was similarly prepared using fluoroacetic acid insteadof cyanoacetic acid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.71 (s, 1H), 8.99 (d, J=0.75 Hz, 1H),8.59 (d, J=5.58 Hz, 1H), 8.34 (s, 1H), 8.02 (s, 2H), 7.38-7.42 (m, 1H),6.90-6.95 (m, 1H), 5.15 (s, 1H), 5.04 (s, 1H). MS (m/z): 366.18 (M⁺).

Example 22 Synthesis ofN-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]propanamide

To a stirred solution of(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone (45mg, 0.15 mmol) and triethylamine (0.04 mL, 0.29 mmol) in tetrahydrofuran(1 mL), propanoyl chloride (0.014 mL, 0.16 mmol) was added drop wise at0° C. The resulting reaction mixture was stirred at room temperature for30 minutes and concentrated under vacuum. The residue was diluted withwater, extracted with ethyl acetate (2×20 mL). The combined organicportion was washed with brine, dried over anhydrous sodium sulphate andconcentrated on rotary evaporator. The residue was taken up in methanol(2 mL), potassium carbonate (25 mg) was added and stirred at roomtemperature for 10 minutes, concentrated on a rotary evaporator, dilutedwith water (10 mL) and extracted with ethyl acetate. The combinedorganic layer was washed with saturated aqueous sodium bicarbonatesolution, water and brine, dried over anhydrous sodium sulphate andconcentrated on rotary evaporator.N-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]propanamide(7.4 mg, 14%) was isolated by silica gel column chromatography usingdichloromethane and methanol gradient as eluent.

¹H NMR (400 MHz, DMSO-d₆): δ 10.50 (br.s., 1H), 8.97-9.01 (m, 1H),8.56-8.61 (m, 1H), 8.31-8.36 (m, 1H), 7.88-7.92 (m, 2H), 7.36-7.40 (m,1H), 6.90-6.94 (m, 1H), 2.40-2.42 (m, 2H), 1.1.08 1.17 (m, 3H). MS(m/z): 362.21 (M⁺).

Methyl[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]carbamate(Compound No. 79) was prepared by treating(4-amino-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanonewith methylchloroformate following a procedure similar to the one usedfor methyl[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate(Compound No. 74).

¹H NMR (400 MHz, MeOH-d₄): δ 7.43 (br. s., 1H), 6.97-7.08 (m, 2H), 6.25(s, 2H), 5.70-5.75 (m, 1H), 5.39 (br. s., 1H), 2.32 (s, 3H). MS (m/z):364.02 (M⁺).

Example 23 Synthesis of ethyl(2E)-3-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enoate

A solution of(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone(100 mg, 0.27 mmol) and ethyl acrylate (3.06 mL, 30.58 mmol) indimethylformamide (3 mL) was stirred at room temperature. Triethylamine(0.15 mL, 1.08 mmol) was added followed by triphenylphosphine (42.6 mg,0.16 mmol) and palladium acetate (18.16 mg, 0.008 mmol). The reactionmixture was purged with argon and heated under reflux for about 20hours. The reaction mixture was cooled to room temperature and theresidue was poured into water and extracted with ethyl acetate. Thecombined organic layer was dried over anhydrous sodium sulfate, filteredand the solvent was removed under rotary evaporator. Ethyl(2E)-3-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enoate(64.8 mg, 61.59%) was isolated by silica gel column chromatography usingethyl acetate in hexane (15-17%) as eluant.

¹H NMR (400 MHz, MeOH-d₄): δ 8.92-8.94 (m, 1H), 8.53-8.56 (m, 1H), 8.50(br. s., 1H), 7.91 (s, 2H), 7.69 (d, J=17.00 Hz, 1H), 7.21-7.25 (m, 1H),6.89 (br. s., 1H), 6.77 (d, J=16.12 Hz, 1H), 4.23-4.33 (m, 2H),1.31-1.37 (m, 3H). MS (m/z): 389.24 (M⁺).

The following compounds were prepared from(4-bromo-2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanonefollowing a similar procedure while using appropriate startingmaterials.

(2E)-3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enenitrile(Compound No. 84)

¹H NMR (400 MHz, DMSO-d₆): δ 9.00 (d, J=0.88 Hz, 1H), 8.58-8.61 (m, 1H),8.32-8.35 (m, 1H), 8.08 (s, 2H), 7.71-7.77 (m, 1H), 7.44 (d, J=4 Hz,1H), 6.94 (d, J=3.83 Hz, 1H), 6.84 (d, J=16.69 Hz, 1H). MS (m/z): 342.19(M⁺).

(2E)-3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enamide(Compound No. 83)

¹H NMR (400 MHz, DMSO-d₆): δ 9.00 (d, J=0.94 Hz, 1H), 8.60 (d, J=5.65Hz, 1H), 8.35 (s, 1H), 7.94 (s, 2H), 7.57-7.60 (m, 1H), 7.47 (d, J=15.87Hz, 1H), 7.43 (d, J=3.83 Hz, 1H), 7.32-7.34 (m, 1H), 6.94 (dd, J=0.66,3.80 Hz, 1H), 6.86 (d, J=15.87 Hz, 1H). MS (m/z): 360.20 (M⁺).

Example 24 Synthesis ofN-(cyclopropylcarbonyl)-N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 85) andN-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 86) Step a:N-[1-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]-N-(cyclopropylcarbonyl)cyclopropanecarboxamide

A solution of(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)(4-bromo-2,6-dichlorophenyl)methanone(40 mg, 0.113 mmol) and triethylamine (0.23 mL, 0.206 mmol) in anhydroustetrahydrofuran was treated dropwise with cyclopropane carbonyl chloride(0.01 mL, 0.11 mmol) under ice-cooled condition and stirred at roomtemperature for 1 hour. Ethyl acetate was added and washed withsaturated aqueous sodium hydrogen carbonate solution, dried overanhydrous sodium sulphate and concentrated to affordN-[1-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]-N-(cyclopropylcarbonyl)cyclopropanecarboxamide.

Step b:N-(cyclopropylcarbonyl)-N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide

A mixture ofN-[1-(4-bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]-N-(cyclopropylcarbonyl)cyclopropanecarboxamide(40 mg, 0.11 mmol), dppf (10 mg, 0.018 mmol), copper cyanide (41 mg,0.45 mmol) and cesium carbonate (110 mg, 0.33 mmol) in 1,4-dioxane (2mL) was heated in a sealed vial at 90° C. for 4 hours. Ethyl acetate wasadded and washed with saturated aqueous sodium hydrogen carbonatesolution, dried over anhydrous sodium sulphate and concentrated to getthe crude residue which was purified by silica gel column chromatographyto affordN-(cyclopropylcarbonyl)-N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamideandN-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide.

N-(Cyclopropylcarbonyl)-N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 85)

¹H NMR (400 MHz, DMSO-d₆): δ 8.58 (d, J=5.62 Hz, 1H), 8.39-8.48 (m, 3H),7.65 (d, J=3.98 Hz, 1H), 6.79 (dd, J=3.92, 0.69 Hz, 1H), 1.84-2.00 (m,2H), 0.94-1.00 (m, 4H), 0.90 (dt, J=7.85, 3.24 Hz, 4H). MS (m/z): 467.04(M⁺).

N-[1-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide (Compound No. 86)

¹H NMR (400 MHz, DMSO-d₆): δ 10.92 (s, 1H), 8.44 (s, 2H), 8.37 (d,J=5.68 Hz, 1H), 8.20 (d, J=5.68 Hz, 1H), 7.39 (d, J=3.92 Hz, 1H), 6.75(d, J=3.85 Hz, 1H), 2.01-2.09 (m, 1H), 0.84-0.95 (m, 4H). MS (m/z):399.04 (M⁺).

Example 25 Synthesis ofN-(1-{2,6-dichloro-4-[(cyclopropylcarbonyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide(Compound No. 109)

This compound was synthesized fromN-{4-[(4-amino-M-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}cyclopropanecarboxamideand cyclopropane carbonyl chloride following a procedure similar to onedescribed forN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide.

¹H NMR (400 MHz, DMSO-d₆): δ 8.32-8.36 (m, 1H), 8.19-8.24 (m, 1H), 7.89(s, 2H), 7.25-7.29 (d, 1H), 6.85-6.95 (d, 1H) 2.03-2.09 (m, 1H),1.78-1.83 (m, 1H), 0.82-0.96 (m, 8H). MS (m/z): 457.32 (M⁺).

The following compounds were prepared following a similar procedure.

N-{1-[4-(Acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(Compound No. 110) was synthesized usingN-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}acetamideand cyclopropane carbonyl chloride.

¹H NMR (400 MHz, DMSO-d₆): δ 10.86 (s, 1H), 10.53-10.58 (m, 1H),8.31-8.37 (m, 1H), 8.19 (d, J=5.65 Hz, 1H), 7.87 (s, 2H), 7.23 (d,J=3.89 Hz, 1H), 6.70 (d, J=3.83 Hz, 1H), 2.13 (s, 3H), 2.02-2.07 (m,1H), 0.86 (s, 4H). MS (m/z): 431.28 (M⁺).

N-(1-{2,6-Dichloro-4-[(ethylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide(Compound No. 103) was prepared following an analogous procedurestarting from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-(ethyl)ureaand cyclopropane carbonyl chloride.

¹H NMR (400 MHz, MeOH-d₄): δ 8.32 (s, 2H), 7.65 (s, 2H), 7.10 (d, J=3.89Hz, 1H), 6.75 (d, J=3.83 Hz, 1H), 3.24 (q, J=7.24 Hz, 2H), 1.93-1.99 (m,1H), 1.15-1.19 (m, 3H), 1.00-1.04 (m, 2H), 0.91-0.96 (m, 2H). MS (m/z):459.96 (M⁺).

N-[1-(2,6-Dichloro-4-{[(2-methoxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 111) was prepared following an analogous procedurestarting from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-(2-methoxyethyl)ureaand cyclopropane carbonyl chloride.

¹H NMR (400 MHz, MeOH-d₄): δ 8.31-8.33 (m, 2H), 7.60-7.68 (m, 2H),7.05-7.15 (m, 1H), 6.92 (s, 1H), 3.49 (br. s., 2H), 3.34-3.43 (m, 6H),1.24-1.32 (m, 1H), 0.96-1.06 (m, 4H). MS (m/z): 489.81 (M⁺).

N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)(methyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 112) was prepared in analogous manner from3-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-1-(2-hydroxyethyl)-1-methylurea.

¹H NMR (400 MHz, MeOH-d₄): δ 8.32 (s, 2H), 7.68 (s, 2H), 7.10 (d, J=3.83Hz, 1H), 6.75 (d, J=3.89 Hz, 1H), 3.74-3.80 (m, 2H), 3.48-3.56 (m, 2H),3.08 (s, 3H cyclopropane carbonyl chloride), 1.93-2.01 (m, 1H),0.84-0.98 (m, 4H). MS (m/z): 490.35 (M⁺).

N-(1-{2,6-Dichloro-4-[(cyclopropylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide(Compound No. 113) was prepared from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-cyclopropylureaand cyclopropane carbonyl chloride.

¹H NMR (400 MHz, MeOH-d₄): δ 8.32 (s, 2H), 7.69 (s, 2H), 7.10 (d, J=3.83Hz, 1H), 6.73-6.78 (m, 1H), 2.57-2.65 (m, 1H), 1.91-2.00 (m, 1H),0.84-0.99 (m, 4H), 0.73-0.81 (m, 2H), 0.50-0.57 (m, 2H). MS (m/z):472.33 (M⁺).

N-(1-{2,6-Dichloro-4-[(cyclopropylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide(Compound No. 114) was prepared from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-cyclopropylurea and acetyl chloride following a similarprocedure.

¹H NMR (400 MHz, MeOH-d₄): δ 8.29-8.36 (m, 6H), 7.69 (s, 5H), 7.11 (d,J=3.95 Hz, 3H), 6.79 (d, J=3.89 Hz, 3H), 2.57-2.64 (m, 1H), 2.22-2.27(m, 3H), 0.73-0.80 (m, 2H), 0.50-0.57 (m, 2H). MS (m/z): 446.30 (M⁺).

N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 115) was prepared from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-(2-hydroxyethyl)ureaand cyclopropane carbonyl chloride following a similar procedure.

¹H NMR (400 MHz, MeOH-d₄): δ 8.28-8.35 (m, 2H), 7.63-7.67 (m, 2H),7.06-7.12 (m, 1H), 6.73-6.78 (m, 1H), 3.61-3.68 (m, 2H), 3.32-3.38 (m,2H), 1.91-2.00 (m, 1H), 0.99-1.06 (m, 2H), 0.89-0.96 (m, 2H). MS (m/z):476.32 (M⁺).

N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide(Compound No. 116) was prepared from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-(2-hydroxyethyl)ureaand acetyl chloride following a similar procedure.

¹H NMR (400 MHz, MeOH-d₄): δ 8.32 (s, 2H), 7.66 (s, 2H), 7.09-7.13 (m,1H), 6.79 (d, J=3.95 Hz, 1H), 3.61-3.68 (m, 2H), 3.32-3.37 (m, 2H),2.22-2.27 (m, 3H). MS (m/z): 450.28 (M⁺).

N-(1-{2,6-Dichloro-4-[(ethylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide(Compound No. 117) was prepared from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-ethylureafollowing a similar procedure.

N-(1-{2,6-Dichloro-4-[(propylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamidewas prepared from1-{4-[(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorophenyl}-3-propylureafollowing a similar procedure.

¹H NMR (400 MHz, MeOH-d₄): δ 8.29-8.35 (m, 2H), 7.63-7.68 (m, 2H),7.08-7.14 (m, 1H), 6.76-6.81 (m, 1H), 3.15-3.22 (m, 2H), 2.23-2.27 (m,3H), 1.51-1.62 (m, 2H), 0.96 (s, 3H). MS: 448.31 (M⁺).

Example 26 Synthesis of(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)(2-chloro-6-fluorophenyl)methanone

Step a:(2-chloro-6-fluorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone

To a stirred solution of 2-chloro-6-fluorobenzoic acid (2.5 g, 14.32mmol) in dichloromethane (20 mL), oxalyl chloride (3.029 ml, 28.64 mmol)was added at 0° C. After stirring at the same temperature for 15 min,dimethylfromamide (2-3 drops) was added, and the reaction was allowed tostir at room temperature for 1.5 hours. The reaction mixture was cooledand concentrated on rotary evaporator. The residue was taken up indichloromethane (20 mL) and treated with 5-azaindole (1.72 g, 14.51mmol) and triethylamine (6.1 mL, 43.52 mmol). The resulting reactionmixture was allowed to stir at room temperature for 20 hours. Thereaction mixture was concentrated under vacuum, diluted with water (50mL) and extracted with ethyl acetate (2×100 mL). The combined organiclayer was washed with saturated aqueous solution of sodium bicarbonate.The organic layer was dried over anhydrous sodium sulfate, filtered andthe solvent was removed under rotary evaporator. The product wasisolated by silica gel column chromatography using ethyl acetate (25%)in hexanes as eluent to yield(2-chloro-6-fluorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone (1.56g, 39.5%).

MS (m/z): 274.68 (M+)

Step b:(2-chloro-6-fluorophenyl){4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}methanone

To a stirred solution of(2-chloro-6-fluorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl) methanone (1 g,3.65 mmol) in dichloromethane (15 mL), was added 3-chloroperbenzoic acid(0.944 g, 5.47 mmol) at room temperature, followed by stirring overnightat the same temperature. The reaction mixture was concentrated on rotaryevaporator, added water (50 mL) and extracted with ethyl acetate (2×100mL). The organic layer was washed with saturated solution of sodiumbicarbonate. The organic layer was dried over anhydrous sodium sulfate,filtered and the solvent was removed under vacuum to afford the N-oxide(1.08 g) that was used as such for the next step.

To a well stirred solution of(2-chloro-6-fluorophenyl)(5-oxido-1H-pyrrolo[3,2-c]pyridin-1-yl)methanone(1.07 g, 3.65 mmol) in chloroform (15 mL) tert-octylamine (2.6 mL, 16.08mmol) was added at room temperature. Then the reaction mixture wascooled to 0° C. and p-toluenesulphonyl chloride (1.53 g, 8.04 mmol) wasadded portion wise at the same temperature. The reaction mixture wasstirred for another 10 minutes, diluted with water (100 mL) andpartitioned with dichloromethane (2×250 mL). The organic layer waswashed with saturated solution of sodium bicarbonate. The organic layerwas dried over anhydrous sodium sulfate, filtered and the solvent wasremoved under vacuum. The compound was purified by silica gel columnchromatography using ethyl acetate in hexane (2%) as eluant to yield(2-chloro-6-fluorophenyl){4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}methanone(0.716 g, 48.78%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.73 (d, J=7.65 Hz, 2H), 7.44-7.62 (m, 3H),7.16-7.20 (m, 1H), 6.96-7.03 (m, 1H), 1.52 (s, 6H), 0.94-0.97 (m, 2H),0.91 (s, 9H). MS (m/z): 401.9 (M⁺).

Step c:(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)(2-chloro-6-fluorophenyl)methanone

To a stirred solution of(2-chloro-6-fluorophenyl){4-[(2,4,4-trimethylpentan-2-yl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}methanone(716 mg, 1.78 mmol) in dichloromethane (15 mL) was added trifluoroaceticacid (1.5 ml) at room temperature. The resulting reaction mixture wasstirred for 2 hours. The reaction mixture was concentrated on rotaryevaporator, added aqueous ammonia solution (10 mL) and the precipitatedsolid was separated by filtration (0.415 g, 80.45%).

¹H NMR (400 MHz, DMSO-d₆): δ 7.70-7.78 (m, 2H), 7.48-7.63 (m, 4H),6.91-6.99 (m, 1H), 6.54 (s, 2H). MS (m/z): 289.70 (M⁺).

Methyl[1-(2-chloro-6-fluorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate(Compound No. 102) was prepared from(4-amino-1H-pyrrolo[3,2-c]pyridin-1-yl)(2-chloro-6-fluorophenyl)methanone and methyl chloroformate as per the procedure followed formethyl 1H-pyrrolo[3,2-c]pyridin-4-ylcarbamate.

¹H NMR (400 MHz, DMSO-d₆): δ 10.24 (s, 1H), 7.72-7.82 (m, 2H), 7.53-7.65(m, 4H), 6.89 (br. s., 1H), 3.70 (s, 3H). MS (m/z): 347.74 (M⁺).

Example 27 Synthesis ofN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide(Compound No. 120)

Step a: Synthesis of 4-bromo-pyridine-1-oxide

A solution of 4-bromo-pyridine hydrochloride (25 g, 128 mmol) indichloromethane (250 mL) was treated with potassium carbonate (21.25 g,153 mmol) and the mixture was stirred for 2 hours, followed by additionof m-chloroperbezoic acid (44 g, 256 mmol). The mixture was stirred atroom temperature for 16 hours, solid precipitated out, filtered andwashed with ethyl acetate (2×200 mL). The filtrate was concentrated togive solid material which was washed with ether and hexane (3×30 mL,1:1). The solid (20 g, 90%) obtained was used as such for next step.

Step b: Synthesis of4-bromo-N-(2,4,4-trimethylpentan-2-yl)pyridin-2-amine

To a solution of 4-bromo-pyridine-1-oxide (20 g, 126 mmol) in chloroform(200 mL) tert-octylamine (71 g, 278 mmol) was added and reaction mixturewas cooled to −5° C. p-Toluenesulphonyl chloride (52.91 g, 278 mmol) wasadded and the reaction mixture was stirred at the same temperature for20 minutes. The reaction mixture was allowed to warm to room temperatureand stirred 16 hours, diluted with dichloromethane (500 mL) and washedwith saturated sodium bicarbonate solution (3×300 mL). The organic layerwas separated and dried over anhydrous sodium sulphate and concentratedto give crude product as sticky material, which was purified by silicagel column chromatography using ethyl acetate and hexane as eluent toyield 8.5 gm (26.5%) of4-bromo-N-(2,4,4-trimethylpentan-2-yl)pyridin-2-amine.

¹H NMR (400 MHz, MeOH-d₄): δ 7.78 (d, J=5.77 Hz, 1H), 6.64 (d, J=1.51Hz, 1H), 6.56 (dd, J=5.52, 1.76 Hz, 1H), 1.91 (s, 2H), 1.43 (s, 6H),0.95 (s, 9H). MS (m/z): 287.05 (M⁺).

Step c: Synthesis of N²-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine

A mixture of 4-bromo-N-(2,4,4-trimethylpentan-2-yl)pyridin-2-amine (7.5g, 260 mmol), sodium azide (5.07 g, 780 mmol), CuI (1.4 g, 7.8 mmol),N,N′-dimethylethane-1,2-diamine (1.3 g, 15 mmol) in dimethylsulfoxide(150 mL) was heated in a sealed reaction vessel at 90° C. for 16 hours.The reaction mixture was diluted with ethyl acetate (500 mL), saturatedammonium chloride (1000 mL) and stirred for 1 hour. The organic layerwas separated and the aqueous layer was again extracted with ethylacetate (3×300 mL). The combined organic layer was washed with brine,dried over anhydrous sodium sulphate and concentrated to give brownsticky mass which was purified by silica gel column chromatography usingmethanol and dichloromethane as eluent to yield 2 g (34%) ofN²-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine.

¹H NMR (400 MHz, MeOH-d₄): δ 7.44 (d, J=7.28 Hz, 1H), 6.17 (dd, J=7.28,2.01 Hz, 1H), 6.03 (d, J=2.01 Hz, 1H), 1.80 (s, 2H), 1.48 (s, 6H), 1.02(s, 9H). MS (m/z): 222.18 (M+1).

Step d: Synthesis of methyl{2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl}carbamate

A solution of N²-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine (3 g,13.5 mmol) and triethylamine (2.7 g, 27 mmol) in dichloromethane (30 mL)was treated with methyl chloroformate (1.91 g, 20.3 mmol) under icecooled condition followed by stirring at room temperature for 2 hours.The reaction mixture upon usual work up and silica gel columnchromatography using methanol and dichloromethane as eluent yield 1.5 g(40%) of methyl{2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl}carbamate.

Step e: Synthesis of methyl{5-iodo-2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl}carbamate

A solution of methyl{2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl}carbamate (1.5 g, 5.3mmol) in acetonitrile was treated with N-iodosuccinimide (1.08 g, 4.8mmol) in small portions while maintaining the temperature at −20° C.followed by stirring for 16 hours. Usual work up yielded 1.3 g (61%) ofmethyl{5-iodo-2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl}carbamate.

¹H NMR (400 MHz, MeOH-d₄): δ 8.10 (s, 1H), 7.25 (s, 1H), 3.78 (s, 3H),1.87 (s, 2H), 1.43 (s, 6H), 0.97 (s, 9H).

Step f: Synthesis of5-iodo-N²-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine

A mixture of methyl{5-iodo-2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl}carbamate (1.3g, 3.2 mmol), potassium hydroxide (898 mg, 16 mmol), ethanol (10 mL) andwater (10 mL) was heated at 80° C. for 2 hours. Ethanol was removedunder vacuum, and the residue was stirred in water. The precipitatedsolid was filtered under vacuum and dried to yield 900 mg (81%) of5-iodo-N²-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine.

Step g: Synthesis ofN²-(2,4,4-trimethylpentan-2-yl)-5-[(trimethylsilyl)ethynyl]pyridine-2,4-diamine

The compound was prepared following the procedure same as that of4-amino-5-[(trimethylsilyl)ethynyl]pyridine-2-carbonitrile starting from5-iodo-N²-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine.

¹H NMR (400 MHz, MeOH-d₄): δ 7.48 (s, 1H), 5.65 (s, 1H), 1.57 (s, 2H),1.20 (s, 6H), 0.77 (s, 9H), 0.22 (s, 9H).

Step h: Synthesis ofN-(2,4,4-trimethylpentan-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine

The compound was prepared following the procedure same as that of1H-pyrrolo[3,2-c]pyridine-6-carbonitrile starting fromN²-(2,4,4-trimethylpentan-2-yl)-5-[(trimethylsilyl)ethynyl]pyridine-2,4-diamine.

¹H NMR (400 MHz, MeOH-d₄): δ 8.24 (s, 1H), 7.05 (d, J=3.51 Hz, 1H), 6.61(s, 1H), 6.38 (d, J=3.26 Hz, 1H), 1.80 (s, 2H), 1.45 (s, 6H), 1.02 (s,9H).

Step i: Synthesis ofN-[1-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide

A mixture ofN-(2,4,4-trimethylpentan-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine (100 mg,0.4 mmol) and triethylamine (103 mg, 1.02 mmol) in anhydrousdichloromethane was treated drop wise with cyclopropane carbonylchloride (93 mg, 0.89 mmol) and stirred at room temperature for 16hours. Usual work up and silica gel column purification using ethylacetate and hexane afforded 80 mg (51%) ofN-[1-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide.

Step j: Synthesis ofN-(1H-pyrrolo[3,2-c]pyridin-6-yl)-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide

A mixture ofN-[1-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide(65 mg, 0.16 mmol), potassium carbonate, methanol and water was stirredat room temperature for 20 minutes. Methanol was removed under vacuum.The residue was stirred in water for 30 minutes. The precipitated solidwas filtered and dried to 47 mg (90%)N-(1H-pyrrolo[3,2-c]pyridin-6-yl)-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide.

¹H NMR (400 MHz, MeOH-d₄) δ: 8.74 (s, 1H), 7.36-7.55 (m, 2H), 6.70 (d,J=3.26 Hz, 1H), 2.11-2.39 (m, 2H), 1.44 (s, 3H), 1.25 (s, 3H), 1.08 (s,9H), 0.80-0.93 (m, 2H), 0.71-0.80 (m, 1H), 0.36-0.55 (m, 2H).

Step k: Synthesis ofN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide

The compound was prepared fromN-(1H-pyrrolo[3,2-c]pyridin-6-yl)-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamideand 2,6-dichlorobenzoyl chloride following the procedure same as that of(2,6-dichlorophenyl)(1H-pyrrolo[3,2-c]pyridin-1-yl)methanone

Step l: Synthesis ofN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide

The compound was prepared by treatingN-[1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamidewith trifluoroacetic acid using the procedure described for benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate.

¹H NMR (400 MHz, MeOH-d₄) δ: 9.18 (s, 1H), 8.62 (s, 1H), 7.59 (s, 3H),6.99 (d, J=3.76 Hz, 1H), 6.76 (d, J=3.76 Hz, 1H), 1.85-2.02 (m, 1H),0.86-1.08 (m, 4H). MS (Mk): 374.68 (M⁺).

The following compounds were prepared following a similar procedure.3,5-dichloro-4-({6-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide(Compound No. 130) was prepared fromN-(1H-pyrrolo[3,2-c]pyridin-6-yl)-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide by treating with 2,6-dichloro-4-(ethylcarbamoyl)benzoylchloride following a procedure as per step k and l in Example 27.

¹H NMR (400 MHz, DMSO-d₆): δ 10.97 (s, 1H), 9.19 (s, 1H), 8.85 (t,J=5.27 Hz, 1H), 8.69 (d, J=1.00 Hz, 1H), 8.12 (s, 2H), 7.26 (d, J=3.76Hz, 1H), 6.84 (dd, J=0.75, 3.76 Hz, 1H), 2.02-2.12 (m, 1H), 1.15 (t,J=7.28 Hz, 3H), 0.79-0.90 (m, 4H). MS: 447.68 (M⁺).

N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide (Compound No. 137) was prepared fromN-(1H-pyrrolo[3,2-c]pyridin-6-yl)-N-(2,4,4-trimethylpentan-2-yl)cyclopropanecarboxamide by treating with 4-cyano-2,6-dichlorobenzoyl chloridefollowing a procedure as per step k and l in Example 27.

1H NMR (400 MHz, DMSO-d₆): δ 10.99 (s, 1H), 9.18 (s, 1H), 8.69 (s, 1H),8.42 (s, 2H), 7.37 (d, J=3.76 Hz, 1H), 6.87 (d, J=3.76 Hz, 1H),1.99-2.11 (m, 1H), 0.78-0.91 (m, 4H). MS: 399.82 (M⁺).

Example 28 Synthesis of3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-N-[2-(dimethylamino)ethyl]benzamide(Compound No. 122) Step a: Synthesis of methyl3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoate

A stirred solution of 2,6-dichloro-4-(methoxycarbonyl)benzoic acid (750mg, 3 mmol, intermediate 32), 1-hydroxy-7-azabenzotriazole (614 mg, 4.5mmol), dimethylaminopyridine (183 mg, 1.5 mmol),2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate methanaminium (1170 mg, 4.5 mmol) inN,N-dimethylacatamide was treated withN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropane carboxamide (605 mg, 3mmol, intermediate 28) and Hunig's base (1.33 ml, 7.5 mmol). Thereaction mixture was stirred at room temperature for about 1 hour andwas heated at 50° C. for about 5 hours. To the reaction mixture, icecold water was added and the precipitated solid was filtered, washedwith water and dried. The solid thus obtained was purified by silica gel(100-200 mesh) column chromatography using methanol and dichloromethanegradient elution to afford methyl3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoate(600 mg, 47%) as an off-white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 8.37 (d, J=5.56 Hz, 1H),8.21 (d, J=5.81 Hz, 1H), 8.17 (s, 2H), 7.31 (d, J=3.79 Hz, 1H), 6.73 (d,J=3.79 Hz, 1H), 3.94 (s, 3H), 2.03-2.07 (m, 1H), 0.83-0.88 (m, 4H). MS:432.75 (M⁺).

Step b: Synthesis of3,5-dichloro-4-{[4-(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid

To the stirred solution of methyl3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoate(500 mg, 1.1 mmol) in tetrahydrofuran and water (1:1, 5 mL) was addedsodium hydroxide (46 mg, 1.1 mmol). The reaction mixture was stirred atroom temperature for about 1 hour. The reaction mixture was thenconcentrated under vacuum and the aquoeus residue was neutralized usingdilute hydrochloric acid. The precipitated solid was filtered, washedwith water and dried to afford3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid (470 m g, 97%) as an off-white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 14.01 (br. s., 1H), 10.91 (s, 1H), 8.37 (d,J=5.56 Hz, 1H), 8.21 (d, J=5.56 Hz, 1H), 8.12 (s, 2H), 7.32 (d, J=4.04Hz, 1H), 6.73 (d, J=4.04 Hz, 1H), 2.01-2.11 (m, 1H), 0.82-0.92 (m, 4H).

Step c: Synthesis of3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-N-[2-(dimethylamino)ethyl]benzamide

To a stirred solution of3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid (40 mg, 0.095 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide(22 mg, 0.115 mmol) and 15 mg 1-hydroxybenzotriazole (15 mg, 0.115 mmol)in dimethylformamide, was added N,N-dimethylethane-1,2-diamine (8.4 mg,0.095 mmol). The resulting reaction mixture was stirred at roomtemperature for about 16 hours. The reaction mixture was poured dropwise into ie-cooled saturated aquoeus sodium bicarbonate solution. Theprecipitated solid was filtered, washed with water and dried undervacuum. The solid thus obtained was triturated with diethyl ether,filtered and dried to get3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-N-[2-(dimethylamino)ethyl]benzamide(11 mg, 25%).

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.81 (t, J=5.56 Hz, 1H),8.37 (d, J=5.81 Hz, 1H), 8.21 (d, J=5.81 Hz, 1H), 8.13 (s, 2H), 7.30 (d,J=3.79 Hz, 1H), 6.72 (d, J=3.79 Hz, 1H), 3.36-3.43 (m, 2H), 2.42 (t,J=6.69 Hz, 2H), 2.18 (s, 6H), 2.01-2.09 (m, 1H), 0.82-0.92 (m, 4H). MS:488.79 (M⁺).

The following compounds were prepared following analogous method usingappropriate starting materials:

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-hydroxypropyl)benzamide(Compound No. 123)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.83 (t, J=5.56 Hz, 1H),8.37 (d, J=5.56 Hz, 1H), 8.21 (d, J=5.81 Hz, 1H), 8.13 (s, 2H), 7.28 (d,J=4.04 Hz, 1H), 6.72 (d, J=3.79 Hz, 1H), 4.51 (t, J=5.18 Hz, 1H), 3.48(q, J=6.06 Hz, 2H), 3.36-3.40 (m, 2H), 2.02-2.09 (m, 1H), 1.70 (quin,J=6.69 Hz, 2H), 0.84-0.93 (m, 4H). MS (ESI): 475.76 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(2-hydroxyethoxy)ethyl]benzamide(Compound No. 124).

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.92 (t, J=5.43 Hz, 1H),8.37 (d, J=5.81 Hz, 1H), 8.21 (d, J=5.56 Hz, 1H), 8.08-8.16 (m, 2H),7.30 (d, J=3.79 Hz, 1H), 6.72 (d, J=3.79 Hz, 1H), 4.61 (t, J=5.31 Hz,1H), 3.54-3.60 (m, 2H), 3.43-3.54 (m, 6H), 1.97-2.10 (m, 1H), 0.85-0.92(m, 4H). MS: 505.8 (M⁺).

3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(morpholin-4-yl)ethyl]benzamide(Compound No. 125)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.84 (t, J=5.81 Hz, 1H),8.37 (d, J=5.56 Hz, 1H), 8.21 (d, J=5.31 Hz, 1H), 8.12 (s, 2H), 7.30 (d,J=3.79 Hz, 1H), 6.72 (d, J=3.79 Hz, 1H), 3.58 (t, J=4.55 Hz, 4H), 3.42(td, J=6.66, 12.69 Hz, 2H), 2.42 (br. s., 4H), 2.00-2.10 (m, 1H),0.85-0.97 (m, 4H). MS: 530.86 (M⁺).

EthylN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-β-alaninate(Compound No. 126)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.96 (t, J=5.31 Hz, 1H),8.37 (d, J=5.56 Hz, 1H), 8.20 (d, J=6.32 Hz, 1H), 8.08-8.13 (m, 2H),7.29 (d, J=4.04 Hz, 1H), 6.72 (d, J=4.04 Hz, 1H), 4.09 (q, J=7.07 Hz,2H), 3.49-3.58 (m, 2H), 2.62 (t, J=6.82 Hz, 2H), 2.01-2.09 (m, 1H), 1.20(t, J=7.07 Hz, 3H), 0.82-0.89 (m, 4H). MS: 517.83 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-methoxypropyl)benzamide(Compound No. 131)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 8.86 (t, J=5.52 Hz, 1H),8.37 (d, J=5.52 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.12 (s, 2H), 7.29 (d,J=4.02 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.36-3.42 (m, 4H), 3.25 (s,3H), 2.01-2.08 (m, 1H), 1.78 (quin, J=6.59 Hz, 2H), 0.82-0.92 (m, 4H).MS: 489.87 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-propylbenzamide(Compound No. 133)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 8.82-8.88 (m, 1H), 8.37 (d,J=5.52 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.13 (s, 2H), 7.29 (d, J=3.76Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.23-3.30 (m, 2H), 2.00-2.09 (m, 1H),1.51-1.61 (m, 2H), 0.91 (t, J=7.40 Hz, 3H), 0.82-0.92 (m, 4H). MS:459.83 (M⁺).

N[3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-β-alanine(Compound No. 135)

¹H NMR (400 MHz, DMSO-d₆): δ 12.32 (br. s., 1H), 10.88 (s, 1H), 8.94(br. s., 1H), 8.36 (br. s., 1H), 8.21 (d, J=5.77 Hz, 1H), 8.12 (s, 2H),7.29 (d, J=3.76 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.50 (d, J=5.02 Hz,2H), 2.55 (br. s., 2H), 2.01-2.09 (m, 1H), 0.82-0.94 (m, 4H). MS: 488.11(M−1).

Example 29 Synthesis of ethylN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alaninate(Compound No. 141)

A stirred solution of3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoicacid (100 mg, 0.23 mmol) in anhydrous dimethylformamide (5 mL) wastreated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (68 mg,0.358 mmol), 1-hydroxy-7-azabenzotriazole (37 mg, 0.276 mmol),N,N-diisopropylethylamine (89 mg, 0.69 mmol). Ethyl alaninate (38 mg,0.25 mmol) was added and the reaction mixture was stirred at roomtemperature for about 16 hours. The reaction mixture was poured intowater (100 mL) and extracted with ethylacetate (2×30 mL). The combinedorganic layer was washed with brine, dried over anhydrous sodiumsulphate and concentrated to give crude product which was purified byflash silica gel column chromatography using linear gradient ethylacetate and hexane to afford ethylN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alaninate(43 mg, 34%).

¹H NMR (400 MHz, DMSO-d₆): δ 10.96 (br.s., 1H), 8.90 (br. s., 1H), 8.37(d, J=5.52 Hz, 1H), 8.15-8.23 (m, 3H), 7.28 (d, J=4.02 Hz, 1H), 6.72 (d,J=4.04 Hz, 1H), 4.49 (t, J=7.07 Hz, 1H), 4.13 (q, j=7.07 Hz, 2H),2.01-2.09 (m, 1H), 1.39-1.48 (m, 1H), 1.21 (t, J=7.07 Hz, 3H), 0.83-0.89(m, 4H). MS: 518.16 (M+1).

The following compounds were prepared from3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoicacid in a similar manner using appropriate amines.

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(2-oxoimidazolidin-1-yl)ethyl]benzamide(Compound No. 142).

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.86 (s, 1H), 8.37 (d,J=5.77 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.12 (s, 2H), 7.28 (d, J=3.76Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.58 (t, J=4.52 Hz, 4H), 2.29-2.40 (m,6H), 2.00-2.11 (m, 1H), 1.63-1.77 (m, 2H), 0.80-0.90 (m, 4H). MS: 530.19(M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyridin-4-yl)ethyl]benzamide(Compound No. 145)

¹H NMR (400 MHz, DMSO-d₆): δ 10.85-10.93 (m, 1H), 8.97 (t, J=5.43 Hz,1H), 8.53 (d, J=5.05 Hz, 1H), 8.37 (d, J=5.81 Hz, 1H), 8.21 (d, J=5.56Hz, 1H), 8.09 (s, 2H), 7.73 (dt, J=1.89, 7.64 Hz, 1H), 7.27-7.34 (m,2H), 7.22-7.26 (m, 1H), 6.71 (d, J=3.79 Hz, 1H), 3.59-3.73 (m, 2H), 3.03(t, J=7.45 Hz, 2H), 2.01-2.10 (m, 1H), 0.83-0.90 (m, 4H).

3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(pyridin-2-ylmethyl)benzamide(Compound No. 147)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 9.52 (t, J=5.81 Hz, 1H),8.51-8.55 (m, 2H), 8.37 (d, J=5.81 Hz, 1H), 8.16-8.24 (m, 3H), 7.35 (d,J=6.06 Hz, 2H), 7.31 (d, J=3.79 Hz, 1H), 6.73 (d, J=4.29 Hz, 1H), 4.55(d, J=5.81 Hz, 2H), 2.01-2.07 (m, 1H), 0.90-1.12 (m, 4H). MS: 509.13(M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyrrolidin-1-yl)ethyl]benzamide(Compound No. 148)

¹H NMR (400 MHz, DMSO-d₆): δ 10.83 (br.s, 1H), 8.8 8.95 (m, 1H), 8.37(d, J=5.52 Hz, 1H), 8.21 (d, J=5.52 Hz, 1H), 8.13 (s, 2H), 7.28 (d,J=4.02 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.40-3.53 (m, 2H), 2.67-2.81(m, 4H), 2.01-2.09 (m, 1H), 1.65-1.74 (m, 4H), 0.85 (d, J=6.02 Hz, 4H).MS: 515.20 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[3-(morpholin-4-yl)propyl]benzamide(Compound No. 149).

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.86 (s, 1H), 8.37 (d,J=5.77 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.12 (s, 2H), 7.28 (d, J=3.76Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.58 (t, J=4.52 Hz, 4H), 2.29-2.40 (m,6H), 2.00-2.11 (m, 1H), 1.63-1.77 (m, 2H), 0.80-0.90 (m, 4H). MS: 545.24(M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(piperidin-1-yl)ethyl]benzamide(Compound No. 150)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.86 (t, J=5.65 Hz, 1H),8.37 (d, J=5.77 Hz, 1H), 8.21 (d, J=5.52 Hz, 1H), 8.11 (s, 2H), 7.29 (d,J=4.02 Hz, 1H), 6.72 (d, J=4.02 Hz, 1H), 3.36-3.45 (m, 2H), 2.34-2.48(m, 6H), 2.02-2.09 (m, 1H), 1.45-1.55 (m, 4H), 1.39 (d, J=5.52 Hz, 2H),0.80-0.90 (m, 4H). MS: 529.25 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(1-hydroxypropan-2-yl)benzamide(Compound No. 151)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.52 (d, J=7.78 Hz, 1H),8.37 (d, J=5.52 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.15 (s, 1H), 7.27 (d,J=3.76 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 4.79 (t, J=6.02 Hz, 1H), 4.04(td, J=6.84, 13.43 Hz, 1H), 3.47 (td, J=5.77, 11.04 Hz, 1H), 3.36-3.41(m, 1H), 2.01-2.11 (m, 1H), 1.15 (d, J=6.78 Hz, 3H), 1.09 (t, J=7.03 Hz,1H), 0.83-0.92 (m, 4H). MS: 476.09 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(1H-indol-3-yl)ethyl]benzamide(Compound No. 139)

¹H NMR (400 MHz, DMSO-d₆): δ 10.88 (d, J=18.82 Hz, 2H), 9.00 (t, J=5.77Hz, 1H), 8.38 (s, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.12 (s, 2H), 7.58 (d,J=7.78 Hz, 1H), 7.35 (d, J=8.28 Hz, 1H), 7.29 (d, J=3.76 Hz, 1H), 7.21(d, J=2.01 Hz, 1H), 7.05-7.11 (m, 1H), 6.97-7.03 (m, 1H), 6.72 (d,J=4.02 Hz, 1H), 2.98 (t, J=7.28 Hz, 2H), 1.94-2.16 (m, 1H), 1.09 (t,J=7.03 Hz, 2H), 0.85-1.02 (m, 4H). MS: 560.44 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2,3-dihydroxypropyl)benzamide(Compound No. 143)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 8.82 (t, J=5.43 Hz, 1H),8.37 (d, J=5.81 Hz, 1H), 8.21 (d, J=5.56 Hz, 1H), 8.15 (s, 2H), 7.28 (d,J=4.04 Hz, 1H), 6.72 (d, J=4.04 Hz, 1H), 4.87 (d, J=5.05 Hz, 1H), 4.61(t, J=5.81 Hz, 1H), 3.17-3.26 (m, 1H), 2.02-2.08 (m, 1H), 0.85-1.02 (m,4H). MS: 492.08 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(thiophen-2-yl)ethyl]benzamide(Compound No. 144)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 9.04 (t, J=5.43 Hz, 1H),8.37 (d, J=5.56 Hz, 1H), 8.21 (d, J=5.56 Hz, 1H), 8.11 (s, 2H), 7.37(dd, J=1.26, 5.05 Hz, 2H), 7.31 (d, J=3.79 Hz, 1H), 6.90-7.03 (m, 3H),6.72 (s, 1H), 3.49-3.61 (m, 2H), 3.10 (t, J=6.95 Hz, 2H), 2.00-2.10 (m,1H), 0.84-0.96 (m, 4H). MS: 528.11 (M⁺).

3,5-Dichloro-N-cyclopropyl-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide(Compound No. 146)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.81 (d, J=4.29 Hz, 1H),8.37 (d, J=5.56 Hz, 1H), 8.21 (d, J=5.81 Hz, 1H), 8.10 (s, 2H), 7.27 (d,J=3.79 Hz, 1H), 6.72 (d, J=3.79 Hz, 1H), 2.90 (dt, J=3.79, 7.33 Hz, 1H),2.00-2.10 (m, 1H), 0.84-0.98 (m, 4H), 0.70-0.81 (m, 2H), 0.57-0.67 (m,2H). MS: 458.01 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-fluoroethyl)benzamide(Compound No. 154)

¹H NMR (400 MHz, DMSO-d₆) δ: 10.89 (s, 1H), 9.11 (t, J=5.52 Hz, 1H),8.37 (d, J=5.77 Hz, 1H), 8.19-8.25 (m, 1H), 8.16 (s, 2H), 7.30 (d,J=3.76 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 4.63 (t, J=4.89 Hz, 1H), 4.51(t, J=4.89 Hz, 1H), 3.66 (q, J=5.10 Hz, 1H), 3.59 (q, J=5.27 Hz, 1H),1.99-2.10 (m, 1H), 0.83-0.89 (m, 4H). MS: 464.00 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2,2,2-trifluoroethyl)benzamide(Compound No. 155)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 9.50 (t, J=6.15 Hz, 1H),8.37 (d, J=5.52 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.19 (s, 2H), 7.33 (d,J=4.02 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 4.18 (dd, J=6.27, 9.54 Hz, 2H),1.88-2.18 (m, 1H), 0.70-1.00 (m, 4H). MS: 500.02 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-ethoxypropyl)benzamide(Compound No. 156)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.85 (t, J=5.40 Hz, 1H),8.37 (d, J=5.77 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.12 (s, 2H), 7.28 (d,J=3.76 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.37-3.48 (m, 6H), 1.98-2.10(m, 1H), 1.72-1.83 (m, 2H), 1.12 (t, J=7.03 Hz, 3H), 0.80-0.90 (m, 4H).MS: 504.12 (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[(2R)-1-methoxypropan-2-yl]benzamide(Compound No. 159)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.65 (d, J=8.03 Hz, 1H),8.37 (d, J=5.77 Hz, 1H), 8.21 (d, J=5.52 Hz, 1H), 8.15 (d, J=1.76 Hz,2H), 7.29 (d, J=3.76 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 4.23 (td, J=6.71,13.68 Hz, 1H), 3.38-3.47 (m, 1H), 3.25-3.31 (s, 3H), 2.00-2.10 (m, 1H),1.13-1.20 (m, 3H), 0.82-0.89 (m, 4H). MS: 490.2′ (M+1).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(1H-pyrrol-1-yl)ethyl]benzamide(Compound No. 168)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 8.98 (br. s., 1H), 8.37 (d,J=5.52 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.08 (s, 1H), 7.30 (d, J=3.76Hz, 1H), 6.78 (s, 2H), 6.72 (d, J=3.76 Hz, 1H), 6.00 (br. s., 2H), 4.10(t, J=6.02 Hz, 2H), 3.59 (d, J=5.27 Hz, 2H), 2.01-2.08 (m, 1H),0.82-0.89 (m, 4H). MS: 510.37 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyridin-3-yl)ethyl]benzamide(Compound No. 169)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s., 1H), 8.98 (s., 1H), 8.46 (d,J=19.32 Hz, 2H), 8.37 (s., 1H), 8.20 (s., 1H), 8.08 (s., 2H), 7.69 (s.,1H), 7.32 (d, J=13.55 Hz, 2H), 6.72 (s, 1H), 3.57-3.68 (m., 2H),2.86-2.91 (m 2H), 2.05 (m., 1H), 0.84-0.92 (m, 4H). MS: 522.38 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(cyclopropylmethyl)benzamide(Compound No. 170)

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.97 (t, J=5.52 Hz, 1H),8.37 (d, J=5.77 Hz, 1H), 8.21 (d, J=5.77 Hz, 1H), 8.15 (s, 2H), 7.30 (d,J=4.02 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 3.19 (t, J=6.15 Hz, 2H),2.01-2.10 (m, 1H), 1.06 (d, J=7.28 Hz, 1H), 0.82-0.90 (m, 4H), 0.42-0.53(m, 2H), 0.26 (q, J=4.60 Hz, 2H). MS: 471.33 (M⁺).

3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[(3R)-piperidin-3-ylmethyl]benzamide(Compound No. 171)

¹H NMR (400 MHz): δ 10.89 (br.s., 1H), 8.15 (d, J=5.87 Hz, 1H), 8.06 (s,3H), 7.66 (d, J=5.91 Hz, 1H), 6.93 (d, J=3.71 Hz, 1H), 6.55 (d, J=3.71Hz, 1H), 3.28-3.39 (m, 1H), 3.17-3.28 (m, 1H), 2.80-2.91 (m, 3H),2.58-2.73 (m, 3H), 1.90 (tt, J=4.90, 8.14 Hz, 1H), 1.63-1.72 (m, 2H),1.38-1.58 (m, 2H), 1.02-1.18 (m, 2H), 0.90-0.98 (m, 2H). MS: 514.40(M⁺).

3,5-Dichloro-N-cyclobutyl-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide(Compound No. 132)

¹H NMR (400 MHz, DMSO-d₆): δ 10.90 (s, 1H), 9.00 (d, J=7.28 Hz, 1H),8.37 (d, J=5.52 Hz, 1H), 8.21 (d, J=5.27 Hz, 1H), 8.14 (s, 2H), 7.27 (d,J=4.02 Hz, 1H), 6.72 (d, J=3.76 Hz, 1H), 4.38-4.48 (m, 1H), 2.20-2.30(m, 2H), 2.00-2.15 (m, 3H), 1.63-1.78 (m, 2H), 0.82-0.89 (m, 4H). MS:471.86 (M⁺).

Example 30 Synthesis of4-{[4-(acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[3-(morpholin-4-yl)propyl]benzamide(Compound No. 162)

This compound was prepared following an analogous procedure as inExample 28.

Step a: Methyl4-{[4-(acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichlorobenzoate

This was prepared using 2,6-dichloro-4-(methoxycarbonyl)benzoic acid andN-(1H-pyrrolo[3,2-c]pyridin-4-yl) acetamide (Intermediate 29) in ananalogous manner.

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 8.36 (d, J=5.81 Hz, 1H),8.20 (d, J=5.56 Hz, 1H), 8.15-8.18 (m, 2H), 7.33 (d, J=3.79 Hz, 1H),6.79 (d, J=3.79 Hz, 1H), 3.95 (s, 3H), 2.16 (s, 3H).

Step b:4-[(4-acetyl-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorobenzoicacid

¹H NMR (400 MHz, DMSO-d6): δ 13.80-14.24 (m, 1H), 10.62 (br. s., 1H),8.37 (br. s., 1H), 8.21 (br. s., 1H), 8.12 (br. s., 2H), 7.34 (br. s.,1H), 6.79 (br. s., 1H), 2.17 (br. s., 3H).

Step c:4-{[4-(acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[3-(morpholin-4-yl)propyl]benzamide

This was prepared analogously from4-[(4-acetyl-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-3,5-dichlorobenzoicacid and 3-(morpholin-4-yl)propylamine.

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 8.86 (t, J=5.27 Hz, 1H),8.36 (d, J=5.77 Hz, 1H), 8.20 (d, J=5.52 Hz, 1H), 8.12 (s, 2H), 7.31 (d,J=3.76 Hz, 1H), 6.78 (d, J=3.76 Hz, 1H), 3.58 (t, J=4.52 Hz, 4H),2.29-2.40 (m, 6H), 2.16 (s, 3H), 1.71 (quin, J=7.03 Hz, 2H). MS: 519.17(M+1).

The following compounds were prepared following analogous procedureusing appropriate starting materials.

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(dimethylamino)ethyl]benzamide(Compound No. 128)

¹H NMR (400 MHz, DMSO-d6): δ 10.60 (s, 1H), 8.72-8.87 (m, 1H), 8.36 (d,J=5.31 Hz, 1H), 8.20 (d, J=5.31 Hz, 1H), 8.13 (s, 2H), 7.32 (d, J=3.79Hz, 1H), 6.78 (br. s., 1H), 3.37-3.44 (m, 2H), 2.38-2.46 (m, 2H),2.11-2.24 (m, 9H). MS: 462.33 (M⁺).

EthylN-(4-{[4-(acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichlorobenzoyl)-b-alaninate(Compound No. 129)

¹H NMR (400 MHz, DMSO-d₆): δ 10.60 (s, 1H), 8.96 (t, J=5.08 Hz, 1H),8.36 (d, J=5.62 Hz, 1H), 8.20 (d, J=5.68 Hz, 1H), 8.11 (s, 2H), 7.31 (d,J=3.98 Hz, 1H), 6.78 (d, J=3.79 Hz, 1H), 4.09 (q, J=7.12 Hz, 2H),3.50-3.56 (m, 2H), 2.62 (t, J=6.82 Hz, 2H), 2.16 (s, 3H), 1.20 (t,J=7.17 Hz, 3H). MS: 491.33 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(3-methoxypropyl)benzamide(Compound No. 134)

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 8.86 (t, J=5.52 Hz, 1H),8.36 (d, J=5.77 Hz, 1H), 8.20 (d, J=5.52 Hz, 1H), 8.13 (s, 2H), 7.31 (d,J=3.76 Hz, 1H), 6.78 (d, J=4.02 Hz, 1H), 3.37-3.42 (m, 3H), 3.24-3.27(m, 3H), 2.16 (s, 3H), 1.78 (quin, J=6.59 Hz, 2H). MS: 463.86 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2-fluoroethyl)benzamide(Compound No. 157)

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 9.12 (t, J=5.40 Hz, 1H),8.36 (d, J=5.77 Hz, 1H), 8.18-8.25 (m, 1H), 8.16 (s, 2H), 7.32 (d,J=3.76 Hz, 1H), 6.78 (d, J=3.76 Hz, 1H), 4.63 (t, J=4.89 Hz, 1H), 4.52(t, J=5.02 Hz, 1H), 3.66 (q, J=5.02 Hz, 1H), 3.59 (q, J=5.27 Hz, 1H),2.16 (s, 3H). MS: 437.92 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(pyridin-2-ylmethyl)benzamide(Compound No. 160)

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 9.52 (t, J=6.02 Hz, 1H),8.54 (d, J=4.27 Hz, 1H), 8.36 (d, J=5.77 Hz, 1H), 8.19-8.23 (m, 3H),7.75-7.83 (m, 1H), 7.39 (d, J=7.78 Hz, 1H), 7.34 (d, J=4.02 Hz, 1H),7.27-7.32 (m, 1H), 6.78 (d, J=3.76 Hz, 1H), 4.62 (d, J=5.77 Hz, 2H),2.16 (s, 3H). MS: 482.31 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(1H-indol-3-yl)ethyl]benzamide(Compound No. 158)

¹H NMR (400 MHz, DMSO-d₆): δ 10.86 (br. s., 1H), 10.61 (br. s., 1H),9.01 (br. s., 1H), 8.36 (d, J=5.27 Hz, 1H), 8.21 (d, J=5.27 Hz, 1H),8.12 (s, 2H), 7.59 (d, J=7.53 Hz, 1H), 7.29-7.39 (m, 2H), 7.22 (br. s.,1H), 7.07 (d, J=7.53 Hz, 1H), 7.01 (d, J=8.03 Hz, 1H), 6.79 (br. s.,1H), 5.76 (s, 1H), 3.60 (t., 2H), 2.98 (t, 2H), 2.16 (.s., 3H). MS:534.39 (M⁺).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(pyridin-2-yl)ethyl]benzamide(Compound No. 161)

1H NMR (400 MHz, DMSO-d₆): δ 10.60 (s, 1H), 8.97 (t, J=5.27 Hz, 1H),8.52 (d, J=4.02 Hz, 1H), 8.36 (d, J=5.77 Hz, 1H), 8.20 (d, J=6.27 Hz,1H), 8.10 (s, 2H), 7.73 (dt, J=2.01, 7.65 Hz, 1H), 7.29-7.33 (m, 2H),7.24 (dd, J=4.77, 7.53 Hz, 1H), 6.78 (d, J=3.76 Hz, 1H), 3.64-3.71 (m,2H), 3.03 (t, J=7.40 Hz, 2H), 2.16 (s, 3H). MS: 497.06 (M+1).

4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2,3-dihydroxypropyl)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 8.81 (t, J=5.65 Hz, 1H),8.36 (d, J=5.77 Hz, 1H), 8.20 (d, J=5.52 Hz, 1H), 8.15 (s, 2H), 7.30 (d,J=4.02 Hz, 1H), 6.78 (d, J=3.76 Hz, 1H), 4.87 (d, J=5.02 Hz, 1H), 4.61(t, J=5.77 Hz, 1H), 3.63-3.71 (m, 1H), 2.16 (s, 3H). MS: 466.01 (M+1).

Example 31 Synthesis of3,5-dichloro-N-ethyl-4-{[4-(propanoylamino)-1H-Pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide(Compound No. 138) Step a: Synthesis ofN-(1H-pyrrolo[3,2-c]pyridin-4-yl)propanamide

This was prepared by treating benzyl4-amino-1H-pyrrolo[3,2-c]pyridine-1-carboxylate with propionyl chloridefollowing a procedure similar to the one described herein.forintermediate 28.

MS: 379.06 (M⁺)

Step b: Synthesis of methyl3,5-dichloro-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoate

A stirred solution of 2,6-dichloro-4-(methoxycarbonyl)benzoic acid (600mg, 2.3 mmol), in dimethylacetamide (10 mL) was treated with2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate methanaminium (1300 mg, 3.45 mmol),1-hydroxy-7-azabenzotriazole (469 mg, 3.45 mmol),N,N-diisopropylethylamine (1.05 mL, 5.75 mmol) and dimethylaminopyridine(140 mg, 1.15 mmol) were added and the mixture was stirred at roomtemperature for about 1 hour. This was followed by addition ofN-(1H-pyrrolo[3,2-c]pyridin-4-yl)propanamide (450 mg, 2.3 mmol) andstirring at room temperature for about 16 hours. The reaction mixturewas poured into water (150 mL) and extracted with ethyl acetate (2×50mL). The combined organic layer was washed with brine (100 mL) andorganic layer was separated and dried over anhydrous sodium sulphate togive crude product which was purified by silica gel (100-200 mesh size)column chromatography using ethyl-acetate and hexane as eluting systemto give pure methyl3,5-dichloro-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoate.(250 mg, 25%)

Step c: Synthesis of3,5-dichloro-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid

A mixture of methyl3,5-dichloro-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoate(250 mg, 0.59 mmol) and sodium hydroxide (23 mg, 0.59 mmol) intetrahydrofuran and water (1:1) was stirred at room temperature forabout 1 hour. Tetrahydrofuran was removed in vaccuo and aqueous layerwas diluted with water (5 mL) and acidified with hydrochloric acid (2N,upto pH 2). The solid thus obtained was filtered and dried to afford3,5-dichloro-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid (170 mg, 70%). The material was taken as such for the next step.

Step d: Synthesis of3,5-dichloro-N-methyl-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide

A solution of3,5-dichloro-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid (50 mg, 0.123 mmol) in anhydrous dimethylformamide (5 mL) wastreated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (36 mg,0.184 moles), Hunig's base (24 mg, 0.185 mmol), 47 mg (0.369 mmol) andethylamine (0.05 mL, 2N tetrahydrofuran solution, 0.123 mmol) ofmethylamine. The resulting mixture was stirred at room temperature forabout 16 hours. The reaction mixture was poured in water (25 mL) andextracted with ethyl acetate (3×20 mL). The combined organic layer waswashed with brine (30 mL), dried over anhydrous sodium sulphate andconcentrated to give crude product which was purified using columnchromatography with ethyl acetate hexane as eluent (13 mg, 21%).

1H NMR (400 MHz, DMSO-d₆): δ 10.55 (s, 1H), 8.86 (t, J=5.40 Hz, 1H),8.36 (d, J=5.52 Hz, 1H), 8.17-8.24 (m, 1H), 8.13 (s, 2H), 7.25-7.34 (m,1H), 6.75 (d, J=4.02 Hz, 1H), 3.36-3.42 (m, 2H), 2.42-2.48 (m, 2H),1.05-1.19 (m, 6H). MS: 433.89 (M⁺).

The following compound was prepared in an analogous fashion usingmethylamine.

3,5-Dichloro-N-methyl-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide(Compound No. 140)

1H NMR (400 MHz, DMSO-d₆): δ 10.54 (s, 1H), 8.84 (d, J=4.77 Hz, 1H),8.36 (d, J=5.52 Hz, 1H), 8.16-8.23 (m, 1H), 8.11 (s, 2H), 7.29 (d,J=3.76 Hz, 1H), 6.76 (d, J=3.76 Hz, 1H), 2.84 (d, J=4.52 Hz, 3H),1.04-1.17 (m, 3H). MS: 419.91 (M⁺).

Example 32 Synthesis ofN-(2-aminoethyl)-3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide(Compound No. 127) Step a: Synthesis of tert-butyl{2-[(3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoyl)amino]ethyl}carbamate

To the stirred mixture of3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoicacid (50 mg, 0.119 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide(26.8 mg, 0.14 mmol) and 1-hydroxybenzotriazole (19 mg, 0.14 mmol) inN,N-dimethylformamide, was added tert-butyl (2-aminoethyl)carbamate (19mg, 0.119 mmol). The reaction mixture was stirred at room temperaturefor about 16 hours. The reaction mixture was poured drop wise into coldsaturated solution of sodium bicarbonate. The precipitated solid wasfiltered, washed with water and dried. Purification by preparative thinlayer chromatography (2% methanol and dichloromethane as eluent)afforded tert-butyl{2-[(3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoyl)amino]ethyl}carbamate(23 mg, 35%).

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.86 (s, 1H), 8.37 (d,J=5.56 Hz, 1H), 8.21 (d, J=6.06 Hz, 1H), 8.10 (s, 2H), 7.25 (d, J=4.04Hz, 1H), 6.97 (s, 1H), 6.73 (d, J=3.79 Hz, 1H), 3.13 (d, J=6.06 Hz, 2H),2.05 (s, 1H), 1.38 (s, 9H), 0.84-0.88 (m, 4H).

Step b: Synthesis ofN-(2-aminoethyl)-3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide

A solution of tert-butyl{2-[(3,5-dichloro-4-{[4-(cyclopropylcarbonyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzoyl)amino]ethyl}carbamate(20 mg, 0.035 mmol) in dichloromethane (5 mL) was treated dropwise withtrifluoroacetic acid (0.1 mL). The resulting reaction mixture wasstirred at room temperature for about 1 hour, concentrated under vacuumand residue was neutralized using saturated sodium bicarbonate solution.Precipitated solid was filtered, washed with water and dried to getN-(2-aminoethyl)-3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide(11 mg, 73%).

¹H NMR (400 MHz, DMSO-d₆): δ 10.83-10.92 (m, 1H), 8.79 (br. s., 1H),8.37 (d, J=5.56 Hz, 2H), 8.21 (d, J=5.56 Hz, 3H), 8.12-8.15 (m, 2H),7.27 (d, J=4.04 Hz, 1H), 6.72 (d, J=4.04 Hz, 1H), 3.12 (br. s., 1H),2.65-2.73 (m, 2H), 2.01-2.09 (m, 1H), 0.82-0.88 (m, 4H). MS 460.31 (M⁺).

Example 33 Synthesis ofN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alanine(Compound No. 152)

A mixture of ethylN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alaninate(20 mg, 0.038 mmol) in tetrahydrofuran and water (1:1, 1 mL) was treatedwith sodium hydroxide (1.5 mg) and stirred at room temperature for about1 hour. Tetrahydrofuran was removed under vaccuo and the residue wasacidified with hydrochloric acid solution (1N, upto pH 2). The solid wasfiltered and dried to get pureN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alanine(12 mg, 66%).

¹H NMR (400 MHz, DMSO-d6): δ 12.57-12.88 (m, 1H), 10.80-11.10 (m, 1H),9.09 (d, J=6.78 Hz, 1H), 8.37 (d, J=5.77 Hz, 1H), 8.14-8.28 (m, 3H),7.34 (d, J=3.76 Hz, 1H), 6.75 (br. s., 1H), 4.46 (s, 1H), 2.06 (s, 1H),1.43 (d, J=7.28 Hz, 3H), 0.82-0.88 (m, 4H). MS: 490.07 (M+1).

Example 34 Synthesis ofN-(1-{2,6-dichloro-4-[(methylamino)methyl]benzoyl}-1H-Pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide(Compound No. 163) Step a: Synthesis ofN-{1-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide

A solution ofN-{1-[2,6-dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(0.37 mmol) in dichloromethane was cooled to 0° C. and was treateddropwise with phosphorous tribromide (0.74 mmol). The reaction mixturewas then stirred at room temperature for about 2 hours, diluted withdichloromethane and washed with saturated sodium bicarbonate solution.The organic layer was separated, dried over anhydrous sodium sulfate andconcentrated to getN-{1-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide as white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.89 (s, 1H), 8.36 (d, J=5.77 Hz, 1H),8.20 (d, J=6.27 Hz, 1H), 7.84-7.88 (m, 2H), 7.22 (d, J=4.02 Hz, 1H),6.72 (d, J=4.02 Hz, 1H), 4.78 (s, 2H), 2.05 (quin, J=5.90 Hz, 1H),0.82-0.88 (m, 4H). MS: 467.15 (M⁺).

Step b: Synthesis ofN-(1-{2,6-dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo-[3,2-c]pyridin-4-yl)cyclopropanecarboxamide

A solution ofN-{1-[4-(bromomethyl)-2,6-dichlorobenzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(50 mg, 0.107 mmol) in acetonitrile was treated with cesium carbonate(69.74 mg, 0.2140 mmol) and stirred for about 15 minutes. The mixturewas cooled to 0° C. followed by the portion wise addition of methylamine (10.68 mg, 0.16 mmol). The reaction mixture was then stirred atroom temperature for about 20 minutes and concentrated under vacuum,followed by addition of ice cold water to giveN-(1-{2,6-dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide(27.5 mg) as white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.88 (s, 1H), 8.36 (d, J=5.77 Hz, 1H),8.20 (d, J=5.52 Hz, 1H), 7.67 (s, 2H), 7.15 (d, J=4.02 Hz, 1H), 6.72 (d,J=3.76 Hz, 1H), 3.75 (s, 2H), 2.24-2.35 (m, 3H), 1.98-2.10 (m, 1H),0.82-0.88 (m, 4H). MS: 417.28 (M⁺).

The following compounds were prepared in an analogous manner usingappropriate amine starting materials.

N-(1-{2,6-Dichloro-4-[(ethylamino)methyl]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide(Compound No. 164)

¹H NMR (400 MHz, DMSO-d₆): δ 10.88 (s, 1H), 8.35 (d, J=5.52 Hz, 1H),8.20 (d, J=5.77 Hz, 1H), 7.67 (s, 2H), 7.15 (d, J=3.76 Hz, 1H), 6.72 (d,J=3.76 Hz, 1H), 3.79 (s, 2H), 2.3-2.75 (m, 2H), 1.99-2.11 (m, 1H),1.00-1.09 (m, 3H), 0.82-0.88 (m, 4H). MS: 431.31 (M⁺).

N-{1-[2,6-Dichloro-4-({[2-(2-oxoimidazolidin-1-yl)ethyl]amino}methyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide(Compound No. 165)

¹H NMR (400 MHz, DMSO-d₆): δ 10.88 (s, 1H), 8.35 (d, J=5.77 Hz, 1H),8.20 (d, J=5.52 Hz, 1H), 7.67 (s, 1H), 7.16 (d, J=3.76 Hz, 1H), 6.71 (d,J=3.76 Hz, 1H), 6.27 (s, 1H), 3.81 (s, 1H), 3.18-3.27 (m, 2H), 3.14 (t,J=6.40 Hz, 2H), 3.14 (t, J=6.40 Hz, 2H), 3.14 (t, J=6.40 Hz, 2H),2.57-2.68 (m, 2H), 1.99-2.10 (m, 1H), 0.82-0.88 (m, 4H). MS: 516.08(M⁺).

N-{1-[2,6-Dichloro-4-({[3-(morpholin-4-yl)propyl]amino}methyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide (Compound No. 166)

¹H NMR (400 MHz, DMSO-d₆): δ 10.88 (br. s., 1H), 8.36 (d, J=5.52 Hz,1H), 8.20 (d, J=5.77 Hz, 1H), 7.67 (s, 2H), 7.14 (d, J=3.76 Hz, 1H),6.72 (d, J=3.51 Hz, 1H), 3.79 (s, 2H), 3.56 (t, J=4.27 Hz, 5H),2.28-2.38 (m, 7H), 1.99-2.10 (m, 1H), 1.53-1.65 (m, 2H), 0.82-0.88 (m,4H). MS: 530.44 (M⁺).

N-[1-(2,6-Dichloro-4-{[(3-hydroxypropyl)amino]methyl}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide(Compound No. 167)

¹H NMR (400 MHz, DMSO-d₆): δ 10.88 (s, 1H), 8.35 (d, J=5.52 Hz, 1H),8.20 (d, J=5.77 Hz, 1H), 7.67 (s, 2H), 7.14 (d, J=4.02 Hz, 1H), 6.72 (d,J=3.76 Hz, 1H), 4.44 (br. s., 1H), 3.79 (s, 2H), 3.48 (t, J=6.15 Hz,2H), 2.56 (t, J=6.78 Hz, 2H), 2.01-2.08 (m, 1H), 1.55-1.65 (m, 2H),0.82-0.94 (m, 4H). MS: 461.34 (M⁺).

Example 35 Synthesis of3,5-dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide(Compound No. 153)

A well stirred mixture of 2,6-dichloro-4-(methylcarbamoyl)benzoic acid(60 mg, 0.25 mmol), 1-hydroxy-7-azabenzotriazole (51.86 mg, 0.38 mmol),N,N-dimethyl aminopyridine (15.50 mg, 0.127 mmol), and2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate methanaminium (145 mg, 0.38 mmol) in dimethylaminewas treated withN-(1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide (63 mg, 0.25mmol) and N,N-diisopropylethyl amine (0.06 mL, 0.38 mmol). The reactionmixture was stirred overnight at room temperature. The contents werediluted with water and extracted with ethyl acetate. The combinedorganic portion was washed with brine, dried over sodium sulfate,filtered and concentrated. The crude product was purified by silica gelcolumn chromatography and eluted with 3% methanol and dichlorometane toafford3,5-dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide(28.4 mg, 24.13%) as an off white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 8.81 (d, J=4.02 Hz, 1H),8.48 (d, J=5.77 Hz, 1H), 8.31 (d, J=5.77 Hz, 1H), 8.09 (s, 2H), 7.80 (s,1H), 2.84 (d, J=4.27 Hz, 3H), 1.90-2.05 (m, 1H), 0.72-0.90 (m, 4H). MS:465.73 (M⁺).

3,5-Dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide(Compound No. 136) was prepared from 1H-pyrrolo[3,2-c]pyridine and2,6-dichloro-4-(ethylcarbamoyl)benzoic acid using analogous procedure.

¹H NMR (400 MHz, DMSO-d₆): δ 10.65 (s, 1H), 8.85 (t, J=5.40 Hz, 1H),8.48 (d, J=5.77 Hz, 1H), 8.32 (d, J=5.52 Hz, 1H), 8.07-8.15 (m, 2H),7.82 (s, 1H), 1.86-1.93 (m, 1H), 1.16 (t, J=7.28 Hz, 3H), 0.72-0.90 (m,4H). MS: 479.75 (M⁺).

Janus Kinase inhibitors of formula (I) as exemplified herein are shownin Table 1 and 2.

TABLE 1

Com- pound No. R″ R⁵ R⁶ R⁹  1 H F Cl H  2 H Cl Cl —C(O)NHC₂H₅  3 H Cl ClNH₂  4 H Cl Cl 2-methoxypyrimidin-5-yl  5 —NHC(O)-cyclopropyl Cl Cl H  6H Cl Cl CN  7 —NHC(O)CH₃ Cl Cl —C(O)NHCH₃  8 —NHC(O)CH₃ Cl F H  9—NHC(O)CH₃ Cl Cl —C(O)NHC₂H₅ 10 H Cl Cl Br 11 —NHC(O)-cyclopropyl Cl F H12 —NHC(O)-cyclopropyl Cl Cl —C(O)NHCH₃ 13 —NHC(O)-cyclopropyl Cl Cl—C(O)NHC₂H₅ 14 H Cl Cl —CONH(CH₂)₂OCH₃ 15 —NHC(O)CH₃ Cl Cl —C(O)NHC₃H₇16 —NHC(O)-cyclopropyl Cl Cl —C(O)NH(CH₂)₂OCH₃ 17 —NHC(O)CH₃ Cl Cl—C(O)NH(CH₂)₂OCH₃ 21 —NHC(O)CH₃ Cl Cl CN 22 —NHC(O)-cyclopropyl Cl Cl Br23 —NHC(O)-cyclopropyl Cl Cl 3,5-dimethyl-1,2-oxazol-4-yl 24 —NHC(O)CH₃Cl Cl Br 25 —NHC(O)-cyclopropyl Cl Cl —C(O)OCH₃ 26 —NHC(O)-cyclopropylCl Cl —NH₂ 27 —NHC(O)-cyclopropyl Cl Cl —NHC(O)CH₃ 28 —NHC(O)C₂H₅ Cl F H29 —NHC(O)-cyclopropyl Cl Cl —C(O)NH(CH₂)₂O(CH₂)₂OH 30—NHC(O)-cyclopropyl Cl Cl —C(O)NH(CH₂)₃OH 31 —NHC(O)-cyclopropyl Cl Cl—C(O)NH(CH₂)₃(morpholin-4- yl) 32 —NHC(O)-cyclopropyl Cl Cl—C(O)NHCH₂C(OH)CH₂OH 33 —NHC(O)-cyclopropyl Cl Cl —C(O)NH(CH₂)₂N(CH₃)₂34 —NHC(O)-cyclopropyl Cl Cl —C(O)NH(CH₂)₂(piperidin-1- yl) 35—NHC(O)-cyclopropyl Cl Cl —C(O)NHCH₂C(O)OCH₃ 36 —NHC(O)-cyclopropyl ClCl —C(O)NHCH₂C(O)OH 38 —NHC(O)C₂H₅ Cl Cl —C(O)NHCH₃ 39 —NHCO-cyclopropylCl Cl CN 40 —NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂N(CH₃)₂ 41 —NHC(O)CH₃ Cl Cl—C(O)NH(CH₂)₂O(CH₂)₂OH 42 —NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂(piperidin-1-yl) 43 —NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂(morpholin-4- yl) 44 —NHC(O)CH₃ ClCl —C(O)NH(CH₂)₂(Pyrrolidin-1- yl) 45 —NHC(O)-cyclopropyl Cl Cl Cl 46—NHC(O)-cyclopropyl Cl Cl 3,5-dimethyl-1H-pyrazol-4yl 47—NHC(O)-cyclopropyl Cl Cl Pyrimidin-5-yl 48 —NHC(O)-cyclopropyl Cl Cl6-methoxypyridin-3-yl 49 —NHC(O)-cyclopropyl Cl Cl 6-fluoropyridin-3-yl50 —NHC(O)-cyclopropyl Cl Cl 1-methyl-1H-pyrazol-4-yl 51—NHC(O)-cyclopropyl F F CN 52 —NHC(O)-cyclopropyl F F —C(O)OCH₃ 53—NHC(O)CH₃ F F CN 54 —NHC(O)-cyclopropyl Cl Cl —C(O)NH-cyclopropyl 55—NHC(O)-cyclopropyl Cl Cl —C(O)NHCH₂-cyclopropyl 56 —NHC(O)-cyclopropylCl Cl —C(O)NH(CH₂)₃OC₂H₅ 57 —NHC(O)-cyclopropyl Cl Cl —C(O)NH(CH₂)₃CH₃58 —NHC(O)-cyclopropyl Cl Cl —CH₂OH 59 —NHC(O)-cyclopropyl F F—C(O)NH(CH₂)₂F 60 —NHC(O)-cyclopropyl F F —C(O)NHC₂H₅ 61—NHC(O)-cyclopropyl F F —C(O)NHCH₃ 62 —NHC(O)-cyclopropyl F F—C(O)NH(CH₂)₃OH 63 —NHC(O)-cyclopropyl F F —CONH(CH₂)₂N(CH₃)₂ 64—NHC(O)-cyclopropyl F F —C(O)NH(CH₂)₃OC₂H₅ 65 —NHC(O)-cyclopropyl F F3,5-dimethyl-1,2-oxazol-4-yl 66 —NHC(O)-cyclopropyl Cl Cl —CH₂NHCH₃ 67—NHC(O)-cyclopropyl Cl Cl —CH₂NHC₂H₅ 69 —NHC(O)-cyclopropyl F F Br R =R′ = R¹ = R⁷ = R⁸ = H

TABLE 2

Com- pound No. R′ R⁵ R⁶ R⁹  72 H Cl Cl —C(O)NHCH₃  73 H Cl Cl—C(O)NHC₂H₅  74 —NHC(O)OCH₃ Cl Cl H  75 H Cl Cl —C(O)NH(CH₂)₂OH  76 H ClCl —CONHCH₂CN  77 —NHC(O)- Cl Cl H cyclopropyl  78 H Cl Cl —NHC(O)NHC₂H₅ 79 H Cl Cl —NHC(O)OCH₃  80 H Cl Cl —NHC(O)NH(CH₂)₂OH  81 H Cl Cl—NHC(O)N(CH₃)₂  82 H Cl Cl —NHC(O)CH₂CN  83 H Cl Cl —(CH═CH)C(O)NH₂  84H Cl Cl —(CH═CH)CN  85 —N(C(O)- Cl Cl CN cyclopropyl)₂  86 —NHC(O)- ClCl CN cyclopropyl  87 —NHC(O)- Cl Cl 3,5-dimethyl-1,2-oxazol-4-ylcyclopropyl  88 —NHC(O)- Cl Cl 3,5-dimethyl-1H-pyrazol-4-yl cyclopropyl 89 —NHC(O)- Cl Cl Pyrimidin-5-yl cyclopropyl  90 H Cl Cl —CH₂OH  91—NHC(O)- Cl Cl —C(O)NH(CH₂)₂OH cyclopropyl  92 —NHC(O)CH₃ Cl Cl—C(O)NHC₂H₅  93 —NHC(O)- Cl Cl —C(O)NHC₂H₅ cyclopropyl  94 H Cl Cl—NHC(O)CH₂F  95 H Cl Cl CN  96 —NHC(O)- Cl Cl —CH₂OH cyclopropyl  97—NHC(O)CH₃ Cl Cl —CH₂OH  98 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂OCH₃ cyclopropyl 99 —NHC(O)CH₃ Cl Cl CN 100 —NHC(O)- Cl Cl —C(O)NH₂ cyclopropyl 101—NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂OCH₃ 102 —NHC(O)OCH₃ Cl F H 103 —NHC(O)-Cl Cl —NHC(O)NHC₂H₅ cyclopropyl 104 H Cl Cl —NHC(O)NH(CH₂)₂OCH₃ 105—NHC(O)CH₃ Cl Cl —C(O)NHCH₃ 106 —NHC(O)- Cl Cl —C(O)NHCH₃ cyclopropyl107 —NHC(O)- Cl Cl —C(O)NHCH(CH₃)₂ cyclopropyl 108 —NHC(O)OCH₃ Cl Cl—C(O)NHC₂H₅ 109 —NHC(O)- Cl Cl —NHC(O)-cyclopropyl cyclopropyl 110—NHC(O)- Cl Cl —NHC(O)CH₃ cyclopropyl 111 —NHC(O)- Cl Cl—NHC(O)NH(CH₂)₂OCH₃ cyclopropyl 112 —NHC(O)- Cl Cl —NHC(O)N(CH₃)(CH₂)₂OHcyclopropyl 113 —NHC(O)- Cl Cl —NHC(O)NH-cyclopropyl cyclopropyl 114—NHC(O)CH₃ Cl Cl —NHC(O)NH-cyclopropyl 115 —NHC(O)- Cl Cl—NHC(O)NH(CH₂)₂OH cyclopropyl 116 —NHC(O)CH₃ Cl Cl —NHC(O)NH(CH₂)₂OH 117—NHC(O)CH₃ Cl Cl —NHC(O)NHC₂H₅ 121 —NHC(O)- Cl Cl —C(O)OCH₃ cyclopropyl122 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂N(CH₃)₂ cyclopropyl 123 —NHC(O)- Cl Cl—C(O)NH(CH₂)₃OH cyclopropyl 124 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂O(CH₂)₂OHcyclopropyl 125 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂(morpholin-4-yl) cyclopropyl126 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂C(O)OC₂H₅ cyclopropyl 127 —NHC(O)- Cl Cl—C(O)NH(CH₂)₂NH₂ cyclopropyl 128 —NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂N(CH₃)₂129 —NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂C(O)OC₂H₅ 131 —NHC(O)- Cl Cl—C(O)NH(CH₂)₃OCH₃ cyclopropyl 132 —NHC(O)- Cl Cl —C(O)NH-cyclobutylcyclopropyl 133 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂CH₃ cyclopropyl 134—NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₃OCH₃ 135 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂COOHcyclopropyl 138 —NHC(O)C₂H₅ Cl Cl —C(O)NHC₂H₅ 139 —NHC(O)- Cl Cl—C(O)NH(CH₂)₂-(1H-indol-3-yl) cyclopropyl 140 —NHC(O)C₂H₅ Cl Cl—C(O)NHCH₃ 141 —NHC(O)- Cl Cl —C(O)NHCH(CH₃)C(O)OC₂H₅ cyclopropyl 142—NHC(O)- Cl Cl —C(O)NH(CH₂)₂(2- cyclopropyl oxoimidazolidin-1-yl) 143—NHC(O)- Cl Cl —C(O)NHCH₂CH(OH)CH₂OH cyclopropyl 144 —NHC(O)- Cl Cl—C(O)NH(CH₂)₂-(thiophen-2-yl) cyclopropyl 145 —NHC(O)- Cl Cl—C(O)NH(CH₂)₂-(pyridin-4-yl) cyclopropyl 146 —NHC(O)- Cl Cl—C(O)NH-cyclopropyl cyclopropyl 147 —NHC(O)- Cl Cl—C(O)NHCH₂-(pyridin-2-yl) cyclopropyl 148 —NHC(O)- Cl Cl—C(O)NH(CH₂)₂-(pyrrolidin-1-yl) cyclopropyl 149 —NHC(O)- Cl Cl—C(O)NH(CH₂)₃-(morpholin-4- cyclopropyl yl) 150 —NHC(O)- Cl Cl—C(O)NH(CH₂)₂-(piperidin-1-yl) cyclopropyl 151 —NHC(O)- Cl Cl—C(O)NHCH(CH₃)CH₂OH cyclopropyl 152 —NHC(O)- Cl Cl —C(O)NHCH(CH₃)COOHcyclopropyl 154 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂F cyclopropyl 155 —NHC(O)-Cl Cl —C(O)NHCH₂CF₃ cyclopropyl 156 —NHC(O)- Cl Cl —C(O)NH(CH₂)₃OC₂H₅cyclopropyl 157 —NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂F 158 —NHC(O)CH₃ Cl Cl—C(O)NH(CH₂)₂-(1H-indol-3-yl) 159 —NHC(O)- Cl Cl —C(O)NHCH(CH₃)CH₂OCH₃cyclopropyl 160 —NHC(O)CH₃ Cl Cl —C(O)NHCH₂-(pyridin-2-yl) 161—NHC(O)CH₃ Cl Cl —C(O)NH(CH₂)₂-(pyridin-2-yl) 162 —NHC(O)CH₃ Cl Cl—C(O)NH(CH₂)₃-(morpholin-4- yl) 163 —NHC(O)- Cl Cl —CH₂NHCH₃ cyclopropyl164 —NHC(O)- Cl Cl —CH₂NHC₂H₅ cyclopropyl 165 —NHC(O)- Cl Cl—CH₂NH(CH₂)₂(2- cyclopropyl oxoimidazolidin-1-yl) 166 —NHC(O)- Cl Cl—CH₂NH(CH₂)₃(morpholin-4-yl) cyclopropyl 167 —NHC(O)- Cl Cl—CH₂NH(CH₂)₃OH cyclopropyl 168 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂(pyrrol-1-yl)cyclopropyl 169 —NHC(O)- Cl Cl —C(O)NH(CH₂)₂(pyridin-3-yl) cyclopropyl170 —NHC(O)- Cl Cl —C(O)NHCH₂-cyclopropyl cyclopropyl 171 —NHC(O)- Cl Cl—C(O)NHCH₂-(piperidin-3-yl) cyclopropyl R = R″ = R³ = R⁷ = R⁸ = H

Kinase Activity Assay

A number of different assays for kinase activity, preferably Januskinase activity can be utilized. In addition to the assay mentioned inthe in vitro enzyme assay below, one of ordinary skill in the art willknow of other assays that can be utilized and can modify an assay for aparticular application. Such assays and modification thereon are withinthe sprit and scope of the present invention. The compounds of thepresent invention are tested for their capacity to inhibit Janus kinaseactivity, wherein the compounds show IC₅₀ of less than 1000 nM,preferably less than 500 nM, more preferably less than 100 nM, even morepreferably less than 50 nM.

In Vitro Enzyme Assay:

Reagent Preparation:

Kinase buffer [50 mM HEPES (pH 7.5), 1 mM EGTA, 10 mM MgCl₂, 2 mM DTTand 0.01% Tween-20) was prepared and dilutions of a compound of formula(I) and other reagents were subsequently made in it. Two timesconcentrated compound of formula (I) solution: A compound of formula (I)was diluted to 100-fold final concentration in DMSO, followed by 50-folddilution with Kinase buffer (1% DMSO final concentration). Four timesconcentrated Substrate/ATP mix solution: Biotin-SRCtide and ATP werediluted to 4-fold final concentration in Kinase buffer. Biotin-SRCtidesolution (purchased from Anaspec) was mixed with ATP solution (1:1).Four times concentrated Enzyme solution: JAK1 or JAK2 or JAK3 or TYK2enzyme [Human baculo virus expressed JAK1, JAK2, JAK3 and TYK2 werepurchased from Carna Bioscience, Inc. All enzymes only contain thecatalytic domain. JAK1 (aa 850-1154) and TYK2 (aa 871-1187) areexpressed with an N-terminally fused GST-tag, and JAK2 and JAK3 with anN-terminally fused His-tag] was diluted to 4-fold final concentration inKinase buffer and always kept on ice. Detection buffer: LANCE detectionbuffer (10 times concentrated) was diluted 10-fold in H₂O. Four timesconcentrated stop solution: EDTA was diluted to a concentration of 40 mMin detection buffer. Four times concentrated ULight/Eu-antibody (fromPerkin Elmer) mix solution: ULight-Streptavidin was diluted to aconcentration of 100 nM (25 ng/mL final concentrations) andEu-anti-phospho-Tyrosine (PT66) (from Perkin Elmer) was diluted to aconcentration of 8 nM (2 ng/mL final concentration) in detection buffer.

Protocol:

Cell-free in vitro kinase assay was performed in 384 well plates. Twotimes concentrated compound solution (5 μL) was pipetted into a HTS384SV Small Volume Plate. Four times concentrated Substrate/ATP mix (2.5μL) solution was added along with 4 times concentrated Enzyme solution(2.5 μL). Plate was covered with TopSeal-A and incubated at roomtemperature for indicated time (Table 3). Four times concentrated Stopsolution (5 μL, 10 mM final concentration) was added and incubated for 5minutes at room temperature. Four times concentrated ULight/Eu-antibodymix solution (5 μL) was added and again plate was covered with TopSealand incubated overnight at 4° C. TopSeal was removed and HTRF signal wasmeasured at 615 nm and 655 nm (excitation at 320 or 340 nm) on TecanM1000 Multi mode plate reader. Ratio (665 nm/615 nm)×10⁴ was calculatedand IC₅₀ values were deduced from Graph-pad prism 4.2.

Abbreviation:

HEP ES: 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acidEGTA: Ethylene glycol tetraacetic acid

DTT: Dithiothreitol Tween-20: Polysorbate 20 DMSO: Dimethylsulfoxide

MgCl₂: Magnesium chlorideEDTA: Ethylenediaminetetraacetic acid

HTRF: Homogeneous Time Resolved Fluorescence H₂O: Water

TABLE 3 Assay condition of kinase assay Final concentration JAK3 JAK2JAK1 TYK2 Enzyme (ng/mL) 100 50 250 250 SRCtide (nM) 100 25 400 200 ATP(μM) 3 10 60 16 Reaction (min) 30 30 120 45In the Table 4 below, IC₅₀ of JAK assay is provided as follows:A=<50 nM, B=<100 nM, C=<500 nM and D=<1000 nM. The IC₅₀ value of TYK2ranges from less than 50 nM to about 100 nM.

TABLE 4 IC₅₀ for the representative compounds of formula (I) CompoundCompound No. JAK1 JAK2 JAK3 No. JAK1 JAK2 JAK3 3 D C D 5 C C C 6 C C C11 C B B 12 C C B 13 D C C 16 D C C 18 D B D 19 C A C 22 C D C 23 D C C26 C C B 27 D C B 29 D D C 30 C C C 31 C D C 32 C C A 33 B B B 34 C C C35 C C C 36 C B A 39 C A A 42 D D D 44 D D D 47 D B B 51 C B A 54 C C C55 C C C 56 C C C 58 D D D 59 C C C 60 C D C 61 D C C 62 D C C 63 C C C64 C D D 66 B B A 67 B C B 77 D C C 86 D C C 87 C B D 89 D A C 93 C D D95 D C C 96 D C C 103 D C C 107 C C C 111 D C C 112 D C C 113 D C C 115D C C 120 B A A 122 D C B 127 C B A 130 C A B 137 C A C 141 D D D 143 DC A 147 C C C 148 C C B 149 C D C 150 C C C 151 D C C 154 D C C 163 C CB 164 C C C 165 D C C 166 C D C 167 C C C 168 D D C 169 D C D 170 C D D171 C B B — — — —

1. A compound having the structure of formula (I),

a pharmaceutically acceptable salt thereof, a prodrug thereof or ahydrate thereof, wherein: A and B independently represent N or CR, withthe proviso that both A and B are not N; R, R′ and R″ independentlyrepresent H, (C₁-C₆) alkyl, halogen, —CN, —NR^(a)R^(b), —NR^(a)COR^(b)or —CONR^(a)R^(b), with the proviso that R′ represents H, halogen or—NR^(a)COR^(b) when A is N and R″ represents H, halogen or—NR^(a)COR^(b) when B is N; R¹ represents H, (C₁-C₃) alkyl or —COR⁴; R²represents H, (C₁-C₃) alkyl, halo or —CN; R³ represents H, (C₁-C₃)alkyl, halo, —CN or —COR⁴; R⁴ represents optionally substituted phenyl,with the proviso that R¹ represents —COR⁴ when A is N and R³ represents—COR⁴ when B is N; R^(a) and R^(b) independently represent H, (C₁-C₈)alkyl, (C₃-C₈) cycloalkyl or OR′″; R^(a) and R^(b) are taken togetherwith the N atom to which they are attached to form 3-8 memberedheterocyclyl, optionally containing additional heteroatom(s) selectedfrom N, O or S, wherein heterocyclyl is optionally substituted; and R′″represents H or (C₁-C₃) alkyl.
 2. The compound, a pharmaceuticallyacceptable salt thereof, a prodrug thereof or a hydrate thereofaccording to claim 1, wherein A represents N, R′ represents H or—NR^(a)COR^(b) and R¹ represents —COR⁴.
 3. The compound, apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof according to claim 1, wherein A represents N, R′ represents—NR^(a)COR^(b) and R¹ represents —COR⁴.
 4. The compound, apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof according to claim 1, wherein B represents N, R″ represents H or—NR^(a)COR^(b) and R³ represents —COR⁴.
 5. The compound, apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof according to claim 1, wherein B represents N, R″ represents—NR^(a)COR^(b) and R³ represents —COR⁴.
 6. The compound, apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof according to claim 1, wherein R¹ represents H or (C₁-C₃) alkyland R³ represents —COR⁴.
 7. The compound, a pharmaceutically acceptablesalt thereof, a prodrug thereof or a hydrate thereof according to claim1, wherein R¹ represents —COR⁴ and R³ represents H, (C₁-C₃) alkyl, haloor —CN.
 8. The compound, a pharmaceutically acceptable salt thereof, aprodrug thereof or a hydrate thereof according to claim 1, wherein R^(a)represents H or (C₁-C₃) alkyl and R^(b) represents H, (C₁-C₃) alkyl,(C₁-C₃) alkoxy or (C₃-C₅) cycloalkyl.
 9. The compound, apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof according to claim 1, wherein R⁴ represents a group selectedfrom:

wherein: R⁷, R⁸ and R⁹ independently represent H, alkyl, alkenyl,alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,heterocyclyl, heterocyclylalkyl, alkoxy, halo, —NO₂,—(CH₂)_(q)C(O)NR^(c)R^(d), —(CH₂)_(q)NR^(c)COR^(d),—(CH₂)_(q)NR^(c)CONR^(c)R^(d), —(CH₂)_(q)NR^(c)C(O)OR^(d),—(CH₂)_(q)NR^(c)R^(d), —(CH═CH)—(CH₂)_(s)C(O)OR^(e),—(CH═CH)—(CH₂)_(s)CONR^(c)R^(d), —(CH═CH)—(CH₂)_(s)CN,—(CH═CH)₄−CH₂)_(s)R^(e), —(CH₂)_(s)C(O)OR^(e), —(CH)_(r)CN,—(CH₂)_(r)OR^(e), —(CH₂)_(r)R^(e), —(CH₂)_(r)C(O)OR^(e), —(CH)_(r)halo,—S(O)_(p)R^(e), —S(O)_(p)NR^(c)R^(d), —NR^(c)S(O)_(p)R^(d), and whereinalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl heterocyclyl areoptionally substituted; R^(c) and R^(d) independently represent H,(C₁-C₈) alkyl, (C₃-C₈) cycloalkyl, aryl, aralkyl, heteroaryl,heteroarylalkyl, —(CH₂)_(r)OR^(e), —(CH₂)_(r)SR^(e), —(CH₂)_(r)CN,—(CH₂)_(r)halo, —(CH₂)_(r)C(O)OR^(e), —(CH₂)_(r)NR^(c)R^(d), —COR^(e),—S(O)_(p)R^(e) or —(CH₂)_(r)R^(e), wherein alkyl, cycloalkyl, aryl andheteroaryl are optionally substituted; R^(c) and R^(d) are takentogether with the N atom to which they are attached to form 3-8 memberedheterocyclyl, optionally containing additional heteroatom(s) selectedfrom N, O or S, wherein heterocyclyl is optionally substituted; R^(e)represents H, (C₁-C₆) alkyl, —CF₃, (C₃-C₈) cycloalkyl, heterocyclyl,aryl or heteroaryl; wherein alkyl, cycloalkyl, heterocyclyl, aryl andheteroaryl are optionally substituted; p represents an integer of 1 or2; q represents an integer of 0, 1, 2 or 3; r represents an integer of0, 1, 2, 3 or 4; and s represents an integer of 0, 1 or
 2. 10. Acompound of claim 1 selected from the group consisting of:(2-Chloro-6-fluorophenyl)(1H-pyrrolo[2,3-c]pyridine-3-yl)methanone,3,5-Dichloro-N-ethyl-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzamide,(4-Amino-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone,[2,6-Dichloro-4-(2-methoxypyrimidin-5-yl)phenyl](1H-pyrrolo[2,3-c]pyridin-3-yl)methanone,N-[3-(2,6-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,3,5-Dichloro-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzonitrile,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-methylbenzamide,N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-ethylbenzamide,(4-Bromo-2,6-dichlorophenyl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone,N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethylbenzamide,3,5-Dichloro-N-(2-methoxyethyl)-4-(1H-pyrrolo[2,3-c]pyridin-3-ylcarbonyl)benzamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-propylbenzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(2-methoxyethyl)benzamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-(2-methoxyethyl)benzamide,N-[3-(2,6-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide,N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide,3,5-Dichloro-4-({5-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide,N-[3-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide,N-[3-(4-Bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,N-{3-[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-[3-(4-Bromo-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide,Methyl3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoate,N-[3-(4-Amino-2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,N-[3-[4-(Acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,N-[3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]propanamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(2-hydroxyethoxy)ethyl]benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-hydroxypropyl)benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[3-(morpholin-4-yl)propyl]benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(2,3-dihydroxypropyl)benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(dimethylamino)ethyl]benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(piperidin-1-yl)ethyl]benzamide,MethylN-[3,5-dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycinate,N-[3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzoyl]glycine,N-[3-(2-Chloro-3,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,3,5-Dichloro-N-methyl-4-{[7-(propanoylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}benzamide,N-[3-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(dimethylamino)ethyl]benzamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(2-hydroxyethoxy)ethyl]benzamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(piperidin-1-yl)ethyl]benzamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(morpholin-4-yl)ethyl]benzamide,4-{[7-(Acetylamino)-1H-pyrrolo[2,3-c]pyridin-3-yl]carbonyl}-3,5-dichloro-N-[2-(pyrrolidin-1-yl)ethyl]benzamide,N-[3-(2,4,6-Trichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,N-{3-[2,6-Dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-{3-[2,6-Dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-{3-[2,6-Dichloro-4-(6-methoxypyridin-3-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-{3-[2,6-Dichloro-4-(6-fluoropyridin-3-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-{3-[2,6-Dichloro-4-(1-methyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-[3-(4-Cyano-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,Methyl4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluorobenzoate,N-[3-(4-Cyano-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]acetamide,3,5-Dichloro-N-cyclopropyl-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(cyclopropylmethyl)benzamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-ethoxypropyl)benzamide,N-Butyl-3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)benzamide,N-{3-[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-(2-fluoroethyl)benzamide,4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-ethyl-3,5-difluorobenzamide,4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-methylbenzamide,4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-3,5-difluoro-N-(3-hydroxypropyl)benzamide,4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-[2-(dimethylamino)ethyl]-3,5-difluorobenzamide,4-({7-[(Cyclopropylcarbonyl)amino]-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-(3-ethoxypropyl)-3,5-difluorobenzamide,N-{3-[4-(3,5-Dimethyl-1,2-oxazol-4-yl)-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-c]pyridin-7-yl}cyclopropanecarboxamide,N-(3-{2,6-Dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide,N-(3-{2,6-Dichloro-4-[(ethylamino)methyl]benzoyl}-1H-pyrrolo[2,3-c]pyridin-7-yl)cyclopropanecarboxamide,N-[3-(2,6-Dichlorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,N-[3-(4-Bromo-2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,N-[3-(2,6-Difluorobenzoyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-7-yl]cyclopropanecarboxamide,3,5-Dichloro-4-({7-[(cyclopropylcarbonyl)amino]-2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl}carbonyl)-N-methylbenzamide,3,5-Dichloro-N-methyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide,3,5-Dichloro-N-ethyl-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide,Methyl [1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate,3,5-Dichloro-N-(2-hydroxyethyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide,3,5-Dichloro-N-(cyanomethyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzamide,N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide,1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-ethylurea,Methyl[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]carbamate,1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-(2-hydroxyethyl)urea,3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-1,1-dimethylurea,2-Cyano-N-[3,5-dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]acetamide,(2E)-3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enamide,(2E)-3-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]prop-2-enenitrile,N-(Cyclopropylcarbonyl)-N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide,N-{1-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-{1-[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-{1-[2,6-Dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-{1-[2,6-Dichloro-4-(pyrimidin-5-yl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,[2,6-Dichloro-4-(hydroxymethyl)phenyl](1H-pyrrolo[3,2-c]pyridin-1-yl)methanone,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-hydroxyethyl)benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-ethylbenzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide,N-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-2-fluoroacetamide,3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)benzonitrile,N-{1-[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-{1-[2,6-Dichloro-4-(hydroxymethyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}acetamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-methoxyethyl)benzamide,N-[1-(2,6-Dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2-methoxyethyl)benzamide,Methyl[1-(2-chloro-6-fluorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]carbamate,N-(1-{2,6-Dichloro-4-[(ethylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide,1-[3,5-Dichloro-4-(1H-pyrrolo[3,2-c]pyridin-1-ylcarbonyl)phenyl]-3-(2-methoxyethyl)urea,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-methylbenzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(propan-2-yl)benzamide,Methyl{1-[2,6-dichloro-4-(ethylcarbamoyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}carbamate,N-(1-{2,6-Dichloro-4-[(cyclopropylcarbonyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide,N-{1-[4-(Acetylamino)-2,6-dichlorobenzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-[1-(2,6-Dichloro-4-{[(2-methoxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide,N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)(methyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide,N-(1-{2,6-Dichloro-4-[(cyclopropylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide,N-(1-{2,6-Dichloro-4-[(cyclopropylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide,N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide,N-[1-(2,6-Dichloro-4-{[(2-hydroxyethyl)carbamoyl]amino}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide,N-(1-{2,6-Dichloro-4-[(ethylcarbamoyl)amino]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)acetamide,3,5-Dichloro-4-[(3-chloro-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]-N-ethylbenzamide,3,5-Dichloro-4-[(3-chloro-1H-pyrrolo[3,2-c]pyridin-1-yl)carbonyl]benzonitrile,N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide,Methyl3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoate,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(dimethylamino)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-hydroxypropyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(2-hydroxyethoxy)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(morpholin-4-yl)ethyl]benzamide,EthylN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-b-alaninate,N-(2-Aminoethyl)-3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(dimethylamino)ethyl]benzamide,EthylN-(4-{[4-(acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichlorobenzoyl)-b-alaninate,3,5-Dichloro-4-({6-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-methoxypropyl)benzamide,3,5-Dichloro-N-cyclobutyl-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-propylbenzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(3-methoxypropyl)benzamide,N-[3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-b-alanine,3,5-Dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-ethylbenzamide,N-[1-(2,6-dichloro-4-cyanobenzoyl)-1H-pyrrolo[3,2-c]pyridin-6-yl]cyclopropanecarboxamide,3,5-Dichloro-N-ethyl-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(1H-indol-3-yl)ethyl]benzamide,3,5-Dichloro-N-methyl-4-{[4-(propanoylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}benzamide,EthylN-[3,5-dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]alaninate,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(2-oxoimidazolidin-1-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2,3-dihydroxypropyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(thiophen-2-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyridin-4-yl)ethyl]benzamide,3,5-Dichloro-N-cyclopropyl-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(pyridin-2-ylmethyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyrrolidin-1-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[3-(morpholin-4-yl)propyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(piperidin-1-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(1-hydroxypropan-2-yl)benzamide,N-[3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)benzoyl]-L-alanine,3,5-Dichloro-4-({3-chloro-4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-methylbenzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2-fluoroethyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(2,2,2-trifluoroethyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(3-ethoxypropyl)benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(2-fluoroethyl)benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(1H-indol-3-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[(2R)-1-methoxypropan-2-yl]benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-(pyridin-2-ylmethyl)benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[2-(pyridin-2-yl)ethyl]benzamide,4-{[4-(Acetylamino)-1H-pyrrolo[3,2-c]pyridin-1-yl]carbonyl}-3,5-dichloro-N-[3-(morpholin-4-yl)propyl]benzamide,N-(1-{2,6-Dichloro-4-[(methylamino)methyl]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide,N-(1-{2,6-Dichloro-4-[(ethylamino)methyl]benzoyl}-1H-pyrrolo[3,2-c]pyridin-4-yl)cyclopropanecarboxamide,N-{1-[2,6-Dichloro-4-({[2-(2-oxoimidazolidin-1-yl)ethyl]amino}methyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-{1-[2,6-Dichloro-4-({[3-(morpholin-4-yl)propyl]amino}methyl)benzoyl]-1H-pyrrolo[3,2-c]pyridin-4-yl}cyclopropanecarboxamide,N-[1-(2,6-Dichloro-4-{[(3-hydroxypropyl)amino]methyl}benzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]cyclopropanecarboxamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(1H-pyrrol-1-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-[2-(pyridin-3-yl)ethyl]benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(cyclopropylmethyl)benzamide,3,5-Dichloro-4-({4-[(cyclopropylcarbonyl)amino]-1H-pyrrolo[3,2-c]pyridin-1-yl}carbonyl)-N-(piperidin-3-ylmethyl)benzamide,N-[1-(2,6-Dichlorobenzoyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]acetamide, or apharmaceutically acceptable salt thereof, a prodrug thereof or a hydratethereof.
 11. A pharmaceutical composition comprising a compound, apharmaceutically acceptable salt thereof, a prodrug thereof, a hydratethereof according to claim 1 as its active ingredient.
 12. (canceled)13. A method for treating or preventing a disease responsive to theinhibition of signal transduction pathway mediated at least in part byprotein kinase activity, comprises administering a compound, apharmaceutically acceptable salt thereof, a prodrug thereof, a hydratethereof according to claim
 1. 14. The method according to claim 13,wherein protein kinase is Janus kinase.
 15. The method according toclaim 14, wherein Janus Kinase is selected from JAK1, JAK2, JAK3, TYK2or combination thereof.
 16. The method according to claim 13, whereinthe disease is auto-immune and/or inflammatory disease selected fromasthma, rheumatoid arthritis, psoriasis, multiple sclerosis, chronicobstructive pulmonary disease, inflammatory bowel disease or cancer.